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Abstract 
 
Aflatoxin exposure through contamination of dietary staples is prevalent in 
developing regions such as sub-Saharan Africa. Aflatoxin exposure has been linked 
to a GT transversion in p53, which has been suggested to be the main mechanism 
of aflatoxin-associated liver carcinogenesis. In young children, in utero and weaning 
exposure has been linked to growth and immune function impairment through 
unknown mechanisms. The role of the insulin-like growth factor (IGF) axis was 
examined in aflatoxin-exposed Kenyan school-children. Through analysis of plasma 
samples, it was identified that 16% of the effect of aflatoxin on growth impairment 
was through disrupted IGF1 levels. It was also observed that mRNA and secreted 
protein levels of IGF growth-axis components were significantly reduced in 
aflatoxin-treated cultured liver cells. In another study using a Gambian mother-child 
cohort, it was determined that in most women aflatoxin exposure was consistently 
high or low during gestation and that this exposure was influenced by season of 
exposure. In infants born to highly aflatoxin-exposed women, significant changes to 
DNA methylation and gene expression patterns in white blood cells were observed in 
a number of genes following whole genome analysis. Among the observed changes, 
hypomethylation of HORMAD2 at the promoter-level and MIR24-2 at the gene-level 
as well as hypermethylation of CD3D at the promoter-level were identified and 
successfully validated by pyrosequencing. Additionally, USP4 and STAT3, 
associated with cancers and growth impairment, were both upregulated in the high 
AFB1 exposure group and were also successfully validated by qPCR. Changes in 
methylation and expression in aflatoxin-treated liver cells were assessed using a 
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whole genome approach. Hypomethylation of IL2 and MIR24-2 at the gene level and 
upregulation of NFKB1A and IL6 were observed in AFB1-treated liver cells 
compared to controls. Overall, the study provides evidence that the IGF axis may be 
involved in aflatoxin-induced growth impairment and the STAT3 and NF-κB 
signalling pathways, associated with hepatocarcinogenesis and growth impairment, 
were found to be activated in both Gambian infants exposed in utero and in treated 
liver cells. These pathways may play important roles in the mechanisms of aflatoxin 
exposure-associated health effects and need to be explored further.   
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1 Introduction 
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1.1 Literature Review 
1.1.1 Discovery of Aflatoxins 
In May 1960, several thousand turkeys in England showed symptoms of loss of 
appetite, lethargy and a high mortality rate leading to a diagnosis of  Turkey ‘X’ 
disease, so called as the cause was undetermined (Blount 1961). The series of 
experiments that followed upon characterisation of the disease revealed no 
involvement of infectious agents (Blount 1961). However, very high mortality rates 
and symptoms indicative of Turkey ‘X’ disease were observed in poults that were 
given suspect feed during feeding trials (Blount 1961). As the common factor in all 
cases was Brazilian imported groundnut meal, it was hypothesised that contaminated 
feed was responsible for manifestation of the disease, directing research towards the 
discovery of aflatoxin-producing Aspergillus  fungal contamination of the groundnut 
meal (Wogan 1966).  
Aflatoxins are secondary metabolites produced primarily by A. paraciticus and A. 
flavus but also by other less commonly occurring fungal species belonging to the 
Aspergillus genus (Pitt 2000). Four main structurally-related types of aflatoxins have 
been characterised and extensively studied: aflatoxin B1, B2, G1 and G2 (Wogan 
1966) so named due to the blue (B1 and B2) and yellow-green (G1 and G2) light 
emitted respectively when exposed to ultraviolet light, with aflatoxin B1 being the 
most commonly occurring in nature (Wogan 1966). When ingested, aflatoxin B1 and 
B2 can be hydroxylated to form subtypes M1 and M2 respectively (Wogan and Pong 
1970). The chemical structures of these main types of aflatoxins are depicted in 
Figure 1.  
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Aflatoxins have been the subject of a wide range of studies aimed to determine the 
effects of exposure on animal and human health. The ubiquitous nature of these 
toxins makes it imperative to fully comprehend sources of exposure, metabolism 
once ingested and the effects on health, the latter of which is the focus of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Chemical structures of the four naturally occuring aflatoxins and 
their hydroxylated metabolites: B1, B2, G1, G2, M1 and M2. Adapted from 
http://www.food-info.net/uk/tox/afla.htm (accessed 12th January 2013) 
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1.1.2 Contamination of crops with aflatoxin 
Contamination of crops by aflatoxin-producing Aspergillus spp. occurs at 
temperatures between 24˚C and 35˚C with 7-10% relative humidity- conditions 
usually observed in countries situated in the tropics (Williams et al. 2004). 
Contamination is therefore usually observed between approximately 40˚N and 40˚S 
of the equator, particularly in developing countries within this region (Cardwell and 
Cotty 2002). It has been estimated that mycotoxins contaminate approximately a 
quarter of the world’s food supply including several dietary staples such as maize 
and groundnuts consumed in developing countries (Strosnider et al. 2006) with 
approximately 4.5 billion people exposed to aflatoxin contamination worldwide 
(Williams et al. 2004).  
Most aflatoxin is produced by A. flavus of which there are two main types based on 
differences in morphology: strains L and S (Cotty 1994). The L strain produces 
larger and fewer sclerotia and differs in its ability to produce aflatoxin with several L 
strain isolates known to be atoxigenic. On the other hand, the S strain produces many 
small sclerotia and tends to produce more aflatoxin. Furthermore, atoxigenic S strain 
isolates are rarely found (Cotty 1994). The soil is the main medium through which 
contamination of crops occurs (Horn 2003). Variability in the distribution of these 
strains can affect the extent to which crops are contaminated with aflatoxin. In a 
study based in Benin, the S strain was found in higher numbers in the soil in the dry 
agroecological zone in the north compared to higher numbers of the L strain 
observed in the soil in the humid and tropical agroecological zone in the south 
(Cardwell and Cotty 2002). Further variation in the production of aflatoxin by the L 
strain can result in irregular contamination in different regions.  
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Contamination of crops with aflatoxin-producing fungi can occur in two distinct 
phases. The first contamination phase may initiate during growth due to mechanical 
insect damage as well as dispersal of aflatoxin-producing fungi by insect activity 
(Cotty 1994). Additionally, the hot and humid climate can increase crop 
susceptibility to contamination and promote fungal growth (Cotty and Jaime-Garcia 
2007). Post-harvest contamination usually constitutes the second phase of 
contamination through storage practices, which can introduce or propagate fungal 
growth and consequently aflatoxin production in grains (Vincelli 1995). Storage 
practices including the type of material used and length of storage can differ by the 
agroecological zone and ethnicity. In Benin, less contamination with aflatoxins was 
detected in maize stored in the ‘Ago’, (a giant basket made from woven raffia palms, 
tree branches or bamboo) when made of bamboo as opposed to woven palms, 
compared to other materials (Bandyopadhyay et al. 2007). Additionally, it was 
observed that aflatoxin production was higher after approximately 6 months of 
storage compared to levels at the beginning of storage. However, when maize was 
stored for longer periods, a lot of care was taken when drying the grains and use of 
insecticides was more common. For this reason, aflatoxin levels were in fact lower in 
grains stored for longer than 6 months (Bandyopadhyay et al. 2007).  
Contamination of crops with aflatoxins is highly dependent on environmental factors 
such as temperature and moisture. Any change to these conditions can alter 
contamination levels and distribution. Indeed, climate is suggested to be the driving 
force of fungal growth and mycotoxin production (Magan et al. 2003). Increased 
heat and draught conditions can lead to increased physical damage to crops such as 
‘hull cracking’ resulting in elevated aflatoxin contamination (Paterson and Lima 
2010). Additionally, increased CO2 levels can result in increased host susceptibility 
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due to a change in physiology and morphology. Warm temperatures also allow 
fungal species to compete well than at cooler temperatures. Therefore, global 
warming may accelerate contamination in regions where temperatures become 
optimal for fungal growth (Paterson and Lima 2010). Indeed, it is expected that as 
global climate changes, developing countries, including those in Africa, will 
experience warmer temperatures with increased risk of draught stress. These changes 
are predicted to increase contamination of crops with aflatoxin in these regions 
(Magan et al. 2011). Therefore, the risk of contamination and of consumption of 
aflatoxin-contaminated foods needs to be assessed in order for effective strategies to 
be put in place for the prevention of acute and chronic dietary exposure.  
 
1.1.3 Impact of aflatoxins on animal and human health 
1.1.3.1 Structure of AFB1 related to health effects 
The discovery of aflatoxins as the causal agent in sickness and deaths in poultry 
marked a spate of studies dedicated to understanding the effects of exposure and the 
mechanism by which aflatoxin affects animal health. Animals and humans are 
exposed to aflatoxins through consumption of contaminated grains. Following the 
detection of aflatoxins in poultry and cattle feed, studies were focussed on 
understanding the effects and dose response of aflatoxin contamination on animals. 
Early research on laboratory rats and guinea pigs discovered the formation of lesions 
in the liver as well as the development of hepatocarcinomas (Brown et al. 1999). 
Initially, continual exposure to aflatoxin through feed was considered a prerequisite 
for liver lesion formation. However, further studies showed that hepatic necrosis and 
tumours in rats could be induced following a single sub-lethal dose of aflatoxins 
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(Butler 1964; Carnaghan 1967). It was soon discovered that periportal necrosis 
occurred slowly over 48-72 hours following exposure with no observed rapid 
recovery (Butler 1964) making aflatoxin B1 the most potent hepatocarcinogen known 
at the time (Carnaghan 1967).   
Hepatic tumours and slowed growth were symptoms common to different species of 
animals exposed to varying doses of aflatoxin in feed (Butler 1969) with cattle and 
sheep being more resistant to the effects of exposure compared to poultry (Robens 
and Richard 1992). Table 1 presents the LD50 concentrations of aflatoxin B1 for 
some animal species, which shows the variation in concentrations that are lethal in 
different species.  
 
Table 1: LD50 doses of AFB1 in different animal species. 
Species LD50 dose (mg/Kg) Reference(s) 
Duckling 0.4 (Carnaghan et al. 1963) 
Rabbit  0.3 (Butler 1969) 
Pig 0.6 (Butler 1969) 
Guinea Pig 1.4 (Butler 1966) 
Rainbow Trout 0.8 (Bauer et al. 1969) 
Rat (neonate) 1.0 (Wogan 1966) 
Rat (weanling) 5.5-7.2 (Butler 1964; Wogan 1966) 
Mouse 9.0 (Butler 1969) 
Hamster 10.2 (Butler 1969) 
 
The basic structure of aflatoxin was first described by Asao et al in 1963 and 
followed up in 1965 (Asao et al. 1963; Asao et al. 1965). Aflatoxin was found to 
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consist of a fused coumarin-cyclopentene system attached to a dihydrofurofuran 
moiety. Additionally, a double bond exists at the 2,3 (8,9 by IUPAC nomenclarture) 
position of the terminal furan ring. In AFB1 and AFB2, a cyclopentenone ring is 
fused to a lactone ring in the coumarin moiety while in AFG1 and AFG2, the 
coumarin moiety consists of a fused lactone ring (Lamplugh et al. 1988; Partanen et 
al. 2010). In two key studies designed to determine the structure-related activity of 
aflatoxins, both naturally occurring aflatoxins (B1, G1, B2 and G2) and synthetic 
compounds were tested in Male Fischer rats at low doses (Josse et al. 2012; 
Randhawa 2008). The potency of the four naturally occurring aflatoxins was 
confirmed to be in the order B1 > G1 > B2 > G2. The synthetic compounds tested 
lacked the dihydrofurofuran ring and contained the fused coumarin-cyclopentene 
ring in varying configurations. While toxicity and development of hepatocellular 
carcinoma (HCC) in the rats was observed with exposure to AFB1 and AFG1, neither 
was detected when rats were fed meals containing the synthetic compounds 
revealing the importance of the dihyrdofurofuran ring in potency and carcinogenicity 
(Josse et al. 2012). Additionally, these compounds were found to be non-toxic in 
ducklings, which are much more sensitive to AFB1 and AFG1 than rats (Josse et al. 
2012). In the second related study, it was also discovered that AFB1 and AFG1 
inhibited hepatocyte RNA polymerase activity and reduced nuclear RNA synthesis. 
Moreover, one of the synthetic compounds studied, 5,7-Dimethoxycyclopentenone 
[2,3-c] coumarin, which was closest in configuration to AFB1, had the highest 
affinity to bind DNA followed by AFB1 (Randhawa 2008). AFB1 binds purine bases 
in single-stranded DNA weakly and the presence of an amino group plays a role in 
the interaction between AFB1 and DNA (Maxwell et al. 1989).  
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1.1.3.2 Metabolism of AFB1 
It was observed that when one-day old ducklings were exposed to the milk obtained 
from cows exposed to AFB1, they produced bile duct hyperplasia similar to that seen 
with direct exposure to AFB1 (Campbell and Hayes 1976). This suggested the 
presence of a toxic metabolite in milk, which was identified as aflatoxin M1 (AFM1), 
a hydroxylated form of AFB1 (De Iongh et al. 1964) and was also excreted in sheep 
milk and urine (Allcroft et al. 1966). AFM1 was revealed to have carcinogenic 
potential in rainbow trout and rats albeit with lower potency than AFB1 (Wogan and 
Paglialunga 1974; Sinnhuber et al. 1974).  
Further inquiry into the metabolism of AFB1 facilitated the identification of another 
metabolite called aflatoxin Q1, which is an isomer of AFM1. AFQ1 was one of two 
metabolites produced when monkey liver microsomes were incubated with an 
NADPH regenerating system, the other metabolite being AFM1 (Masri et al. 1974). 
Using a bacterial Salmonella typhimurium strain TA 98 test, AFQ1 was found to be 
mutagenic although at least 50 times less potent than AFB1 (Wong and Hsieh 1976). 
It was also found to be 100 times less carcinogenic than AFB1 in rainbow trout 
(Hendricks et al. 1980). 
Another metabolite that in the form of a conjugate is the main component of urine of 
AFB1-exposed rhesus monkeys and rats is the AFP1, which is a phenol product of 
demethylated AFB1 (Dalezios et al. 1971; Wogan et al. 1967). This metabolite was 
found to be slightly toxic in new-born mice at a 150 mg/kg dose causing 
approximately 13% mortality (Buchi et al. 1973) but was mostly non-toxic and non-
teratogenic in both new-born mice and fertile chicken eggs (Buchi et al. 1973; 
Stoloff et al. 1972).  
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AFB1 is also biologically reduced to a metabolite called aflatoxicol by liver enzymes 
(Pawlowski et al. 1977), which is almost as carcinogenic as AFB1 in rainbow trout 
(Schoenhard et al. 1981). Metabolism of AFB1 to aflatoxicol at the human placental 
interface in vitro provides evidence for the extension of the effects of AFB1 from 
mother to the foetus (Partanen et al. 2010).   
When water reacts with the 8,9 double bond in the terminal furan ring of AFB1, 
aflatoxin B2a is formed and is therefore the monohydroxylated derivative of AFB1. 
As with the other identified metabolites, AFB2a is also much less toxic than AFB1 
and has a lower capacity to bind DNA (Ciegler and Peterson 1968; Lillehoj and 
Ciegler 1969).  
It was first suggested by Schoental in 1970 that aflatoxin may be metabolised to an 
epoxide that has elevated toxicity, binds to DNA and to which animals may be more 
vulnerable (Randhawa and Cohen 2005; Schoental 1970). Subsequently, this 
metabolite was discovered in an assay subjecting Salmonella typhimurium TA 1530 
to liver microsomes derived from rats exposed to AFB1 (Agag 2004). The unknown 
metabolite was found to bind tightly to liver microsomes (Gurtoo and Campbell 
1974). This epoxide was proposed to be a 2,3-oxide (8,9-oxide by IUPAC 
nomenclature) of aflatoxin B1 and found to be important in the in vitro binding of 
AFB1 to DNA (Essigmann et al. 1977). This was further supported by the fact that 
most of the binding of AFB1 to liver DNA and ribosomal RNA (rRNA) in rats was 
by the AFB1-2,3-oxide and that this oxide was also produced in vitro by human liver 
microsomes (Swenson et al. 1974). The formation of the epoxide-DNA adduct was 
confirmed in an in vivo system in rats and the epoxide was found to mainly bind the 
N
7
 atom of guanine via an SN2 reaction forming the 2,3-dihydro-2-(guan-7-yl)-3-
hydroxy-aflatoxin B1 DNA adduct (Lin et al. 1977; Croy et al. 1978; Johnson and 
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Guengerich 1997). Further analysis of the epoxide revealed the potent toxin to be a 
highly unstable exo-epoxide while an endo-epoxide, which being more stable did not 
interact with DNA and was classed as non-mutagenic, was also identified (Iyer et al. 
1994). The instability of the exo-epoxide is due to the presence of a positively 
charged imidazole ring. The adduct can then either undergo depurination resulting in 
the formation of an apurinic site or under alkaline conditions, it can be converted to 
the relatively more stable imidazole ring-opened AFB1-formamidopyrimidine 
(AFB1-FAPY) (Marzilli et al. 1998). A significant proportion of adducts formed in 
vivo comprises AFB1-FAPY in rats (Croy and Wogan 1981) as well as in human 
liver tissue (Hsieh et al. 1988). The formation of AFB1-FAPY involves considerably 
less alteration to the structure of DNA compared to the AFB1-N
7
-Gua adduct, which 
makes it easier for it to bypass most DNA repair mechanisms. It has therefore been 
suggested that the susceptibility to AFB1-induced carcinogenesis is a result of the 
variation in DNA repair systems among mammals (Bedard and Massey 2006).  
It was soon established that the metabolic activation to the more toxic epoxide was 
catalysed by the cytochrome (CYP) P450 system in the liver (Shimada and 
Guengerich 1989) particularly the CYP 1A2, 2A3, 2A7, 3A3 and 3A4 forms 
(Aoyama et al. 1990). The fact that the bioactivation of AFB1 had been observed to 
occur in human livers (Shimada and Guengerich 1989; Shimada et al. 1989) 
warranted research on the potential effects of the epoxide on human health. CYP 
3A4 has been identified as the main enzyme involved in the bioactivation of AFB1 in 
humans and is largely present in the liver as well as the small intestine (Guengerich 
et al. 1998). It has also been found to only form the mutagenic exo-epoxide and 
AFQ1 (Ueng et al. 1995). CYP 1A2 is also considered very important in the 
oxidation of low concentrations of AFB1 (Gallagher et al. 1994) and can form the 
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endo- and the exo-expoxide as well as metabolic products AFM1 and small amounts 
of AFQ1 (Ueng et al. 1995).  
Liver enzymes not only activate ingested AFB1 but also engage in a detoxification 
pathway. In fact, formation of an 8,9-exo-AFB1 epoxide-glutathione conjugate made 
up about 10% of the dose given to female Wistar rats (Degen and Neumann 1978). 
Glutathione-S-transferases (GST), produced by liver microsomes, inhibits the 
binding of the 8,9-exo-AFB1 epoxide to DNA and has provided further evidence of a 
detoxification pathway via glutathione (GSH) conjugation (Lotlikar et al. 1980). It 
has also been suggested that differences in rate of conjugation with GSH contributes 
towards species variation in susceptibility to AFB1 (Degen and Neumann 1981) with 
the mouse liver cytosol conjugating the exo-epoxide almost exclusively, the rat liver 
cytosol conjugating mostly the endo-epoxide and human liver cytosols conjugating 
both epoxides but at very low levels (Raney et al. 1992).  While the half-life of the 
exo-epoxide has been determined to be approximately 1 second in an aqueous buffer 
of neutral pH at 23°C, it reacts almost immediately with DNA and GSTs 
(Guengerich et al. 1996). It has been suggested that variations including genetic 
polymorphisms in the P450 enzymes can alter the rate of activation and 
detoxification of AFB1 and therefore susceptibility to the carcinogenic effects of 
AFB1 (Peter Guengerich and Shimada 1998).  The metabolism of AFB1 is depicted 
in Figure 2. 
 
 
 
  
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.4 A brief history of the effects of AFB1 on the human 
liver 
As more research on AFB1 revealed it to be a potent hepatocarcinogen in animals, it 
became apparent that exposure to aflatoxins also potentially contributes to certain 
health effects in humans. An early study on the effects of AFB1 on human cell 
cultures reported increased toxicity and inhibited growth in HeLa and Chang liver 
cells (Gabliks et al. 1965). In an embryonic lung cell line, L-132, AFB1 was found to 
reduce cell numbers by suppressing mitosis. It was also observed to reduce protein 
and DNA content and alter morphology of the cells with increasing dose (Legator 
1966).  
 
Figure 2: Metabolism of AFB1- activation to the endo- and exo-epoxides and detoxification 
to AFM1, AFQ1 and AFP1 metabolites. Adapted from (Kensler et al. 2011). 
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Human liver microsomes were known to activate AFB1 to its toxic epoxide 
(Shimada and Guengerich 1989; Shimada et al. 1989) but it was also observed that 
AFB1 bound DNA in human bronchus and colon cell lines forming a DNA adduct 
similar in structure to those seen in animals studies previously (Autrup et al. 1979). 
It was first proposed by Oettlé in 1965 that aflatoxin exposure through diet may be a 
contributing factor in the relatively high liver cancer incidence in African countries 
compared to Western countries (Oettle 1964). An epidemiological study by Shank et 
al, found that aflatoxin levels in ingested food in the Ratburi region in the north was 
about 9-10 times higher than that consumed in the Songkhla region in the south 
(Shank et al. 1972b). They also discovered that liver cancer incidence in the Ratburi 
area was about 3 times greater than that in the Songkhla area (Shank et al. 1972a) 
providing preliminary clues as to the causal effect of aflatoxins on human liver 
carcinogenesis. In two studies by Peers et al, aflatoxin levels in food measured by 
thin-layer chromatography (TLC) were significantly associated with liver cancer 
incidence in the Murang’a district, Kenya and in Swaziland (Peers and Linsell 1973; 
Peers et al. 1976).  In a study based in The Philippines, aflatoxin levels in different 
food items were first determined using TLC. The diet of 90 liver cancer patients and 
90 controls was then assessed using a questionnaire and the aflatoxin load calculated 
using the results from the aflatoxin analyses. As association was found between 
aflatoxin load and liver cancer (Bulatao-Jaym et al. 1982).    
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1.1.4.1 Evidence of a potential mechanism of AFB1-associated 
cancer 
A key characteristic of many carcinogens is their ability to form covalent bonds with 
DNA in somatic and/or reproductive cells, with the resulting interaction product 
called a DNA adduct (Harris 1989). The formation of a DNA adduct is usually the 
precursor lesion to a mutation, which can occur through replication errors during 
DNA synthesis (Marnett and Burcham 1993). Following exposure, a carcinogen is 
usually metabolically activated to form a reactive metabolite, which is then either 
inactivated through detoxification mechanisms or forms an adduct with DNA. Repair 
mechanisms aimed at the resulting carcinogen-DNA adduct are attempted. If these 
fail, the adduct can lead to mutations and eventually carcinogenesis (Strickland et al. 
1993). In the past, 
32
P post labelling and immunoassays laid the groundwork for the 
detection and determination of DNA adducts in humans (Strickland et al. 1993). A 
number of interesting factors were noted about DNA adducts. It has been discovered 
that adduct formation can occur in target as well as in non-target tissues. Also, 
specific sites of carcinogen reaction can have different efficacies in tumour 
formation. For instance, potent carcinogens that were large were found to mostly 
form adducts at the N
7
 position of guanine while O-alkylation was more effective for 
smaller alkylating agents. Interestingly, the stability of the adducts was related to the 
probability of tumour formation and in some cases, more DNA adducts were formed 
in tissues of animals sensitive to carcinogenic potential than in resistant species 
(Hemminki 1993).   
Mutation spectra have enabled researchers to determine common sites of mutations 
in tumours in specific cancers. With this information, it has been possible to compare 
the site of DNA adduct formation and potentially the site of mutations to the 
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mutation spectra of tumour suppressor genes or oncogenes in specific cancers in 
order to determine if the mutational signature of a particular carcinogen corresponds 
to the mutations most commonly observed in tumours. This provides evidence 
towards the mechanism of carcinogenesis induced by covalent DNA adduct 
formation (Pfeifer et al. 2002). Indeed, specific G->T transversions in p53 in lung 
cancer patients who are smokers have been associated with the site of polycyclic 
aromatic hydrocarbon (PAH) adduct formation in the p53 gene (Smith et al. 2000). 
Additionally, G->T transversions have been found to be significantly higher in lung 
cancer patients who are smokers than in patients who are non-smokers (Hainaut and 
Pfeifer 2001).  
The carcinogenic mechanism of aflatoxin is typical of this DNA adduct/mutation 
paradigm. In an in vitro study using Escherichia coli (E. coli), the aflatoxin 8,9-exo-
epoxide was found to induce a G:C -> T:A transversion in the lacI gene (Foster et al. 
1983). When phage M13AB28 DNA modified with AFB1-2,3-dichloride was 
transfected into E. coli, this transversion was detected in the lacZ M13 phage gene in 
the E. coli host together with a G-to-A transition (Sambamurti et al. 1988). In rats, 
the G:C rich regions flanking N-ras and c-Ki-ras oncogenes were found to be sites 
of aflatoxin-induced damage (Mcmahon et al. 1990) suggesting that alterations in 
this region may be specific to AFB1 mutagenesis. The tumour suppressor gene, p53, 
has been observed to be frequently mutated in several human cancers (Hollstein et al. 
1991). In HCC patients from Qidong, China, G -> T and G -> C transversions were 
seen in the third-base of codon 249 in the p53 gene (Hsu et al. 1991). This specific 
mutation was confirmed in HCC patients from south African and some Asian 
countries but was not detected in patients from North America, Europe and the 
Middle East. Also, the codon 249 mutation was detected in about 50% of patients 
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from Mozambique, where aflatoxin intake was observed to be higher compared to 
only 8% of patients from Transkei, a district in South Africa where aflatoxin intake 
was lower (Bressac et al. 1991).   
 
1.1.4.2 Hepatitis B virus, aflatoxins and liver cancer 
As research into the health impact of aflatoxins on animals and potentially in humans 
was being conducted, primary liver cancer was already being thoroughly 
investigated particularly due to the fact that it is one of the most common cancers 
afflicting African people (Berman 1959). Hepatitis B virus (HBV) infection, which 
is highly prevalent in Africa and Asia, was suggested as the stimulus leading to 
development of HCC in Africa (Higginson 1963). Indeed, the PLC/PRF/5 hepatoma 
cell line was shown to produce the hepatitis B surface antigen (HBsAg) without any 
artificial infection providing an in vitro clue to the association between HBV and 
HCC (Macnab et al. 1976) and these cells were also found to contain at least six 
viral integration sites in the host DNA (Edman et al. 1980). The association between 
HBV infection and HCC was further demonstrated by the presence of HBV DNA 
integrated into HCC tumour tissue and the PLC/PRF/5 hepatoma cell line (Brechot 
et al. 1980). When introduced into transgenic mice, the HBV viral regulatory gene, 
HBx, alone was observed to induce morphological changes, which developed into 
liver cancer (Kim et al. 1991). However, it has been suggested that infection with 
HBV is the first insult, which precedes HCC development possibly by several years. 
This could be followed by a carcinogenic event in the form of aflatoxin exposure 
which ultimately leads to HCC development (Enwonwu 1984). In a cohort of 7917 
men based in Southern Guangxi, China, it was found that 91% of men who died of 
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primary hepatocellular carcinoma (PHC) were positive for blood HBsAg. 
Additionally, estimates of aflatoxin intake in this region had a near linear 
relationship with PHC mortality rates (Yeh et al. 1989).  
While signifying important associations between aflatoxin exposure and 
development of HCC, these studies are reliant on potentially inaccurate data on 
aflatoxin load in intake and therefore lack a well-validated and comprehensive 
marker to determine aflatoxin exposure. A consistent biomarker of exposure would 
provide assurance into observations of associations between AFB1 and liver cancer 
with and without the presence of HBV infection but would also represent a 
biologically effective dose (Groopman et al. 1994).  
Several of the described studies using either food consumption data, measurement of 
toxin levels in food samples or validated biological markers of exposure have 
consistently observed high exposures to aflatoxins in developing regions and its 
associations with adverse health effects, particularly liver cancer. This work led to 
the upgrade of naturally occurring mixtures of aflatoxins from ‘possibly carcinogenic 
to humans’ (Group 2a) to ‘carcinogenic to humans’ (Group 1) by the International 
Agency for Research on Cancer (IARC) in 1993 (International Agency for Research 
On 1993), an assertion which was maintained in a following monograph in 2002 
(Iarc 2002). 
 
1.1.5 Advantages of biomarkers 
In epidemiological studies assessing the impact and influence of exposures, precise 
measurement of these exposures is necessary. Identification and rigorous validation 
of biomarkers of exposures or effects is therefore paramount to make accurate 
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inferences providing confidence to any findings. There are two main types of 
biomarkers: biomarkers of exposure, which are useful in risk prediction, and 
biomarkers of disease, which are used to diagnose and monitor disease progression 
(Mayeux 2004). These markers can allow for the identification of disease risk at an 
early point following exposure and can reflect changes as a result of exposures (Gil 
and Pla 2001).  
In some cases, the metabolites of a compound can be measured in body fluids and 
can be biomarkers for the internal dose. Some biomarkers of the ‘biologically 
effective dose’ can be measured in the target organ or a surrogate source. For 
example, exposure to lead could be determined by air pollution statistics. However, 
measurement of lead or its metabolites in tissues including blood can provide a more 
accurate framework of exposure (Mayeux 2004). In addition to potential 
inaccuracies of questionnaire measurements and workplace exposure monitoring, 
individual variations in absorption and metabolism of external exposures can further 
confound any results from epidemiological studies relying on these measures to 
determine exposure (Timbrell 1998). 
   
1.1.6 Molecular markers of AFB1 exposure 
It was first identified that the AFB1-N
7
-Gua DNA adduct found in liver tissues of 
rats could also be detected in urine in a dose-dependent manner using high-pressure 
liquid chromatography (HPLC) (Bennett et al. 1981). Using affinity chromatography, 
these adducts were also detected in urine from people living in Guangxi, China 
where dietary aflatoxin exposure was estimated by measuring peanut oil and corn 
consumed by the people in the study (Groopman et al. 1985). In a small study 
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consisting of 20 subjects from The Gambia, AFB1 was measured using antibody-
affinity HPLC in food items collected over a period of one week and AFB1 
metabolites- AFB1-N
7
-Gua DNA adduct, AFQ1 and AFP1 in urine were measured 
using a competitive enzyme-linked immunosorbent assay (ELISA). Dietary AFB1 
load was strongly correlated to AFB1-N
7
-Gua DNA adduct levels in urine but no 
association between HBsAg surface antigen status and urine adduct levels was 
observed  (Groopman et al. 1992a). Dietary AFB1 intake was also strongly correlated 
with urine AFB1-N
7
-Gua adduct levels in 42 subjects from Guangxi, China, which 
leant further credence to the use of the AFB1-DNA adduct as a biomarker of dietary 
AFB1 exposure (Groopman et al. 1992b).  
Ross et al. performed a comprehensive case-control study nestled within a 
prospective cohort study of 18,244 middle-aged men from Shanghai, China. 
Importantly, this study used biomarkers of aflatoxin exposure to determine the 
association between exposure and liver cancer. A total of 22 liver cancer patients and 
140 controls matched for age, time of sample collection and neighbouring residence 
were recruited and urine samples were used to measure AFB1, AFM1, AFP1 and 
AFB1-N
7
-Gua adduct levels. Higher levels of aflatoxin metabolites were observed in 
liver cancer patients than in controls. Furthermore, there was a strong interaction 
between aflatoxin exposure and HBsAg status associated with liver cancer incidence 
than with either factor alone (Ross et al. 1992). However, as the sample size was 
relatively small, an absolute inference cannot be made. This study was taken further 
to include a total of 50 HCC cases and 267 matched controls (Qian et al. 1994). 
Measured urinary AFB1 and its metabolites were once again found to be significantly 
higher in HCC cases than in controls. Also, the individual HCC risk for patients with 
HBsAg antigen positivity and for urinary aflatoxin presence was 7.3- and 3.4-fold 
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respectively. However, when subjects were positive for both factors, there was a 
59.4-fold increase in HCC risk (Qian et al. 1994). However, only a few other studies 
have found similar impressive risks of HCC development with either HBV or AFB1 
exposure alone or with both (Chen et al. 1996b; Wang et al. 1998).  
AFB1-N
7
-Gua and other metabolites measured in urine only reflect short-term 
dietary exposure (Groopman et al. 1993). Therefore, the discovery markers that 
reflect longer-term exposure was undertaken. AFB1 has also been observed to bind 
plasma albumin paralleling DNA binding and after 7-14 days following exposure, 
has been seen to accumulate to a level 3-fold higher than the dose administered in 
rats (Wild et al. 1986). This relatively new adduct was subsequently isolated in 
AFB1-treated rats and it was found that the AFB1 predominantly bound lysine in 
albumin. It was also observed to have a half-life of 2.5 days, which is similar to the 
half-life of albumin in rats. This would translate to a half-life of approximately 20 
days in man and could therefore reflect exposure over a period of weeks or months 
(Sabbioni et al. 1987). Additionally, this adduct is produced through the binding of 
the 8,9-exo-AFB1 epoxide to albumin and is proportional to the degree of DNA 
damage in the liver (Wild et al. 1986; Sabbioni et al. 1987). One of the first human 
studies to confirm the validity of aflatoxin-albumin (AF-alb) adduct as a biomarker 
was done by Gan et al in 1988 (Gan et al. 1988). Blood from 42 residents from 
Guangxi, China was analysed for AF-alb levels by a competitive radioimmunoassay 
and aflatoxin intake and urinary AFM1 levels were also measured. AF-alb levels 
were found to correlate significantly with both food intake as well as urinary AFM1 
levels (Gan et al. 1988). These blood samples were also analysed using fluorescence 
measurements to quantify AF-alb adduct levels and on comparison with food intake 
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data, it was determined that 4% of ingested aflatoxin was bound to serum albumin 
(Gan et al. 1989).  
 
1.1.6.1 Methods of AF-alb measurement 
The discovery and characterisation of AF-alb adducts warranted the development of 
techniques for the accurate, quick and simple measurement of adduct levels in blood. 
Previously used techniques involving radioimmunoassays (RIA) and fluorescence 
measurements quantified total aflatoxin-albumin adduct levels in the serum. 
However, the RIA technique assumed similar affinity of the antibody to both AF-alb 
adducts as well as AFB1, which was used as a standard (Gan et al. 1988). However, 
it has since been shown that the specific antibody used has a 10 times greater affinity 
to AF-alb than to AFB1, resulting in an overestimation of the amount of adduct in the 
serum (Sabbioni et al. 1990). Also, the fluorescence method used intact protein 
without the separation of lysine residues bound to aflatoxin (Gan et al. 1989). 
Subsequently, an HPLC method was developed to overcome these issues and to 
accurately quantify AF-lysine residues (Sabbioni et al. 1990). In this method, sera 
from 42 Guangxi residents were first digested with pronase followed by filtration 
using a monoclonal antibody immunoaffinity column and were finally analysed by 
HPLC. Comparison of the results from this technique with those of the RIA by Gan 
et al. confirmed that RIA detected 3.6 times more AF-alb than the HPLC method, 
probably due to the inappropriate standards used in the former (Sabbioni et al. 1990). 
The HPLC technique with an added purification step involving the use of C18 
cartridges, an ELISA on unmodified albumin and a competitive ELISA on digested 
and hydrolysed albumin were compared by Wild et al. using serum samples from 
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The Gambia, Kenya, Thailand and France (Wild et al. 1990b). Of the three methods 
tested, the competitive hydrolysis ELISA and hydrolysis HPLC with fluorescence 
measurement had much lower detection limits compared to the direct ELISA, 
although the recovery, determined by measurement of [
14
C]-AFB1 bound to albumin 
in rats, was less than 30% in both assays. However, the hydrolysis ELISA was 
decided to be the better technique due to the overall low cost, ease of performance 
and the large numbers of samples that could be quantified at once (Wild et al. 1990b). 
This ELISA was developed and tested further by Chapot and Wild and included an 
albumin extraction and hydrolysis stage followed by purification with C18 cartridges. 
The purified albumin was incubated with specific antibodies and this was then 
analysed on plates coated with an AFB1-ovalbumin antigen (Chapot and Wild 1991). 
This competitive ELISA has been used in a number of studies to understand the 
effects of AFB1 exposure on human health (Wild et al. 2000; Gong et al. 2002; Gong 
et al. 2004; Turner et al. 2007). 
The measurement of AF-alb adducts in 102 Kenyan serum samples collected during 
the 2004 aflatoxicosis outbreak (Azziz-Baumgartner et al. 2005) by hydrolysis 
ELISA, HPLC with fluorescence detection (HPLC-f) and HPLC with isotope 
dilution mass spectrometry (IDMS) revealed that all three methods performed at 
different laboratories correlated well across all samples tested and were predictive of 
outcome when samples were classed as cases or controls. Additionally, it was noted 
that the IDMS method was the most sensitive with HPLC-f being the least sensitive 
(Mccoy et al. 2008).   
The development of these non-laborious, accurate and quick methods has allowed 
for easier quantification of AF-alb adducts in sera. Importantly, these techniques 
have enabled a number of studies to link exposure levels with health outcomes, 
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thereby contributing greatly to our understanding of the consequences of dietary 
exposure.  
 
1.1.7 Aflatoxin exposure levels and associated health effects 
1.1.7.1 AFB1 exposure and liver cancer risk 
Liver cancer is the fifth most prevalent cancer in the world and is the fourth most 
leading cause of cancer-related mortality resulting in 8.2% of total cancer-related 
mortality. Eighty per cent of liver cancer cases occur in developing countries 
particularly in West and Central Africa (Parkin et al. 2008).  
The identification and validation of AFB1-N
7
-Gua DNA and AF-alb adducts have 
enabled discovery of stronger associations between exposure and health effects 
including liver cancer and have improved our understanding of the mechanistic 
action of aflatoxins on animal and human health. Using an immunoassay based 
approach together with HPLC fluorescence for positive samples, AF-alb adducts 
were detected in nearly all of Gambian child and adult sera with levels up to 350 
picogram AFB1-lysine equivalent per milligram albumin (350 pg/mg). On the other 
hand, no adducts were detected in sera from Poland and France. AF-alb adducts were 
also detected in sera samples from Senegal, Kenya, Uganda and Thailand although at 
lower levels than in The Gambia (Wild et al. 1990a). These results indicated that 
AFB1 exposure is higher in regions where liver cancer incidence is reported to be 
higher but is also suggestive of the varied dietary staples in these different 
geographical locations (Wild et al. 1990a).  
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1.1.7.1.1 Cohort studies on AFB1 exposure  
HBsAg surface markers and urinary AFB1-N
7
-Gua adduct levels were compared 
with liver cancer incidence in 983 subjects from districts in the Central, Eastern and 
Western provinces in Kenya and found to vary over region (Autrup et al. 1987). 
Interestingly, in this study, multiplicative and additive analyses did not reveal any 
synergistic association between aflatoxin exposure and HBV infection status.  Also, 
while aflatoxin exposure was not significantly associated with liver cancer incidence, 
there was an association between them only when considering the Bantu ethnic 
group. This suggested potential differences in diet or an existing genetic 
predisposition in these people (Autrup et al. 1987).  
Wang et al. conducted a cohort study based in seven townships of Taiwan with a 
total of 12,024 males and 13,594 females being recruited. Serum samples were 
assayed for HBsAg antigen and HCV infection and participants were monitored for 
HCC development. Fifty-six HCC cases were identified and 220 controls were 
matched for age, sex and township. Aflatoxin metabolites including AF-alb, B1, B2, 
G1, G2 and P1 were measured in blood and urine samples. It was found that the odds 
ratio for liver cancer corresponding to AF-alb adducts was 4.6 (95% CI: 2.0-10) 
before adjustment for HBsAg and 1.6 (95% CI: 0.4-5.5) after adjustment. 
Additionally, for the high aflatoxin metabolite levels, the odds ratio was 3.3 (95% CI: 
1.4-7.7) before adjustment for HBsAg and 3.8 (95% CI: 1.1-13) after adjustment. 
Interestingly, among HBsAg-negative subjects, there was little or no effect of 
aflatoxin biomarkers on HCC. However, in HBsAg-positive subjects, there was quite 
a strong effect.  
In another cohort study on 357 adults based in The Gambia, plasma AF-alb levels 
analysed by a competitive ELISA, were found to vary by region and season (Wild et 
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al. 2000). People residing in rural regions had 1.5-fold higher AF-alb levels than 
those living in urban regions. Also, AF-alb levels were approximately twice as high 
in the dry season compared to the rainy season potentially due to consumption of 
stored grains with accumulated aflatoxin contamination during the dry season. 
However, this study also failed to find any association between HBV infection status 
and aflatoxin exposure. Additionally, different genotypes of GSTs were not found to 
influence AF-alb exposure (Wild et al. 2000).  
In contrast, when Turner et al. analysed samples from 444 Gambian children, a 
strong association between plasma AF-alb levels and HBV infection status was 
observed with levels averaging among uninfected children at 31.6 pg/mg, chronic 
carriers at 44.9 pg/mg and acutely infected children at 96.9 pg/mg. A seasonal 
variation in plasma AF-alb levels did exist with exposure being twice as high during 
the dry season compared to the rainy season. Also, there were no differences in 
aflatoxin exposure within the ethnic groups involved in the study (Turner et al. 
2000).  
 
1.1.7.1.2 Case-control studies associating AFB1 exposure with liver cancer risk 
In a small case-control study based in different regions in Thailand, 65 HCC cases 
and 65 controls matched for age, sex and residence were recruited. Aflatoxin 
metabolite levels in urine and AF-alb adduct levels in blood were measured and were 
not found to vary by region and were not different between cases and controls 
(Srivatanakul et al. 1991).  
Mandishona et al. (Mandishona et al. 1998) carried out a small case-control study in 
South Africa with the aim to determine the role of dietary iron in the aetiology of 
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HCC. However, they also measured AF-alb adducts in 24 cases with two control 
series. One set of 48 controls were matched for age, sex and ethnicity while the 
second set of 75 controls consisted of relatives and family members. In addition, 
HBsAg antigen levels and HCV infection status were determined. It was found that 
the median of AF-alb levels was lower in cases than in both sets of controls while 
HBsAg levels were higher in cases than in controls (Mandishona et al. 1998). The 
discrepancy in these results may have been due to the comparison of medians in 
groups, which may not reflect the numbers of samples with high exposure values per 
group.  
Besides plasma biomarkers, urinary AFM1 levels, analysed in 43 HCC cases 
compared to 86 matched controls in a study based in Taiwan, were found to have a 
dose-dependent association to the risk of HCC development in chronic HBV carriers 
(Yu et al. 1997) providing more evidence for an association between AFB1 and HBV 
infection in the development of HCC. Additionally, urinary AFB1-N
7
-Gua adduct 
levels and HBV infection status were strongly associated with higher risk of HCC 
development. With an odds ratio (OR) of 10.0 (95% confidence intervals (95% CI) = 
1.6, 60.9) people with both detectable AFB1-N
7
-Gua adducts and plasma AF-alb 
levels were at a very high risk of HCC development (Yu et al. 1997).   
However, these case-control studies have relatively small sample sizes and may have 
other confounding factors including HCV infections status, ethnicity and village. 
Therefore, the association between AFB1 exposure, HBV infection and liver cancer 
risk would need to be reanalysed in larger studies. 
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1.1.7.1.3 p53 mutation as a mechanism of AFB1-associated liver carcinogenesis 
An insight into the potential mechanisms of these interactions was provided by Chen 
et al, in a study analysing AF-alb adduct levels in newly diagnosed HCC patients and 
matched controls all of whom were HBsAg carriers. A significant association 
between AFB1 exposure and HCC in HBsAg carriers was only observed if the 
patients with null GST M1 and T1 genotypes, while this was not observed in patients 
with non-null genotypes. The study concluded that HBsAg surface antigen positive 
people with high AFB1 exposure and no GST M1 and T1 detoxification enzymes 
were at 10 times increased risk of developing HCC (Chen et al. 1996a).  
The p53 gene is mutated in more than half of all human cancers and over 70% of 
mutations are missense resulting in mutant proteins. Due to the large number of 
missense mutations in p53 than in other tumour suppressor genes, it has been 
suggested that the p53 mutations confer a selective advantage in carcinogenesis 
(Hussain and Harris 1998). Indeed, p53 mutations are thought to encourage the 
clonal expansion of pre-neoplastic and neoplastic cells particularly in livers 
chronically infected with HBV (Harris 1996). It has been observed that when p53-
deficient Hep3B cells were transfected with mutant p53-249ser, the survival and 
mitosis rates increased significantly compared to non-transfected cells. However, the 
tumourigenic potential of the mutant cell line was not unequivocally determined due 
to conflicting results (Ponchel et al. 1994). 
A specific G -> T transversion in codon 249 of the p53 gene has been suggested to 
be the mechanism of aflatoxin-associated HCC. However, the vast majority of the 
studies showing a link between the p53 mutation and aflatoxin exposure have not 
directly measured exposure instead relying on aflatoxin levels in food, food intake 
frequency and geographic residence information (Lasky and Magder 1997). 
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Therefore, the majority of the evidence does not strongly support the specific p53 
mutation as the mechanism of AFB1-induced carcinogenesis.  
A transgenic mouse model with a p53ser246 mutation, equivalent to the human 
p53ser249, was generated and used to determine the mechanism of AFB1-induced 
HCC. In AFB1 treated mice, the lowest incidence of tumours were observed in wild 
type mice negative for HBsAg. A higher percentage of tumours was found in 
heterozygous mice negative for HBsAg and the highest percentage of tumours were 
detected in HBsAg-positive mice homozygous for the p53 mutation. These results 
were suggestive of an important role for the mutant p53 protein in the co-
carcinogenesis of AFB1 and HBV infection (Ghebranious and Sell 1998).  
Another animal model to further explore the mechanism of AFB1-associated HCC 
made use of the Hupki mouse, which is a human p53 gene knock-in mouse. These 
mice were treated with AFB1 and followed for 80 weeks after which it was observed 
that HCC developed in 44% of the Hupki mice compared to only 19% of control 
mice. Interestingly, examination of the liver tumours and normal surrounding tissue 
did not find any mutations in the p53 gene (Tong et al. 2006). However, it is possible 
that the mutation was not detected due to the lack of expression of HBV antigens, 
which may play an important role in AFB1-induced carcinogenesis (Wild and 
Montesano 2009).  
A potential role for the p53 mutation in the interaction between AFB1 and HBV 
infection in HCC development has been disputed by Stern et al., who besides 
determining p53 mutation incidence in HCC patients from southern Guangxi, China, 
also conducted a meta-analysis of 48 studies. While their study found that 36% of 
patients carried the p53 249
ser
 mutation, the meta-analysis observed a strong 
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correlation between the p53 249
ser
 mutation and AFB1 exposure but no association 
with HBV status (Stern et al. 2001).  
Interestingly, significant adduct formation was observed in HepG2 cells exposed to 
AFB1 that were metabolically activated by rat liver microsomes. While the single 
base mutation in codon 249 was detected, mutations in other codons including 244, 
245 and 248 were also observed, in some cases at a higher frequency (Denissenko et 
al. 1998).  This suggests that a mutation in codon 249 in p53 may not be specific 
with potentially other mutations and mechanisms at play in hepatocarcinogenesis.  
In a retrospective study based in Qidong, China, only 2 of 234 plasma samples from 
HBsAg carriers were positive for the p53 mutation in codon 249. However, neither 
patient went on to develop HCC. Also, while 67% of the subjects were positive for 
AF-alb biomarkers, the levels were low and equally distributed among cases and 
controls. The p53 mutation was detected in 61% of HCC tumours suggesting that 
tumours containing the mutation can occur in the absence of recent exposure to high 
levels of AFB1 (Szymañska et al. 2009). The fact that the p53 mutation was detected 
in tumours despite the overall low AFB1 exposure in this population suggests either 
that previous higher exposure may have initiated the carcinogenesis process leading 
to the mutation and tumour development, or that the complete picture of the 
mechanistic action of AFB1 in the development of HCC is still lacking.  
 
1.1.7.2 Epigenetics: Role in cancer prediction, diagnosis and 
prognosis 
In 1939, Conrad Waddington introduced the concept of epigenetics to explain the 
relation between genetics and development biology (Holliday 2006). He described 
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the ‘epigenotype’ as being a complex of developmental processes, linked in a 
network, which exists between the genotype and the phenotype. He also suggested 
that early disruptions to these processes could slowly lead to greater changes in 
different tissues (Waddington 2012). Eventually, epigenetic alterations were defined 
as heritable changes in gene expression that do not alter the actual DNA sequence. 
These changes result in patterns, which can be inherited mitotically and/or 
meiotically and include DNA methylation and histone methylation and acetylation 
(Holliday 2006). 
One of the most studied epigenetic changes is the methylation of cytosine in CpG 
islands, which usually overlap with the promoter regions of several genes (Esteller 
2008). Hypermethylation of a gene promoter region typically results in 
transcriptional inactivation while the opposite is true of hypomethylation. In normal 
cells, repetitive sequences are hypermethylated to avoid chromosomal instability and 
reactivation of transposable genomic sequences (Esteller 2008). DNA 
methyltransferases (DNMTs) are responsible for de novo methylation in previously 
unmethylated regions but also for maintaining pre-existing methylation during DNA 
replication (Klose and Bird 2006).   
In addition to DNA methylation, changes to histone profiles can also affect gene 
expression. Acetylation, methylation and phosphorylation at specific positions in 
histone residues either activate or inactivate gene transcription depending on the 
residue where the change occurs (Esteller 2008). For instance, methylation of H3 
lysine 4 is associated with transcriptional activation while methylation of H3 lysine 9 
is associated with repression (Bernstein et al. 2007). As lysine methylation can be 
monomeric, dimeric or trimeric and as histones can also undergo other 
posttranslational modifications, there are numerous combinations of histone 
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modifications potentially constituting a ‘histone code’, which can be read into 
biological functions (Jenuwein and Allis 2001). Additionally, histone modifications 
are now known to interact with DNA methylation (Egger et al. 2004) adding another 
layer of complexity to the epigenetic regulation of gene expression. 
Genomic imprinting is another epigenetic mechanism to distinguish between 
maternal and paternal alleles of a gene (Feinberg et al. 2002). It is the preferential 
expression of a specific parental allele in somatic cells through hypermethylation of 
one parental allele. It is also important in the reduction of gene dosage in X 
chromosome inactivation in female mammals (Feinberg et al. 2002).    
Environmental carcinogens not only alter gene expression through mutations but 
also through reversible epigenetic events (Jones and Baylin 2007). As a 
consequence, a number of studies are now focussing on identifying markers of gene 
expression and epigenetic changes due to carcinogen exposure leading to eventual 
cancer development (Andrew et al. 2008; Liu et al. 2009; Lu et al. 2006; Chen et al. 
2003; Couvert et al. 2008). The specific gene expression and epigenetic profiles 
generated as a result can be used to predict cancer development and prognosis thus 
enabling certain preventive and protective measures to be put into place. These 
profiles are especially significant since epigenetic changes are potentially reversible. 
Some characteristic epigenetic changes have been discovered in aflatoxin-related 
HCC, which are potential markers of cancer development. In a series of studies, 
Zhang et al. attempted to identify methylation changes in specific tumour suppressor 
genes in tumour tissues from HCC patients. Hypermethylation of the promoter 
regions of RASSF1A, p16 and O
6
-methylguanine-DNA methyltransferase (MGMT) 
were detected in 85%, 47% and 39% of tumour tissues, respectively. The 
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methylation status of all three genes was also significantly linked to AFB1-DNA 
adducts in the tumour tissues (Zhang et al. 2002; Zhang et al. 2003). They also 
correlated AF-alb adducts in plasma with AFB1-DNA adduct levels in tumours 
before finding an association between p16 hypermethylation and AF-alb adduct 
levels in the plasma of HCC patients, which upon further validation could possibly 
be used as a marker for development of HCC (Zhang et al. 2006). Hypermethylation 
in the promoter region of p16 is a commonly observed epigenetic change in cancer 
patients detectable both in tumour tissues as well as in the plasma (Nakahara et al. 
2006; Wong et al. 1999). However, one study failed to find a direct biological 
influence with relation to cell cycle regulation in multiple myeloma. This was 
because it was determined that methylation in the promoter region mostly occurred 
in non-crucial regions and thus did not affect gene expression. For this purpose, p16 
methylation has been suggested as a marker of overall epigenetic changes during 
myeloma disease progression (Gonzalez-Paz et al. 2007). 
Another epigenetic change in HCC patients as a result of AFB1 exposure is the 
hypermethylation of the promoter region of the glutathione S-transferase P1 (GSTP1) 
gene that codes for the detoxifying GSTs. This hypermethylation has also been 
significantly associated with AFB1-DNA adducts in HCC tumour tissue (Zhang et al. 
2005). Furthermore, reduced expression of the GSTP1 gene was observed in 
aflatoxin-exposed tree shrews that developed HCC (Li et al. 2008).  
Zhao et al. demonstrated that AFB1 induced demethylation of synuclein-gamma 
(SNCG) in the HCC cell line, HepG2, which was treated with 1 µM (~0.3 ng/ml) 
AFB1 for 1 or 3 days. It was also shown that SNCG was demethylated in the early 
stages of HCC and the SNCG protein was highly expressed in the later stages of the 
cancer (Zhao et al. 2006). Altered gene expression of SNCG through demethylation 
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has also been observed in the advanced stages of gastric cancer and has been 
suggested to be a proto-oncogene (Yanagawa et al. 2004). 
Human populations chronically exposed to aflatoxins may exhibit similar alterations 
to gene expression and methylation patterns affecting genes linked to cancer 
development. When discovered and validated, these changes could serve as 
predictive, diagnostic and prognostic markers of aflatoxin exposure-induced liver 
carcinogenesis. A model designed by Farazi and DePinho shows the different factors 
thought to contribute to hepatocarcinogenesis and has been modified in Figure 3.   
 
 
Figure 3: Model depicting the mechanisms of HCC development through exposures to 
AFB1 and HBV/HCV. Exposures can induce epigenetic and genetic changes that can 
eventually lead to HCC development. Modified from (Farazi and Depinho 2006). 
 
  
35 
 
1.1.7.3 Identifying mechanistic markers of gene expression and 
epigenetic alterations 
Gene expression and epigenetic markers can be utilised for three main applications: 
prediction, diagnosis and prognosis of cancer (Simon 2003).  These markers are 
important for elucidating the effects of childhood carcinogenic exposure due to the 
prospect of reversing or modulating the effects of the carcinogen.  
The advent of microarrays has enabled us to identify differences in gene expression 
in tumours versus normal tissue and within tumour subtypes. In fact, it is possible to 
use gene expression profiles generated using microarray technology to determine the 
mechanism of action of various toxins. Indeed, by developing such profiles, Waring 
et al were able to group together different hepatotoxins based on their mode of 
toxicity (Waring et al. 2001). This approach was also used by Thomas et al. enabling 
them to classify 24 different treatments in mice based on the mRNA expression 
profiles examined using custom cDNA microarrays  (Thomas et al. 2001). 
A number of concerns have been put forward about the reliability of microarrays in 
discovering robust and stable disease markers owing to dissimilarities in gene 
expression profiles generated for the same tumours in different studies. However, it 
has been shown that even though there are few overlapping altered genes in similar 
microarray experiments, the different gene expression profiles generated reveal the 
same information about disease diagnosis and prognosis (Sotiriou and Piccart 2007). 
This was observed by Fan et al. who attempted to compare different gene expression 
models for breast cancer prediction and prognosis on a single data set of 295 
patients. Four of the five sets of gene expression profiles identified in different 
studies were significantly similar in the prediction of the outcome in this data set 
  
36 
 
proving that concordance exists among gene expression profiles generated by 
different studies (Fan et al. 2006).  
A number of methods including bisulfite sequencing, pyrosequencing, chromatin 
immunoprecipitation (ChIP) and genome-wide methylation arrays have been 
developed for the identification of epigenetic changes (Ho and Tang 2007). Due to 
the relatively limited information obtained from methylation studies focussing on 
single genes of interest (GOI), the spotlight is slowly shifting to genome-wide 
studies. A few methods have been developed to determine the methylation status of 
the entire genome through the use of enzymes and antibodies that detect methylated 
portions of the genome (Esteller 2007). One such method is Restriction Landmark 
Genome Scanning (RLGS), through which DNA is first cut by restriction enzymes 
that are methylation-sensitive and is then labelled with a radioactive isotope. These 
DNA fragments are then run on a 2-dimensional gel and differences in spots and 
patterns are compared between different treatment groups on an autoradiogram 
(Kawai et al. 1993). Using RLGS with Notl, which selectively recognises 
unmethylated DNA, Yaoi et al were able to identify 48 spots showing altered 
methylation following bisphenol A exposure in murine forebrains (Yaoi et al. 2008).   
Illumina’s Infinium technology has made it possible to investigate DNA methylation 
levels at a single nucleotide resolution. The Illumina Infinium 27K bead chip array, 
which studied methylation in 27, 578 CpG sites, has been used to determine 
methylation patterns in several cancers (Teschendorff et al. 2010; Fackler et al. 
2011; Rodriguez et al. 2012). This array was improved upon to produce the Infinium 
450K bead chip array, which interrogates more than 485, 000 CpG loci. These sites 
cover about 99% of the genome with an average 17 CpG sites per gene. Besides CpG 
islands, the array also covers island shores and surrounding regions (Dedeurwaerder 
  
37 
 
et al. 2011a; Zhang et al. 2012). These assays enable a comprehensive examination 
of DNA methylation patterns as a result of environmental exposures.  
For instance, using the Illumina Infinium 27K methylation bead chip array, Wang et 
al. were able to identify an association between hypomethylation of thymic stromal 
lymphopoietin (TSLP) with high cord blood cotinine levels, representing prenatal 
smoke exposure, in 14 Taiwanese children. Methylation status of TSLP was further 
associated with prenatal smoke exposure as well as atopic disorder (AD) in 150 
Taiwanese children who were followed up for 2 years. Altered methylation was 
successfully validated using methylation-dependent fragment separation (MDFS) 
(Wang et al. 2013).    
Differences in environmental exposures due to location can also affect DNA 
methylation patterns as has been observed in a study based in the Czech Republic. 
Benzo[a]pyrene (B[a]P) concentrations measured by the Czech Hydrometeorological 
Institute were compared with whole genome DNA methylation using the Infinium 
27K array in Ostrava, which is highly polluted and in Prachatice, which was treated 
as a control. Hypomethylation of more than 10% was observed in 58 individual CpG 
sites in genes involved in the immune response, signalling and metabolism in people 
living in Ostrava than in Prachatice (Rossnerova et al. 2013).  
Investigating the mechanism of in utero exposure to smoking, Joubert et al. used the 
Infinium 450K array to examine changes to the methylome following birth. Maternal 
plasma cotinine levels were significantly associated with differential methylation in 
26 CpG sites in 10 genes. One of the genes identified, AHRR, has also been observed 
to be differentially methylated in adult smokers versus non-smokers. Another gene, 
GFI1, which is involved in developmental processes, had not been previously 
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implicated in response to smoking and therefore was a novel finding of the study 
(Joubert et al. 2012).  
The Illumina Infinium 450K array together with the Illumina Human HT12 v.4 were 
used to examine the influence of arsenic exposure in adult Argentinian Andean 
women and in new born Bangladeshi infants. Eight single nucleotide polymorphisms 
(SNPs) in arsenic methyltransferase (AS3MT), seen specifically in people living in 
the Argentinian Andean region, increase arsenic metabolism. While this haplotype 
does exist in the Bangladeshi population, it is present at a much lower frequency. 
The study determined that the AS3MT haplotype status strongly predicted DNA 
methylation and gene expression of AS3MT as well as a number of neighbouring 
genes, thus potentially novel genes involved in arsenic metabolism (Engström et al. 
2013).  
Advances in technology have produced myriad techniques available for the 
identification and validation of unique markers of environmental exposures on health 
effects. These techniques can be utilised effectively to contribute to our 
understanding of the mechanisms involved in AFB1-assocaited health effects. 
Careful investigation into the results of whole genome examinations as a result of 
early life exposures can potentially be used to prevent certain adverse health 
outcomes in later life.  
 
1.1.8 Child growth and development 
It has been estimated that in 2008, the number of children under 5 years of age that 
died was 8.8 million. Of these, nearly half of the deaths occurred in India, Pakistan, 
China, Nigeria and the Democratic Republic of Congo (Black et al. 2010). The 
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number of child deaths in Africa was more than 20-fold the number of deaths 
recorded in Europe and USA. Diarrhoea and infectious diseases were the major 
contributors to child mortality in Africa and Asia while non-communicable diseases 
were the main concern in developed regions (Black et al. 2010). Additionally, 
stunting, severe wasting, under nutrition, vitamin A and zinc deficiencies have been 
recognised as the underlying causes of a third of the deaths of children under 5 years 
(Black et al. 2008).  
While death is usually the final outcome of consistent insults to child development, it 
has also been suggested that more than 200 million children under 5 years from low 
income regions do not attain their full developmental potential as a result of 
undernutrition and nutritional deficiencies, poverty, infectious diseases and 
environmental exposures usually occurring concurrently (Walker et al. 2007). Nearly 
37% children in developing countries are estimated to live in poverty, which has 
been identified as the main contributor to poor nutrition and sanitation and can make 
a child prone to stunting and infections (Grantham-Mcgregor et al. 2007). 
Consequently, nearly 30-40% of children under 5 years are stunted in sub-Saharan 
African, South-East and South-Central Asian countries (De Onis and Blössner 
2003). 
Several intervention trials, using either single or multi nutritional supplementation, 
have reported a lower incidence of stunting in children (Chhagan et al. 2009; 
Remans et al. 2011; Umeta et al. 2000). However, these trials only recover a fraction 
of the growth potential in children suggesting that other factors besides nutritional 
deficiencies play an important role in child stunting.  
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1.1.9 AFB1 exposure and effects on growth   
One of the first observations of the effect of AFB1 on growth in animals was 
reported by Butler and Barnes in 1963 (Butler and Barnes 1963). In this study, rats 
were fed groundnut meal that had been shown to be either toxic or non-toxic to 
ducklings. One group of rats was given 50% toxic meal continuously while another 
was given 50% non-toxic meal and a third group was given 50% toxic meal for 16 
weeks followed by normal diet for a total of 36 weeks. Rats in the first group had 
slower growth rates compared to the rats in the second group. Also, growth rates 
improved in the third group of rats after around 4 weeks following a change in diet 
although the growth never reached the same level as the rats in the non-toxic meal 
group (Butler and Barnes 1963).  
In another early study using known concentrations of AFB1, 10-day old ducklings 
and weanling rats were fed doses of 60 and 600 µg/Kg/day respectively for 5 
consecutive days. Following the treatment, which represented 10-12% of the LD50 
dose, it was observed that weight gain and liver size were drastically reduced in 
treated animals compared to controls (Shank and Wogan 1966).  
Specific doses of AFB1 were found to either have no effect or cause reduced weight 
gain as was observed in weanling pigs and cattle (Keyl et al. 1970). When meals 
containing up to 233 ppb AFB1 for pigs and 300 ppb AFB1 for cattle for 120-130 
days were fed to animals, no change in weight gain was seen compared to controls. 
However, when given meal containing more than 465 ppb AFB1 for pigs and 700 
ppb AFB1 for cattle, weight gain was significantly reduced in treated animals (Keyl 
et al. 1970). Significant effects on growth were observed in broiler breeder hens 
exposed to dietary AFB1 at 5 µg/g and 10 µg/g for four weeks. Egg hatchability and 
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weights were significantly lower in hens treated with the higher dose of AFB1 and 
chicks born of these hens were considerably lighter (Howarth and Wyatt 1976).  
Interestingly, it was observed that when pregnant rats were administered AFB1 at a 
dose that was ¼ of the LD50, the effects on the rats and their foetuses depended on 
time of treatment. When given on day 6 of pregnancy, the effects on the mothers 
were similar to non-pregnant rats and there were no significant effects on the 
foetuses in terms of growth. However, when AFB1 was given on Day 16 of 
pregnancy, more severe effects on the livers were observed in the mothers and the 
foetuses were significantly stunted compared to controls. It was also suggested that 
the observed stunting was secondary to the effects of AFB1 on the maternal livers as 
at certain AFB1 doses, stunting was not seen in foetuses when liver lesions were not 
present in mothers (Butler and Wigglesworth 1966).  
Growth retardation in foetuses was observed in hamsters given either 4 mg/kg or 6 
mg/kg on days 8 or 9 of gestation. The foetuses were examined on days 11 or 15 
following gestation and the observed stunting was most striking on day 15 in 
hamsters given either dose of AFB1 on day 9 of gestation compared to those 
observed on day 11, suggesting that a single dose of AFB1 at a time point in 
pregnancy can affect foetal growth and can continue to have an effect as pregnancy 
progresses (Schmidt and Panciera 1980). These initial studies suggest that AFB1 
plays a key role in growth and development of foetuses throughout pregnancy but is 
potentially more significant towards the later stages.  
Early work studying humans have also observed similar effects on growth associated 
with AFB1 exposure. Examination of 125 Kenyan pregnant women found that 53% 
of the women and 37% of cord bloods were positive for aflatoxins as ascertained by 
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analysis using fluorescence HPLC, which can detect AFB1, B2, M1, M2, G1, G2 and 
aflatoxicol. Among females, infants born to aflatoxin-positive mothers were 
significantly lighter than infants born to aflatoxin-negative mothers. However, male 
infants born to aflatoxin-positive mothers showed an increase in weight compared to 
those born to aflatoxin-negative mothers, although this was not found to be 
significant. This discrepancy could be attributed to the much smaller sample size for 
male infants from aflatoxin-positive mothers compared to all other groups (Vries et 
al. 1989).   
Gong et al (Gong et al. 2002; Gong et al. 2003) confirmed the potentially adverse 
effect of dietary AFB1 exposure on growth in children from Benin and Togo. The 
study included 480 children aged 9 months to 5 years belonging to different 
geographical zones. AF-alb levels were measured using the competitive ELISA 
described by Chapot et al (Chapot and Wild 1991) and were detected in 99% of the 
samples. Children with stunting and who were underweight had 30-40% higher AF-
alb adducts than those in the control group. Additionally, maize consumption as 
ascertained by detailed dietary questionnaires was associated with AFB1 exposure in 
these children (Gong et al. 2003; Gong et al. 2002). The higher AF-alb levels were 
also associated with increased A. flavus infestation in maize, higher levels of 
aflatoxins in maize and greater consumption of maize (Egal et al. 2005). However, 
micronutrient deficiency and HBV infection status were not determined and could 
potentially be confounders to the observed association between AFB1 exposure and 
growth impairment.  
These findings were analysed further with a longitudinal study over 8 months in 
Benin involving 200 children aged 16-37 months recruited from villages of either 
high or low aflatoxin exposure (Gong et al. 2004). AF-alb levels measured using 
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ELISA were detected in nearly all samples studied at three time points and were 
higher in fully weaned children compared to partially breast-fed children. The main 
weaning food was a maize-based porridge, which was the potential source of the 
exposure. Also, children belonging to the highest quartile of AFB1 exposure had a 
mean 1.7 cm reduction in height compared to children in the lowest AFB1 quartile. 
Moreover, no association was observed between AF-alb levels and vitamin A and 
zinc levels in plasma suggesting that these nutrients do not have a confounding effect 
on the association between AFB1 exposure and growth (Gong et al. 2004). While 
some micronutrient levels were measured, total energy intake and levels of other 
important micronutrients were not measured and could be confounding factors in the 
study. Additionally, HBV or HCV infection status were not determined.  
Higher maternal AFB1 exposure determined through measurement of AF-alb levels 
was significantly associated with infant birth and height gain providing evidence for 
the in utero effects of AFB1 on foetal development (Turner et al. 2007). In this 
study, maternal blood was collected at two time points during pregnancy and 138 
infants were followed for 1 year following birth. AF-alb levels were detected in all 
maternal samples, approximately half of cord blood samples and in a few infant 
samples. This is consistent with the in utero exposure through the maternal diet and 
also with the lower exposure in infants during breast-feeding. Interestingly, in this 
cohort, it has been predicted that for a 6 month old female infant with medium 
height-for-age Z score (HAZ), if the maternal exposure was reduced from 110 to 10 
pg/mg, the corresponding height would increase by 0.8 cm (Turner et al. 2007). 
However, socio-economic status, which can have a strong impact on diet and 
micronutrient levels were not assessed for this population and therefore could be 
confounders. 
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Although aflatoxin biomarkers were not analysed by Okoth and Ohingo, a 
significant association between wasting in Kenyan children aged 3-36 months and 
aflatoxin-contaminated flour was observed. However, wasting was only observed in 
6% of the 242 children studied making it a very small sample size of about 14 
children (Okoth and Ohingo 2004).   
 
1.1.9.1 Mechanisms of growth impairment 
Growth faltering in children in developing regions is a common phenomenon with 
malnutrition being frequently implicated as the major cause (Goulet 2010). However, 
strategies to supplement children with essential nutrients have failed to allow normal 
expected growth in some children (Chhagan et al. 2009). This has led to other 
theories being put forward including a role for infections in child stunting, which can 
result in micronutrient deficiency or nutrient malabsorption (Stephensen 1999). 
Diarrhoea has also been implicated in growth faltering with the odds of stunting 
increasing by 1.13 (95% CI = 1.07, 1.19) for every diarrhoeal episode (Checkley et 
al. 2008). Enteropathy leading to an inefficient intestinal nutrient transport could 
also consequently cause growth impairment (Campbell et al. 2003).  
Other mycotoxins have been found to have an effect on nutrient transport and 
intestinal function. Ochratoxin A, which is a mycotoxin also produced by 
Aspergillus species, was observed to disrupt glucose transport in a human colon 
carcinoma caco-2 cell line. The results of the study further suggested that ochratoxin 
A may enhance its own absorption through a paracellular route by destabilising the 
tight junctions of the monolayer (Maresca et al. 2001). In another study, the effects 
on nutrient transport of deoxynivalenol (DON) were studied using another human 
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intestinal cell line, HT-29-D4 and it was found that DON inhibited the uptake of 
glucose, fructose and L-serine in these cells (Maresca et al. 2002). Treatment with 
AFB1 significantly compromised integrity of the intestinal barrier, which is an 
important defence against pathogens and toxins (Gratz et al. 2007). This effect was 
observed to be time-dependent. Co-incubation with Lactobacillus rhamnosus GG 
strain, present in probiotic yoghurt, appeared to alleviate some of this disruption 
(Gratz et al. 2007). Therefore, lack of access to certain food items together with 
chronic AFB1 exposure may explain a part of the mechanism of AFB1-associated 
growth impairment.  
However, although a strong association between dietary AFB1 exposure and child 
growth impairment has been observed in several studies based in Africa, the 
complete mechanisms remain unclear.  
Infants with intrauterine growth restriction, described as having a birth weight below 
the 5-10
th
 percentile following gestation, are known to have a substantially increased 
risk of morbidity and mortality compared with infants having higher birth weights 
(Aucott et al. 2004). Incidence of low birth weight is high in developing countries 
and has been attributed to intrauterine growth restriction rather than preterm births 
(Kramer 2003).  
Infections and environmental exposures during gestation have been identified as 
being the potential causative agents of intrauterine growth restriction. For instance, 
exposure to organophosphorous insecticides either in utero or after birth was 
significantly associated with intrauterine growth restriction with an adjusted odds 
ratio of 2.3 (95% CI = 1.0, 5.3) (Levario-Carrillo et al. 2004). Also, in a prospective 
cohort study examining 1,578 mother-child pairs, gestational arsenic exposure up to 
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100 µg/L measured in urine was significantly associated with lower birth weight and 
head and chest circumferences such that a 1 µg/L increase in arsenic levels in urine 
was associated with 1.68 g reduction in birth weight (Rahman et al. 2009). 
Intrauterine growth restriction has also been attributed to maternal smoking during 
pregnancy in Brazilian mother-child pairs with an odds ratio of 2.07 (95% CI = 1.69, 
2.53) (Horta et al. 1997) 
A number of studies have attempted the identification of mechanistic associations 
between exposures and a growth restricted outcome. It has been observed that the 
expression of CYP1A1 and CYP2E1 genes was significantly higher in maternal liver 
microsomes and placenta samples of rats exposed to nicotine during pregnancy. 
Also, the nicotine exposure was strongly linked to lower birth weights of the 
foetuses. The study suggests that increased expression of the CYP genes leads to 
increased oxidative stress and lipid peroxidation (Wang et al. 2009), which in turn 
have been associated with intrauterine growth restriction (Elsayed 2001). In women 
homozygous for the A1 allele in the CYP17 gene, increased foetal restriction was 
observed compared to women who had an A2 allele. Additionally, increased foetal 
retardation was seen in women with the GSTM1 (glutathione-S-transferase M1) null 
genotype compared to women who carried the GSTM1 gene (Yamada et al. 2004). 
While the presence of the A2 allele in CYP17 had been associated with increased 
oestrogen, which in turn has been linked to placental growth (Bukovsky et al. 2003), 
GSTM1 is involved in the detoxification of xenobiotic molecules including aflatoxin 
(Mcglynn et al. 1995).  
A similar mechanism may be at play in aflatoxin-associated growth impairment 
although polymorphisms in important carcinogen-activating and -deactivating genes 
may be the result of natural individual genetic variability. However, these 
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differences would alter susceptibility to growth impairing agents such as aflatoxin 
and thus set the stage for the actual mechanism of aflatoxin-induced growth 
retardation.    
One hypothesis for the mechanism of aflatoxin-associated growth restriction 
suggests that AFB1 alters the insulin-like growth factor (IGF) pathway thus affecting 
growth and development. IGF1 is a mediator of the growth hormone (GH) and is 
also involved in embryonic development although the latter function is independent 
of GH activity while IGF2 is the main hormone involved in prenatal growth (Baker 
et al. 1993). The effects of the IGFs are mediated by activation via the IGF1 receptor 
(IGF1R), which is a transmembrane tyrosine kinase and plays a major role in foetal 
growth (Adams et al. 2000). The bioactivity and availability of the IGFs are 
regulated by a family of six binding proteins (IGFBPs), which prolong the half-life 
of IGFs in the system but can also work independently of IGFs as growth factors 
(Mohan and Baylink 2002).  
It has been observed that serum IGF1 levels are markedly lower in infants with 
intrauterine growth restriction compared to controls. Although IGF1 levels increase 
significantly during pregnancy, the actual values at both the second as well as the 
third trimesters were reduced in growth restricted children compared to controls. 
However, no difference was seen in IGF2, IGFBP3 and GH levels between the two 
groups (Leger et al. 1996). In another study, elevated levels of serum IGFBP2 and 
IGFBP4 were observed in guinea pig foetuses with growth restriction while IGFBP3 
levels were much lower compared to controls and there were no changes in IGF1 and 
IGF2 mRNA expression in growth restricted guinea pigs (Carter et al. 2005).  
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Exposures during pregnancy can alter foetal development including growth, which 
can manifest through an altered IGF growth axis (Figure 4). In fact, elevated serum 
IGFBP1 and IGFBP2 levels were observed in sheep exposed to testosterone during 
pregnancy and were linked to growth restriction in the foetuses (Manikkam et al. 
2004), which may be part of the mechanism through which testosterone can affect 
foetal growth. In another study, while all selective serotonin reuptake inhibitors 
(SSRIs) administered during pregnancy were associated with lower birth weight and 
length, only infants born to mothers exposed to citalopram had significantly lower 
cord blood IGF1 levels compared to the other SSRI groups and controls (Davidson et 
al. 2009). 
DON is another mycotoxin that has been identified as a causative agent in reduced 
weight gain in several animal species (Pestka 2007). It has been suggested that DON 
induces this growth suppression through a disrupted IGF axis. Reduced mRNA 
expression of the IGF-acid labile subunit (IGFALS), which forms a part of the IGF1-
IGFBP3-IGFALS binding complex, was observed in mice chronically exposed to 
DON over a period of 8 weeks. The mice also showed reduced weight gain and had 
lower circulating plasma IGF 1 levels compared to controls (Amuzie and Pestka 
2010). These effects were confirmed in another study where mice fed on high fat 
diets had lower weight gain and significantly reduced plasma IGF1 and IGFALS 
levels compared to controls (Kobayashi‐Hattori et al. 2011).  
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Figure 4: Model depicting the hypothesis that AFB1 exposure alters growth through 
disruption of the IGF growth axis. Growth hormone, produced by the pituitary gland, 
signals the production of IGF1 in the liver as well as other tissues, through the growth 
hormone receptor (GHR). IGF1 bioavailability is modulated through binding factors 
including IGFBP3, forming a complex with an acid labile subunit (ALS). Both IGF1 and 
IGF2 exert their growth promoting potential through binding with the IGF1-receptor 
(IGF1R). Dietary AFB1 may inhibit the growth promoting process at several stages 
(represented by the red, dashed lines).  
 
Microarray experiments comparing placentas of intra-uterine growth restricted 
pregnancies and normal placentas have revealed differential expression in growth 
suppression. Increased expression of leptin, vascular endothelial growth factor 
receptor (VEGF-R), human chorionic gonadotropin (HCG), follistatin-like 3 and 
hypoxia-inducible factor 2α (HIF-2α) was observed in growth restricted placentas 
suggesting that hypoxia may have a role to play in placental growth (Mccarthy et al. 
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2007). Elevated expression of follistatin-like 3 as well as IGFBP1 have been 
reported in another study on growth restricted placentas (Okamoto et al. 2006).  
 
1.1.9.2 Role of epigenetic modifications in growth 
Certain epigenetic mechanisms have also been associated with growth suppression. 
In further support of role that the disrupted IGF axis plays in growth impairment, 
epigenetic modifications were identified in growth restricted rats (Fu et al. 2009). 
There was differential CpG methylation in the promoters P1 and P2 of IGF1 and 
hepatic histone H3 methylation and acetylation was altered in the growth restricted 
rats compared to controls. mRNA expression and serum levels of IGF1 were also 
significantly reduced in these rats and could be due to the observed epigenetic 
changes (Fu et al. 2009).  
Intra-uterine growth restriction has been associated with a number of changes in 
DNA methylation at loci in rat pancreatic islet tissue affecting genes involved in cell 
proliferation, insulin secretion and cell death (Thompson et al. 2010). A whole 
genome approach using Illumina’s Infinium HumanMethylation 27K bead chip array 
was used to analyse DNA methylation patterns in cord blood obtained from infants 
of women supplemented with folate during pregnancy. The analysis revealed 
significant associations between DNA methylation predominantly in CpG islands 
and birth weight centiles. Methylation levels of two such genes were described in 
this study: BMX (bone marrow non-receptor tyrosine kinase) methylation, which was 
positively correlated and AMN (amnion associated transmembrane protein), which 
was inversely correlated with birth weight centiles (Fryer et al. 2011).      
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Analysis of umbilical cord blood samples from Chinese infants showed that 
hypermethylation of the paternally expressed gene 10 (PEG10) differentially 
methylated region (DMR), determined by pyrosequencing, was significantly 
associated with lower birth weight and this was consistent with lower expression of 
PEG10. Also, increased mRNA expression of pleckstrin homology like domain, 
family A, member 2 (PHLDA2) was correlated with lower birth weight (Lim et al. 
2012). Indeed, the presence of a 15 basepair (bp) repeat sequence (RS1) within the 
PHLDA2 promoter reduces its efficiency and when the maternally inherited RS1 
sequence was homozygous, the corresponding infant birth weight was significantly 
higher (Ishida et al. 2012).  
Methylation levels of APOE, MSX1, GRB10, PGRMC1, RGS14 and SHMT2 
analysed by using Illumina GoldenGate Methylation array on umbilical cord blood 
and placental samples, accounted for 78% of the birth weight variance. Also, 
methylation in MSX1, CDK2 and GRB10 were positively correlated with transcript 
levels of genes suspected to be involved in foetal and placental growth including 
APOE and PSG4. The authors suggest that despite the relative stability in 
methylation, inter-individual differences in methylation patterns at birth may 
predispose infants to development of disease in later life (Turan et al. 2012).   
 
1.1.10 The foetal origins of adult disease 
‘Programming’ has been described as a general process by which insults including 
environmental exposures during early development can alter the development of the 
foetus in order to prepare them for a similar environment in adulthood. These insults 
only have long-term effects on outcome when they occur at a critical period during 
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foetal development (Lucas 1991). Early studies by Barker et al. suggested that 
undernutrition during early life strongly influenced ischaemic heart disease risk in 
adulthood (Barker and Osmond 1986; Barker et al. 1989). This led to the ‘foetal 
origins of adult disease’ hypothesis, which states that ischaemic heart disease, stroke, 
hypertension and diabetes are the result of adaptations made by the foetus during 
early development to poor nutrition (Barker 2001). Several epidemiological studies 
have discovered links between low birth weight (in some cases together with 
environmental exposures) and adult disease providing some evidence for the foetal 
origins hypothesis (Barker et al. 1991; Rich-Edwards et al. 1997; Curhan et al. 1996; 
Frankel et al. 1996; Leon et al. 1998), and is therefore referred to as the 
‘developmental origins of health and disease’ (DOHaD) (Hochberg et al. 2011). 
However, the validity of these findings has been questioned due to the inappropriate 
statistical methodologies used. In some cases, the inverse association between birth 
weight and adult disease has been suggested to be chiefly due to random error (Tu et 
al. 2005). Additionally, a systematic review of epidemiological studies based in low-
to-middle income countries revealed only a weak association between size at birth 
and outcomes related to chronic adult disease (Victora et al. 2008). Also, it was 
determined that there was insufficient evidence to link poor nutrition with long-term 
immune function changes but an association with cancer incidence was better 
supported. However, overall, it was found that undernutrition was strongly linked to 
long-term impairment including stunted growth and lower offspring birth weight 
(Victora et al. 2008).  
It has been argued that exposure resulting in low birth weight and impaired growth 
could also be contributing factors to adult disease development, especially if the 
exposure is constant through life (Byrne and Phillips 2000). Chronic exposure to 
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aflatoxins from in utero through childhood and into adulthood could likely be the 
cause of growth impairment as well as susceptibility to adult disease including 
cancer in high exposure regions.  
The ‘plastic’ nature of human development allows the genotype to give rise to 
different morphological and physiological outcomes depending on the different 
developmental environmental conditions (Barker 2004). Developmental plasticity 
relies in part on epigenetic mechanisms including DNA methylation and histone 
modifications (Gluckman et al. 2008), which are heritable and can potentially 
influence disease risk in future generations (Jirtle and Skinner 2007). Alterations in 
the promoter regions of key genes are one of the main ways in which the epigenome 
plays a role in increased susceptibility to disease.  
The Dutch Hunger Winter cohort produced important evidence of an association 
between potential adult disease risk through epigenetic changes and adverse 
environmental conditions during early development (Heijmans et al. 2008; Tobi et al. 
2009). Methylation of the imprinted IGF2 differentially methylated region was 
examined in 60 individuals prenatally exposed to a famine during 1944-1945 and in 
their same-sex unexposed siblings six decades following exposure. It was discovered 
that methylation levels were significantly low in exposed individuals than in their 
unexposed siblings (Heijmans et al. 2008). This was expanded to include the 
examination of methylation levels in 15 loci involved in growth and metabolic 
disease including IL10 and GNASAS (Tobi et al. 2009). Methylation of INSIG was 
found to be significantly lower in exposed individuals than in their unexposed 
siblings, while methylation levels of IL10, LEP, GNASAS, ABCA1 and MEG3 were 
reported to be higher in exposed versus unexposed individuals (Tobi et al. 2009).  
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Changes to genes with metastable epialleles are also important targets of 
environmental exposure-modulated adult disease risk (Jirtle and Skinner 2007). 
Metastable epialleles are epigenetically modified alleles that have variable 
expression in genetically identical individuals. The epigenetic modifications are 
established during early foetal development and are mostly influenced by 
environmental factors (Rakyan et al. 2002). For example, the degree of methylation 
of the intracisternal A particle (IAP) gene, which is a transposable element 100 Kb 
upstream of the agouti mouse gene, affects the expression of the agouti gene and 
therefore alters the colour of the mouse fur coat as well as diabetes, obesity and 
tumourigenesis risk, resulting in either obese yellow (unmethylated) or normal 
brown (methylated) mice. If the methylation of the IAP occurs later during 
development affecting only some embryonic cells, the fur coat is mottled (Wolff et 
al. 1998). 
A number of enzymes are responsible for the maintenance and development of 
methylation patterns during development and cell proliferation. DNA 
methyltransferase-1 (DNMT1) is responsible for maintaining the methylation 
patterns of DNA by methylating nascent DNA immediately after replication (Bestor 
2000). While existing DNA methylation patterns need to be maintained and 
replicated, de novo methylation is necessary during early development to establish 
new patterns, sometimes in relation to environmental cues (Dolinoy et al. 2007).  
DNMT1 is known to be involved in certain types of de novo methylation, including 
most methylation occurring in embryo lysates (Bestor 2000). DNMT3a and DNMT3b 
also play an important role in de novo methylation during early embryonic 
development (Okano et al. 1999). Early embryos undergo genome-wide 
demethylation separately for paternal and maternal genomes after which both are 
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remethylated by de novo methylation at the same time (Reik et al. 2001). At these 
points in development, the embryo is vulnerable to environmental influences 
resulting in changes to the epigenome and the genome thereby potentially 
predisposing the child to adverse health effects in later life. Investigation of the 
genome-wide effects of early life AFB1 exposure on gene expression and DNA 
methylation can contribute toward our understanding of the mechanisms involved in 
exposure-related health effects.  
  
 
 
 
 
 
 
 
 
 
 
 
  
56 
 
1.2 Project Aims 
The main aims of this project are: 
1. To test the hypothesis that AFB1 exposure affects IGF1 and/or IGFBP3 
protein levels in children and in vitro and to contribute to our understanding 
of AFB1-associated growth impairment. This has been investigated using a 
cohort of Kenyan schoolchildren as well as non-tumourigenic liver cells 
(HHL-16) exposed in vitro to AFB1  
2. To determine exposure levels and seasonality of the AF-alb biomarker in 
pregnant women and to ascertain if in utero AFB1 exposure affects growth in 
infants. A Gambian mother-child cohort was used to examine these questions 
3. To develop gene expression and epigenetic profiles of AFB1 exposure in 
children by dichotomising infants into AFB1 exposure groups and comparing 
infant DNA methylation status and gene expression patterns between groups. 
These profiles could provide valuable markers of AFB1 exposure in relation 
to growth and immune function impairment and eventual cancer 
development.  
4. To develop gene expression and epigenetic profiles of in vitro AFB1 
exposure by studying whole genome changes in HHL-16 cells exposed to 
three doses of AFB1 at two time points, to support the findings of the human 
study.  
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2 Materials and Methods 
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2.1 AF-alb measurement ELISA 
Serum samples were analysed for AF-alb levels by a competitive ELISA described 
previously (Chapot and Wild 1991). Albumin was extracted using a two step 
approach taking advantage of the properties of albumin. In the first step, 375 µl cold 
ammonium sulphate (Sigma, Dorset, UK, dissolved in distilled water) was added to 
250 µl sample serum in a drop-wise manner. This was done to increase the surface 
area of contact of the ammonium sulphate with the serum. At low salt concentrations, 
the solubility of a protein increases with increasing ionic strength, an effect termed 
salting in. As the salt concentration (ionic strength) is increased further, the solubility 
of the protein begins to decrease. At sufficiently high ionic strength, the protein will 
be almost completely precipitated from the solution (salting out). Therefore, by the 
addition of ammonium sulphate, unwanted globulins are precipitated out while 
albumin is still in solution. The mixture of ammonium sulphate and plasma was then 
vortexed and centrifuged at 9000 g at 0°C for 15 minutes. The supernatant was 
transferred to a fresh microcentrifuge tube and 50 µl of 1 M glacial acetic acid 
(Sigma, Dorset, UK) was added. The addition of acid lowers the pH of the mixture 
allowing the remaining albumin to precipitate out of the solution. The mixture was 
vortexed and centrifuged at 9000 g at 0°C for 15 minutes. The supernatant was 
discarded and the pellet was reconstituted in 500 µl phosphate buffered saline (PBS) 
(8g NaCl, 0.2g KCl, 0.2g KH2PO4 and 1.15g Na2HPO4 dissolved in distilled water, 
adjusted to pH 7.4, all chemicals from Sigma, Dorset, UK). The albumin was then 
quantified using Biorad reagent (Bio-Rad laboratories, Hemel Hempstead, 
Hertfordshire, UK) in a coloured protein assay. The objective of this assay was to 
determine the concentration of solubilised albumin protein in solution by using 
  
59 
 
Coomassie blue dye, which binds to basic and aromatic amino acid residues of 
protein. The albumin was first diluted 500-fold with distilled water and assayed 
against human serum albumin (HSA; Sigma, Dorset, UK) standards. 40 µl of Biorad 
reagent was added to each well containing 160 µl of sample or standard and the plate 
was read at 620 nm wavelength. Based on the quantification results, 2 mg albumin 
was then digested with 1 mg/ml pronase (Roche, West Sussex, UK) and PBS to 
make up the final volume to 800 µl. The samples were incubated at 37°C overnight. 
The albumin was then hydrolysed with 1.8 ml 100% ethanol (Sigma, Dorset, UK) 
and 100 mg/ml bovine serum albumin (BSA; Sigma, Dorset, UK) for at least 2 hours. 
Hydrolysed albumin was centrifuged at 1000 g for 15 minutes at 4°C and the 
supernatant transferred to separate falcon tubes. The albumin was diluted with PBS 
to make the final volume to 30 ml. This was then purified using Sep Pak C18 
cartridges (Waters, Hertfordshire, UK). The cartridges were first activated using 5 ml 
of 80% methanol (Rathburn, Walkerburn, Scotland, UK) in distilled water, followed 
by equilibrating the cartridge surface with 10 ml distilled water. The samples were 
then run through the cartridges at a slow rate. The cartridges were washed with 5 ml 
distilled water followed by 5 ml of 5% methanol in distilled water. Finally, the 
aflatoxin-lysine residues were eluted with 5 ml of 80% methanol. Eluted samples 
were dried overnight in a speed vac (SPD1010 speed vac, Thermo Scientific, 
Langenselbold, Germany) and reconstituted in 500 µl PBS. 
The samples were then analysed by a competitive ELISA. Greiner high-binding 
plates (Greiner, Stoenhouse, Gloucestershire, UK) were coated with 0.4 µg/ml of 
AFB1-ovalbumin (ovalbumin, Sigma, Dorset, UK) per well overnight and soaked 
and washed in PBS/Tween 20 (Tween 20, Sigma, Dorset, UK). The wells were 
blocked with 5% milk (skimmed milk powder, Sainsbury’s own brand, dissolved in 
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distilled water) for 1 hour. A set of 8 AFB1-lysine standards, samples and PBS blank 
were incubated with 1:500,000 primary anti-aflatoxin antibody produced in rabbits 
with 0.75% fetal calf serum (FCS, Sigma, Dorset, UK), at a 1:1 ratio for 30 minutes. 
Following blocking, plates were washed in PBS/Tween 20 and drained and 50 µl 
each of standards and samples were added to the wells. The plates were incubated 
for 90 minutes at room temperature with shaking following which the plates were 
washed and a 2500-fold dilution of a goat anti-rabbit IgG peroxidase-labelled 
antibody (Sigma, Dorset, UK) was added to each well. The plates were incubated for 
90 minutes at room temperature with shaking and washed 5 times in PBS/Tween 20 
with an additional final wash in distilled water. Substrate mix prepared by combining 
20 ml of 14.7 mg/ml citrate buffer (Sigma, Dorset, UK), 200 µl of 10 mg/ml 
3,3′,5,5′-Tetramethylbenzidine (TMB, Sigma, Dorset, UK) and 4 µl of 30% 
hydrogen peroxide (Sigma, Dorset, UK) was then added to each sample and the 
plates were incubated at 37°C for 20 minutes. The plates were then read at 450 nm 
on a Labsystems iEMS plate reader (Thermo Scientific, Langenselbold, Germany). 
Each sample was read against the aflatoxin-lysine standard curve and the percentage 
inhibition was calculated by Ascent software linked to the plate reader. Final AF-alb 
concentrations were presented as picogram (pg) of aflatoxin per milligram (mg) of 
albumin. The detection limit for this assay was 3 pg/mg albumin. Each sample was 
analysed in triplicate on at least two days. One negative and three positive controls 
with known AF-alb levels were run with each batch of the samples. Intra-assay 
coefficient of variation (CV) was < 15% and inter-assay CV was ≤ 25%. This CV is 
much higher than typically acceptable values for sensitive assays. There are a few 
sources of error throughout the assay, mostly due to the fact that this is a multi-step 
process. Not all albumin is extracted in the initial stages and this albumin may be 
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diluted through the presence of other proteins that were not removed during the 
process. However, to eliminate a major source of error at this stage, only 2 mg 
albumin is purified and analysed. Some variation is introduced at this point due to 
the potential presence of other proteins besides albumin, especially as the protein 
measurement method used is not exclusive to the measurement of albumin. 
Furthermore, digested albumin may be lost during the Sep Pak purification stage as 
some may pass through the cartridge during a wash step or alternatively, some 
albumin may remain on the cartridge during the elution step. Variation during the 
ELISA may also introduce further sources of error due to differences in actual 
antibody, coating antigen or substrate levels between samples or wells.  
 
2.1.1 Modified AF-alb measurement ELISA  
Serum samples were analysed for aflatoxin-albumin adduct (AF-alb) levels by a 
modified competitive ELISA described previously (Chapot and Wild 1991) and in 
Chapter 2, section 1. The only alteration to the methodology was in the initial stages 
of sample preparation. In this modified method, albumin extraction was by-passed 
and 150-250 µl plasma was directly digested with 250 µl 10 mg/ml pronase at 37°C 
overnight. A 20 µl aliquot of each sample was not digested and instead stored for 
albumin measurement using a bromocresol green (BCG) reagent (San Diego, 
California, USA). Ten µl of the plasma aliquot was added to each well of a Sarstedt 
96-well plate (Sarstedt, Leicester, UK) and 200 µl of BCG reagent was added. The 
plate was incubated at room temperature for 5 minutes and read at 650 nm. 
Concentrations of albumin were calculated against human albumin standards.  
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Following overnight digestion with pronase, the rest of the protocol was followed as 
described in Section 1. Due to the modifications eliminating any potential loss of 
albumin, the detection limit for this assay was 0.6 pg/mg albumin. The final 
calculation was adjusted to account for the missing albumin extraction step. Each 
sample was analysed in triplicate on at least two days. One negative and three 
positive controls with known AF-alb levels were run with each batch of the samples. 
Intra-assay CV was < 15% and inter-assay CV was ≤ 25%.  
 
2.2 IGF1 and IGFBP3 ELISA measurement 
2.2.1 Plasma samples 
IGF1 and IGFBP3 levels in plasma samples were measured using separate IGF1 and 
IGFBP3 Quantikine ELISA kits (R&D Systems, Abingdon, UK) following the 
manufacturer’s instructions. Plates, provided in the kits, were pre-coated with a 
mouse monoclonal antibody against IGF1 or IGFBP3.  
For IGF1, 20 µl of each sample was first treated with Pre-treatment Buffers A and B. 
This was done to dissociate IGF1 from its binding proteins including IGFBP3. 
Samples on plates were incubated with Assay Diluent while shaking for 2 hours at 
4˚C followed by the addition of a polyclonal antibody against IGF1 conjugated to 
horseradish peroxidase and further incubation for 1 hour at 4˚C. The assay was then 
developed by a substrate mix containing hydrogen peroxide and TMB and incubated 
for 30 minutes at room temperature protected from light. One positive quality control 
(Human Serum, Sigma, Dorset, UK) was included in each assay and the samples 
were read against an IGF1 standard curve. 
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For IGFBP3, 10 µl plasma was diluted 100-fold with Calibrator Diluent. Samples on 
pre-coated plates were incubated with Assay Diluent for 2 hours at 4˚C. A polyclonal 
antibody against IGFBP3 conjugated to horseradish peroxidase was then added and 
the plates incubated at the same conditions. The assay was developed with a mixture 
of hydrogen peroxide and TMB for 30 minutes at room temperature protected from 
light. Human Serum was run as a positive control with the samples and these were 
compared against an IGFBP-3 standard curve.   
Twenty-four randomly-selected samples for both IGF1 and IGFBP3 assays were re-
measured to determine inter-assay variation. The inter-assay CV% for these repeated 
samples and the quality controls (QCs) was below 10% and intra-assay CV% was 
below 3% for both assays. 
 
2.2.2 Cell media samples 
Following AFB1 treatment of cells for 24 and 48 hours, conditioned cell media from 
each treatment were collected and centrifuged at 1000 g for 5 minutes to separate 
cell debris. The supernatant was enriched using Vivaspin 2 ultrafiltration columns 
with 3000 Molecular Weight Cut Off (MWCO) polyethersulfone (PES) membrane 
(Sigma, Dorset, UK). The columns were centrifuged at 4000 g for 50 minutes at 
room temperature to obtain approximately 30-times concentrated media, which were 
analysed immediately.  
IGF1 and IGFBP3 levels in concentrated conditioned cell media supernatants were 
measured using separate IGF1 and IGFBP3 Quantikine ELISA kits (R&D Systems, 
Abingdon, UK) following the manufacturer’s instructions as described in section 2.1. 
For IGF1, cell media samples were not pre-treated and for IGFBP3, samples were 
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diluted 2-fold with Calibrator Diluent. For both assays, samples were analysed on 
two separate days. The intra-assay CV% was below 3% for both assays. 
 
2.3 Non-tumourigenic cell work 
2.3.1 Cell maintenance 
HHL-16, a non-tumourigenic human liver cell line, was kindly provided by Dr. 
Arvind H. Patel (MRC Virology Unit, Glasgow). Cells were maintained in 
Advanced Modified Eagle’s Medium (Invitrogen, Paisley, UK) supplemented with 
10% fetal calf serum, 1% L-glutamine, 1% penicillin/streptomycin and 1% non-
essential amino acids (all chemicals from Sigma, Dorset, UK). The cells were 
maintained at 37˚C in a humidified atmosphere with 5% CO2 and were sub-cultured 
with 0.05% Trypsin-EDTA (ethylenediaminetetraacetic acid) (both chemicals from 
Sigma, Dorset, UK) in sterile PBS every 3-4 days or when cells reached ~80% 
confluence.  
 
2.3.2 Cell cytotoxicity assay 
AFB1 used to treat HHL-16 cells was purchased from Sigma (Dorset, UK) and 
dissolved to a 20 mg/ml stock concentration in dimethyl sulfoxide (DMSO, Sigma, 
Dorset, UK). Cells at passage 9 were seeded at 2x10
4
 cells/well onto 96-well plates 
and treated with AFB1 concentrations: 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 µg/ml, 5 
µg/ml, 10 µg/ml, 20 µg/ml, 50 µg/ml and 100 µg/ml. Cells were incubated with 
AFB1 for 24, 48 and 72 hours with 8 repeats per treatment within the same plate. 
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Non-treated cells and cells treated with 0.1% and 0.5% DMSO were used as controls, 
as these were the DMSO concentrations present in the 20 µg/ml and 100 µg/ml 
AFB1, respectively. Following treatment, 20 µl of CellTiter 96® AQueous One 
Solution Reagent (Promega, Southampton, UK) was added to each well and the plate 
was incubated at 37˚C in a humidified incubator with 5% CO2 for 4 hours before 
reading it at 490 nm on an iEMS plate reader (Thermo Scientific, Langenselbold, 
Germany). Percentage viability was calculated as follows:  
 
Untreated cells were used as the baseline for DMSO controls and the DMSO 
controls were used as a baseline for all AFB1 treatments.  
 
2.3.3 Cell treatment with AFB1 
HHL-16 cells grown in 25 cm
2
 flasks (Corning, New York, USA) to approximately 
80% confluence were treated with 0.5 µg/ml, 5 µg/ml and 20 µg/ml AFB1 dissolved 
in DMSO for either 24 or 48 hours in triplicate. Each dose was selected due to low 
observed cell toxicity. DMSO levels for cells treated with 0.5 µg/ml and 5 µg/ml 
were at 0.0025% and those for cells treated with 20 µg/ml were at 0.1% DMSO.  
Cells treated with DMSO levels corresponding to treatment DMSO levels served as 
controls to exclude potential toxicity from DMSO alone.  
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2.3.4 DNA extraction 
DNA extraction for HHL-16 cells (both controls and treated cells) was carried out 
using the QIAamp DNA Mini Kit (Qiagen Ltd, West Sussex, UK) according to 
manufacturer’s instructions. Cells from each flask were trypsinised and washed once 
in PBS before lysis with 600 mAU/ml protease enzyme and Buffer AL. This mixture 
was then incubated at 56˚C for 10 minutes followed by DNA precipitation with 
equal volume of 96-100% ethanol. This was added to the QIAamp DNA column and 
centrifuged for 13000 rpm for 1 minute. The columns were washed in Buffers AW1 
and AW2 and incubated for 10 minutes at 37˚C to facilitate complete ethanol 
evaporation. Columns were then incubated with 200µl DNase/RNase-free water for 
5 minutes at room temperature and DNA eluted by centrifuging the column at 13000 
rpm for 1 minute. Concentrations and DNA purity were determined by measurement 
on a NanoDrop ND-1000 Spectrophotometer V3.0.1 (Thermo Scientific, 
Langenselbold, Germany).  
 
2.3.5 RNA extraction 
DNA extraction for HHL-16 cells (both controls and treated cells) was done using 
the RNeasy Mini Kit (Qiagen, Ltd, West Sussex, UK) according to the 
manufacturer’s instructions. Cells from each flask were trypsinised and washed once 
in PBS. They were lysed with Buffer RLT followed by homogenisation with a 
QIAshredder by centrifuging at 20,000g for 2 minutes. 70% ethanol was mixed with 
the homogenised lysate and this was added to an RNeasy column and centrifuged at 
13000 rpm for 1 minute. The column was then washed with Buffers RW1 and RPE 
and RNA was eluted with 50 µl RNase-free water by centrifuging at 13000 rpm for 1 
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minute. Concentrations and RNA purity were determined by measurement on a 
NanoDrop ND-1000 Spectrophotometer V3.0.1 (Thermo Scientific, Langenselbold, 
Germany). 
 
2.3.6 Quantitative PCR (qPCR) 
Primers for all genes analysed by qPCR were designed using the Primer3 software 
(http://frodo.wi.mit.edu/primer3/). 
One microgram of total RNA was reverse-transcribed to cDNA using SuperScript II 
First-Strand Synthesis Mix (Invitrogen, Paisley, UK). A master mix containing 24 µl 
random nonamers (50 µM, Sigma, Dorset, UK), 48 µl reaction buffer (5-times 
concentrated), 12 µl deoxyribonucleotide triphosphate (10 µM dNTP, Promega, 
Southampton, UK)  mix, 12 µl dithiothreitol (0.1M DTT) and 12 µl SuperScript II 
reverse transcriptase (Invitrogen, Paisley, UK). To this, 14 µl total RNA was added, 
mixed well and incubated at 42°C for 2 hours. Samples were stored at -20°C until 
qPCR.  
The PCR mix was prepared with 5 µl magnesium chloride buffer (Invitrogen, Pailsey, 
UK), 1 µl forward primer (10 µM), 1 µl reverse primer (10 µM) (both primers from 
Invitrogen, Paisley, UK) and 1 µl distilled water and 2 µl DNA per sample. The 
cDNA was amplified using SYBR Green (Applied Biosystems, California, USA). 
The qPCR reactions were run on an ABI 7900HT real-time PCR analyser (Applied 
Biosystems, California, USA) using absolute quantification and results were 
determined using the Sequence Detection System (SDS) software. Each reaction was 
duplicated and a negative control routinely included. Gene expression was 
normalised against endogenous GAPDH or HPRT gene expression. Each PCR 
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reaction was run for 40 cycles and included a denaturation step at 95°C for 15 
seconds.  After 40 cycles, a dissociation curve was produced for each PCR product at 
95°C for 15 seconds and 60°C for 15 seconds.  
 
2.4 DNA methylation and gene expression analyses 
2.4.1 DNA methylation analysis 
2.4.1.1 DNA extraction 
Three millilitres of whole blood was diluted four-fold in 9 ml ice-cold Tris-EDTA 
(20mM Tris-5mM EDTA, pH 8.0; Sigma, Dorset, UK) solution and mixed well by 
inverting the tube. This was then incubated on ice for 20 minutes and centrifuged it 
at 3500 rpm at 4˚C for 20 minutes. The supernatant containing lysed red blood cells 
was discarded and the cell pellet resuspended in 4 ml Tris-EDTA buffer. The 
mixture was mixed well by vortexing and the volume adjusted to 40 ml with Tris-
EDTA buffer (Sigma, Dorset, UK). This was then mixed by inverting and 
centrifuged at 3500 rpm at 4˚C for 20 minutes. These washing steps with Tris-EDTA 
buffer were repeated till the cell pellet appeared pink-white in colour and when the 
supernatant was no longer red. The washed cell pellet was resuspended in 1.5 ml 
Tris-EDTA buffer. Seventy-five µl of 20% Sarcosyl (Sigma, Dorset, UK) was added 
to the cell suspension and mixed well by inverting several times. Twenty µl of 
proteinase K (10 mg/ml solution, Sigma, Dorset, UK) was added and the tube was 
gently mixed by inverting and incubated overnight in a shaking water bath at 42˚C-
55˚C. Samples were brought to room temperature and mixed with 1 ml 7.5 M 
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ammonium acetate (Sigma, Dorset, UK). Five µl of ice-cold absolute ethanol (Sigma, 
Dorset, UK) was then added and this was mixed well by inverting the tube. The 
resulting precipitated DNA was removed using a plastic inoculation loop and 
transferred to a tube containing 4 ml Tris-EDTA-NaCl (20 mM EDTA, 5 mM EDTA 
and 0.2 M NaCl, all chemicals from Sigma, Dorset, UK). The DNA was incubated in 
a shaking water bath at 42˚C-55˚C until the DNA dissolved. This was then 
centrifuged at 4000 rpm for 30 minutes at 40˚C. The supernatant was discarded and 
the pellet was air-dried for 20 minutes. The pellet was resuspended in 500 µl Tris-
EDTA (20mM Tris and 1mM EDTA) buffer. The DNA was incubated in a shaking 
water bath at 37˚C-42˚C overnight. The DNA was then transferred to labelled tubes, 
quantified by using a Nanodrop ND-1000 Spectrophotometer V3.0.1 (Thermo 
Scientific, Langenselbold, Germany) and stored at -20˚C.  
 
2.4.1.2 Bisulfite conversion and pyrosequencing 
The extracted DNA was bisulfite modified using the EZ DNA Methylation kit 
(Zymo Research, California, USA) following the manufacturer’s instructions for 
Illumina Infinium Methylation Assay. Five µl of M-Dilution Buffer was added to 
500 ng of DNA and the total volume was adjusted to 50 µl with distilled water. The 
samples was mixed by repeated pipetting and then incubated at 37˚C for 15 minutes. 
One hundred µl of the CT conversion reagent was then added to each sample and 
mixed followed by an overnight incubation in a thermocycler with the following 
conditions: 95˚C for 30 seconds, 50˚C for 60 minutes repeated for 16 cycles and then 
held at 4˚C. The samples were loaded onto Zymo-Spin IC columns containing 400 µl 
of M-Binding buffer and mixed well by inverting the column several times. The 
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columns were then centrifuged at 10000 g for 30 seconds and the flow through 
discarded. One hundred µl of M-wash buffer was then added and the columns were 
centrifuged at 10000 g for 30 seconds. M-Desulphonation buffer (200 µl) was added 
to the columns, which were incubated at room temperature for 20 minutes and then 
centrifuged at 10000 g for 30 seconds. The M-wash buffer (200 µl) was added twice 
to the columns with a centrifuge step at 10000 g for 30 seconds after each addition. 
Finally, the columns were placed in fresh 1.5 ml microcentrifuge tubes and the 
bisulfite treated DNA was eluted with the addition of 10 µl of M-Elution buffer 
followed by a centrifuge step at 10000 g for 30 seconds. DNA was stored at -20˚C 
until needed for PCR and pyrosequencing.  
The methylation status in LINE1 was assessed by pyrosequencing, which is a highly 
quantitative method for the analysis of DNA methylation at multiple CpG sites (Tost 
and Gut 2007). The pyrosequencer program also has built-in internal controls to 
check for the completion of bisulfite conversion. DNA amplifications were carried 
out on bisulfite-treated DNA using a biotinylated 'TAGGGAGTGTTAGATAGTGG' 
as the forward primer and 'AACTCCCTAACCCCTTAC' as the reverse primer with 
an annealing temperature of 58°C.  About 20-25 ng of modified DNA was amplified 
by PCR in a final volume of 50.25 μl. The mix for PCR included 5 µl Qiagen buffer 
(10x), 1 µl dNTP mix (10 mM), 1 µl Forward primer (10 mM), 1 µl Reverse primer 
(10 mM), 0.5 µl Qiagen Taq polymerase, 40.75 µl distilled water and 1 µl DNA. All 
chemicals were from Qiagen Ltd, West Sussex, UK except for primers, which were 
purchased from Sigma, Dorset, UK. PCRs were run using the conditions presented in 
Table 2. 
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Table 2: PCR conditions for pyrosequencing. 
 Temperature (°C) Time  Number of cycles 
Denaturation 95 10 minutes  
 95 30 seconds 
50 cycles Annealing (varies per gene analysed) 30 seconds 
 72 30 seconds 
Elongation 72 10 minutes  
 18 ∞   
 
Using the PCR product, 10 µl was analysed on a 1 % agarose gel and the remaining 
40 μl was used in a pyrosequencing assay using sequencing primers per gene. The 
sequencing primer for LINE1 was 5’ 'CAAATAAAACAATACCTC'.  
Sequencing primers were diluted 250-fold in annealing buffer (20mM Tris and 2mM 
MgCl2 from Sigma, Dorset, UK in distilled water, adjusted to pH 7.6 with 4M acetic 
acid) to prepare 40 µl per sample. Streptavidine Sepharose High Performance beads 
(GE Healthcare, Hatfield, Hertfordshire, UK) were diluted 13-fold in binding buffer 
(10 mM Tris, 2 M NaCl, 1 mM EDTA and 0.1% Tween 20 in distilled water, 
adjusted to pH 7.6 with HCl, all chemicals from Sigma, Dorset, UK) to prepare 40 µl 
per sample. Beads in binding buffer were mixed with 40 µl of the PCR product and 
agitated for 10 minutes. Sequencing primer dilutions were added to a 96-well PSQ 
plate (Biotage, Sweden) at 40 µl/well.  
The beads mixed with DNA were first transferred onto the 96 filter probes on a 
hand-held vacuum pump and then denatured by aspirating 70% Ethanol (Sigma, 
Dorset, UK) followed by 0.2 M NaOH (Sigma, Dorset, UK) for 30 seconds each.  
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Finally, the DNA was washed by aspirating washing buffer (10 mM Tris in distilled 
water, adjusted to pH 7.6 with 4 M acetic acid) for 30 seconds. Aspiration was then 
stopped and the beads released into the plate containing the sequencing primers. The 
contents of each well were mixed and then the plate was heated at 80°C for 2 
minutes. The plate was transferred into the pyrosequencer and allowed to cool down 
for 20 minutes. 
The experiment details were input into the software program PSQ96MA 2.1.1, 
which proved the calculations for the dNTPs, enzyme and substrate mix provided by 
the PyroMark Gold Reagent kit (Qiagen Ltd, West Sussex, UK). Based on the 
calculated amounts, they were added to the cartridge and fixed into the 
pyrosequencer. Following the 20-minute incubation, the program was run.  
The methylation levels at the target CpGs were evaluated by converting the resulting 
pyrograms to numerical values for peak heights and expressed as the percentage of 
methylation of individual CpG sites. 
 
2.4.1.3 Whole genome DNA methylation assay 
One of the major aims of this project was to identify unique DNA methylation 
signatures of in utero dietary aflatoxin exposure. Infant DNA was therefore analysed 
using the Illumina Infinium HD 450K DNA Methylation array (Illumina, Freddy van 
Riemsdijkweg, The Netherlands), which investigates DNA methylation in 485 764 
CpG sites covering 99% of RefSeq genes distributed over the promoter, body, 5’ 
UTR and 3’ UTR regions (Sandoval et al. 2011). These arrays employ two types of 
Infinium probe designs: Infinium I and Infinium II technology. Infinium I utilises 
two bead types per DNA template, one for an unmethylated locus and another for a 
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methylated locus. Therefore, if the input DNA template is unmethylated, it would 
successfully bind and get extended on the ‘unmethylated’ probe, while there would 
be no binding to the ‘methylated’ probe (Bibikova et al. 2011).  
The Infinium II probe design incorporates one bead type for each locus. The 
methylation state in this case is determined by single-base extension. For instance, if 
the input DNA template is unmethylated and therefore the ‘C’ nucleotide is 
converted to ‘T’ during bisulfite conversion, ‘A’ nucleotide will be incorporated 
during extension. However, if the template is methylated, the methylated ‘C’ will 
remain unchanged and ‘G’ will be incorporated instead. Each nucleotide during 
single-base extension is labelled with a different dye and so methylation state can be 
determined by the intensity of the signal (Bibikova et al. 2011).   
The method in brief involves denaturing and neutralising bisulfite-converted DNA 
samples followed by whole genome amplification. The samples then went through 
enzymatic fragmentation and were hybridised onto the bead chips. DNA bound to 
the chips underwent single-base extension and staining and finally imaging to read 
the signals.  
Initially, 20 µl of MA1 was added to each well in the MSA4 plate. Four µl of the 
bisulfite-converted samples was added to each well followed by 4 µl of 0.1N NaOH 
to denature the DNA. The plate was then sealed, vortexed at 1600 rpm for 1 minute 
and pulse centrifuged to 280 g. The plate was incubated at room temperature for 10 
minutes and 68 µl of RPM was added to each well to neutralise the sample. Finally, 
75 µl of the Multi-Sample Amplification Master Mix (MSM) was also added. The 
plate was re-sealed, vortexed and pulse centrifuged under the same conditions and 
incubated in the Illumina Hybridization Oven at 37˚C for 24 hours. The plate was 
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pulse centrifuged and 50 µl of FMS was added to each well to enzymatically 
fragment the DNA. The plate was vortexed and centrifuged as before and placed on 
a heat block set at 37˚C for 1 hour. In order to precipitate the DNA, 100 µl PM1 was 
added to each well of the MSA4 plate. The plate was vortexed at 1600 rpm for 1 
minute and then incubated at 37˚C for 5 minutes. The plate was pulse centrifuged 
and 300 µl of 100% 2-propanol was added to each well. The plate was sealed and the 
contents of the wells were mixed by inverting the plate 10 times. The plate was then 
incubated at 4˚C for 30 minutes and centrifuged to 3000 g at 4˚C for 20 minutes. The 
supernatant was immediately decanted and remaining liquid was drained onto 
absorbent paper by repeated tapping for at least 1 minute. The plate was left inverted 
onto a tube rack for 1 hour at room temperature to air dry the pellets. The 
precipitated DNA pellets were then resuspended in 46 µl of fresh RA1. The plate 
was heat sealed with foil and then placed in the Illumina Hybridization Oven at 48˚C 
for 1 hour. The plate was vortexed at 1800 rpm for 1 minute, pulse centrifuged and 
then placed on the heat block at 95˚C for 20 minutes to denature the samples. The 
plate was then placed on the benchtop at room temperature for 30 minutes to cool 
and pulse centrifuged. Fifteen Multi-Sample Amplification Master Mix of each 
sample was then added onto the BeadChips, which were placed into the Hyb 
chamber inserts. These inserts were then loaded into the Illumina Hyb chamber and 
the lid was then securely fastened. The Hyb chamber was then incubated in the 
Illumina Hybridization Oven at 48˚C for 20 hours. The BeadChip arrays were 
washed in PB1 buffer by repeated submersion of the arrays using wash racks into a 
wash dish containing 200 ml PB1 buffer.  
For each bead chip, a black frame was placed into a multi-sample bead chip 
alignment fixture pre-filled with PB1 buffer. The bead chips were transferred onto 
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the black frames and a clear spacer was added on top of each bead chip. A clean 
glass plate was added on top of the bead chips and bound together with metal clamps. 
The Hyb Chamber reservoirs were then washed with distilled water. The bead chips 
were removed from the alignment fixture and the spacer and back plates were 
removed. The chips were added into a staining rack and washed in PB1 buffer by 
repeated submerging and finally soaked in the buffer for 5 minutes. The bead chips 
were moved into a dish containing the XC4 stain. The slides were stained by 
repeated submerging and finally soaking for 5 minutes. The bead chip slides were 
moved onto a tube rack and the whole set up was placed in a vacuum desiccator set 
at 675 mm Hg for 55 minutes. The assay was conducted at the Epigenetic Group 
laboratory at IARC, Lyon, France. The chips were finally analysed at the Faculty of 
de Medicine and Pharmacy of Lyon - ISPBL, ProfileXpert-LCMT, Lyon, France.  
A series of controls were also included in each array to account for variation due to 
sample preparation, hybridisation and signal generation. Additionally, each array had 
a number of technical replicates, which were randomly distributed across the array. 
Table 3 lists the different controls included in the assay. 
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Table 3: Description of controls included in the Illumina Infinium 450K bead array. 
Control Category Role Number of probes 
Staining Contains dinitrophenyl (DNP) or biotin attached to beads 4 
Extension Test the extension efficiency of A, T, C and G nucleotides  2 
Hybridisation 
Synthetic targets complementary to array sequence. They are present in the Hyb buffer at high (5 pM), 
medium 1 pM) and low concentrations (0.2 pM) 
3 
Target removal Tests the efficiency of the stripping step following extension 1 
Bisulfite conversion I 
Utilises two probes, one for converted DNA and another for unconverted DNA, to confirm successful 
bisulfite conversion 
4 
Bisulfite conversion II Uses single base extension. If conversion was successful, incorporates ‘A’ and if not incorporates ‘G’  1 
Specificity I Monitors allele-specific extension for Infinium I probes 2 
Specificity II Monitors allele-specific extension for Infinium II probes 1 
Non-polymorphic 
Tests the overall performance of the assay by querying a non-polymorphic base with DNP or biotin-
labelled nucleotides 
2 
Negative Random sequences that do not hybridise to the DNA template 2 
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2.4.2 Gene expression analysis 
2.4.2.1 RNA extraction 
Three ml blood was collected from infants between 3-6 months of age and 
centrifuged at 1000 g for 15 minutes at room temperature to isolate the whole blood 
cells. Plasma was removed from the top of each tube using a Pasteur pipette and 1.3 
ml RNALater per 500 µl whole blood cell fraction was added, mixed well and stored 
at -20˚C for shipment to the Epigenetics Group at the International Agency for 
Research on Cancer (IARC), Lyon, France.  
RNA was extracted from the whole blood fractions preserved in RNALater using the 
RiboPure Blood RNA extraction kit (Ambion, Paisley, UK) following the 
manufacturer’s instructions. The samples were centrifuged for 1 minute at 13,200 
rpm in a microcentrifuge and the supernatant discarded. Eight hundred microliters of 
lysis solution and 50 µl sodium acetate solution were added to the pellet and 
vortexed thoroughly. This was followed by inverting the tubes to homogenise the 
lysate. Five hundred microliters of acid-phenol:chloroform was taken from below the 
aqueous layer and added to the cell lysate followed by 30 seconds of vortexing.  The 
mixture was then incubated at room temperature for 5 minutes and centrifuged for 1 
minute at 13,200 rpm. The upper aqueous phase containing RNA was transferred to 
a fresh 2 ml tube and 600 µl 100% ethanol (Sigma, Dorset, UK) added and the 
mixture vortexed well. The tubes were then centrifuged briefly to collect any 
droplets in the lid of the tube to the bottom. Seven hundred microliters of this 
mixture was then added to a filter cartridge assembly and centrifuged for about 10 
seconds at 13,200 rpm. The flow through was discarded and 700 µl of sample was 
added to the filter cartridge and centrifuged again. The cartridge was washed with 
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700 µl wash buffer 1 and centrifuged for 10 seconds at 13,200 rpm and the flow-
through discarded. This was followed by a second wash with 700 µl wash buffer 2/3 
and centrifuged for 10 seconds at 13,200 rpm. The second wash step was repeated 
again and the filter cartridge centrifuged for 1 minute at 13,200 rpm to remove any 
residual fluid. Finally, the RNA was eluted using 50 µl elution buffer, which had 
been pre-heated to 75˚C. The cartridge was centrifuged for 30 seconds and the 
elution step was repeated with a further 50µl elution buffer. The eluted RNA was 
quantified using the Nanodrop 1000 (Thermo Scientific, France) and stored at -20˚C. 
 
2.4.2.2 Whole genome gene expression direct hybridization assay 
In order to explore infant gene expression variation associated with maternal 
aflatoxin exposure during gestation, the Illumina Human HT12-v4 Expression 
BeadChip Kit (Illumina, Freddy van Riemsdijkweg, The Netherlands) which is 
based on the Illumina Whole-Genome Gene Expression Direct Hybridization Assay 
system, was used at IARC, Lyon, France.  
The system makes use of the BeadArray technology, in which beads, with several 
copies of a single oligonucleotide attached to each bead, are included in each sample 
slot on the BeadChip.   
Extracted total RNA was first quantified using the Agilent 2100 Bioanalyser 
(Agilent Technologies, Berkshire, UK). The RNA 6000 Nano kit was used for this 
purpose following the manufacturer’s instructions. First the RNA ladder was heat 
denatured for 2 minutes at 70°C, cooled on ice and stored at - 70°C till needed. The 
provided RNA gel matrix was filtered using a spin filter and centrifuging at 1500 g 
for 10 minutes at room temperature. Next the gel-dye mix was prepared by adding 1 
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µl of dye concentrate to 65 µl of filtered gel matrix and mixed well by vortexing 
followed by centrifuging at 13000 g for 10 minutes at room temperature. Nine 
microliters of the gel-dye mix was then loaded onto the wells on the RNA 6000 
Nano chip on the chip priming station. Five microliters of the RNA marker was 
loaded onto all wells. One µl of the RNA ladder was added to the well marked for 
the ladder and 1 µl of each sample was added into individual wells. The chip was 
vortexed for 1 minute at 2400 rpm and analysed on the Bioanalyser within 5 minutes.  
The quantified total RNA was then reverse transcribed to single stranded cDNA 
followed by second strand synthesis resulting in double stranded cDNA. Any 
residual RNA was removed and then in vitro transcription which amplifies and labels 
several copies of biotinylated cRNA was carried out. These were achieved by using 
the Illumina TotalPrep RNA Amplification Kit (Illumina, Freddy van Riemsdijkweg, 
The Netherlands) following the manufacturer’s instructions. Approximately 500 ng 
total RNA was brought to 11 µl with nuclease-free water. The Reverse transcription 
matser mix was prepared by mixing 1 µl T7 Oligo(dT) primer, 2 µl 10x First Strand 
Buffer, 4 µl dNTP mix, 1 µl RNase inhibitor and 1 µl ArrayScript per reaction. Nine 
µl of this master mix was added to each RNA sample, mixed well and incubated in a 
thermocycler at 42°C for 2 hours. The samples were then placed on ice while the 
second strand master mix was prepared on ice. For a single reaction, 63 µl nuclease-
free water, 10 µl 10x Second Strand Buffer, 4 µl dNTP mix, 2 µl DNA Polymerase 
and 1 µl RNase H were mixed together and 80 µl of this was transferred to each 
cDNA sample. The samples were incubated at 16°C for 2 hours. Following the 
incubation, 250 µl of cDNA binding buffer was added to each sample, mixed well 
and added to the cDNA filter cartridges. The cartridges were centrifuged for 1 
minute at 10000 g, the flow through discarded and 500 µl wash buffer was added to 
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each cartridge. The cartridges were centrifuged as before and transferred to the 
cDNA elution tubes. Twenty µl of preheated nuclease-free water was added to the 
cartridges and these were then incubated at room temperature for 2 minutes. The 
tubes were centrifuged for 1 minute at 10000 g to elute the double stranded cDNA. 
The IVT master mix was then prepared at room temperature by mixing 2.5 µl T7 10x 
Reaction Buffer, 2.5 µl T7 Enzyme Mix and 2.5 µl Biotin-NTP Mix for a single 
reaction and 7.5 µl of this mix was added to each cDNA sample. The samples were 
incubated at 37°C for 14 hours. Finally, 75 µl of nuclease-free water was added to 
each sample to stop the reaction. To purify the cRNA, 350 µl cRNA binding buffer 
and 250 µl 100% ethanol was added to each sample and mixed by pipetting. The 
samples were then passed through cRNA filter cartridges, centrifuged for 1 minute at 
10000 g and the flow through discarded. The samples were washed with 650 µl 
Wash Buffer and centrifuged for 1 minute at 10000 g. The cartridges were spun 
again for 1 minute to remove any residual buffer, transferred to cRNA collection 
tubes and 200 µl preheated nuclease-free water was added to the filter cartridges. 
The samples were incubated at 55°C for 10 minutes and centrifuged for 1.5 minutes 
at 10000 g to elute the purified and biotin-labelled cRNA. Finally the cRNA was 
quantified using RNA 600 Nano chips on the Bioanalyser prior to hybridization onto 
the BeadChips.   
The cRNA was incubated at 65˚C for 5 minutes, vortexed and pulse centrifuged at 
250 g. After cooling the cRNA to room temperature, the amount of cRNA is 
normalised according to the size of BeadChip being used. In this case, 750 ng of 
each cRNA sample was dispensed into each hybridization tube. Five µl of RNase-
free water and 10 µl HYB was then added to each hybridization tube. Two hundred 
µl of HCB buffer was added to humidifying buffer reservoirs on the hybridization 
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chamber and gasket. Fifteen µl of each sample was loaded onto the bead chips, 
which were placed in hybridization chamber inserts. The chamber inserts were then 
placed into the hybridization chamber and gasket and the whole apparatus was sealed 
well and placed in the hybridization oven at 58˚C for 14 hours. The BeadChips were 
removed and placed in a beaker containing E1BC buffer. The cover-seal covering 
the BeadChips were then taken off carefully and the BeadChips transferred to a dish 
containing E1BC buffer. The BeadChips were transferred to a waterbath containing 
High-Temp Wash buffer and incubated at 55˚C for 10 minutes. The BeadChips were 
transferred again to a dish containing fresh E1BC buffer and repeatedly plunged in 
and out of the dish 10 times. The dish containing the BeadChips was shaken at 
medium speed for 5 minutes at room temperature. The BeadChips were then washed 
in 100% ethanol by plunging in and out of the dish 10 times followed by shaking at 
room temperature for 10 minutes. The BeadChips were once again washed in E1BC 
following the same steps as before. Each BeadChip slide was moved to a wash tray 
containing Block E1 buffer and washed while shaking at medium speed for 10 
minutes. The BeadChips were transferred to fresh wash tray containing Cy3-
Streptavidin at a 1:1000 dilution in block E1 buffer and incubated covered for 10 
minutes while shaking at medium speed. The BeadChips were then washed for a 
third time in Wash E1BC buffer by plunging the slides in and out of the dish 5 times 
and with a final wash in this buffer for 10 minutes while shaking at medium speed. 
The slides were centrifuged at 1,400 rpm at room temperature for 4 minutes after 
which they were ready to be analysed. The scanning was done using an iScan reader 
at IARC, Lyon.  
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A series of controls were also included in each array to account for variation due to sample preparation, hybridisation and signal generation. 
Additionally, each array had a number of technical replicates, which were randomly distributed across the array. Table 4 lists the different 
controls included in the assay.  
 
Table 4: Description of controls included in the Illumina Human HT12 bead array. 
Control 
Category 
Role 
Number of 
probes 
Housekeeping Measures intactness of biological sample; these genes should be expressed in any cellular sample 14 
Cy3 
Hybridisation 
Cy3 labelled oligonucleotides present in the HYB buffer in low, medium and high concentrations are 
used to check for efficient hybridisation 
6 
Low stringency 
hybridisation 
These controls are matched with the medium and high concentration-oligonucleotides in the Cy3 
hybridisation category to test for stringency. If stringency is high, these oligonucleotides produce a 
low signal. If stringency is low, a higher signal matching the signal of their counterparts in the Cy3 
hybridisation control is produced 
4 
Biotin 
Complementary biotin-tagged oligonucleotides are present in the HYB buffer to check for signal 
generation 
2 
Negative 
These probes have oligonucleotides with sequences that have been designed such that they do not 
correspond to any target within the genome 
2 
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3 Insulin-like growth factor axis: a possible 
mechanism for aflatoxin-related child 
growth impairment? 
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3.1 Introduction 
Staple diets in many parts of Kenya mainly constitute locally grown maize, which is 
frequently contaminated with aflatoxins. Growth-promoting conditions for aflatoxin-
producing Aspergillus Spp. on grains, including warm temperatures and high 
humidity, are prevalent in Kenya (Williams et al. 2004). Indeed, an acute outbreak of 
aflatoxin poisoning with over 100 deaths was reported in Kenya in a toxicosis 
incident in 2004. This outbreak was attributed to aflatoxin exposure with doses up to 
220-times greater than the accepted food limit of 20 ppb (Probst et al. 2007).  
Child malnutrition is a key underlying cause of child death, which accounts for more 
than one third of childhood mortality under the age of 5 in the developing world 
(Black et al. 2003). Aflatoxin exposure as indicated by blood AF-alb biomarker 
levels, has been associated with growth retardation in children in Benin and Togo 
over an 8-month observation, with children belonging to the higher aflatoxin 
exposure quartile being 1.7 cm shorter than those belonging to the lower quartile 
(Gong et al. 2002; Gong et al. 2004). In another study based in Kenya, weaning flour 
samples were analysed for the presence of aflatoxin and the height and weight of 242 
children aged 3-36 months consuming the maize foods were recorded. It was 
observed that significantly more children with wasting were fed aflatoxin-
contaminated flour compared to children without wasting (Okoth and Ohingo 2004). 
Moreover, research based in The Gambia and Ghana has shown that exposure to 
aflatoxin in utero is associated with reduced body weight and height in infants at 
birth (Turner et al. 2007; Shuaib et al. 2010). Whilst these studies consistently 
indicate an association between dietary aflatoxin exposure and reduced growth 
velocity, evidence to demonstrate the causal association is needed as the aetiological 
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mechanism through which aflatoxin-induced growth impairment occurs is still 
unknown. Understanding the mechanistic link between aflatoxin and child stunting 
will contribute to establishing the causative association, and help in developing 
effective intervention strategies to minimize the aflatoxin attributed economic and 
public health burden.   
As well as being the main site for aflatoxin metabolism in the body, the liver is also 
a major production site for  IGF, which facilitates the growth promoting effects of 
GH, and hence is a key factor influencing child growth (Woods et al. 1996). Liver-
derived IGF1 is primarily found in the serum bound to any member of a group of 
binding proteins, most notably to IGFBP3 (Ohlsson et al. 2009). The bound complex 
of IGF1 with binding proteins serves as an IGF1 reserve in the circulation, thus 
extending the short half-life of the growth factor (Ohlsson et al. 2009). The influence 
of IGF1 on body growth is substantiated by the significant association between low 
child birth weight and short stature, and polymorphisms in the IGF1 promoter 
region, which lower IGF1 levels in circulation (Arends et al. 2002; Vaessen et al. 
2002).  
The growth promoting effects of both IGF1 and IGF2 are manifested through a 
signalling pathway that utilises the IGF1-receptor (IGF1R). Additionally, IGF2 
exerts its effects through IGF2R (Grimberg and Cohen 2000). Indeed, mutations in 
the IGF1R gene have been associated with postnatal growth retardation in a few 
small scale studies (Walenkamp et al. 2006; Abuzzahab et al. 2003).   
A study on male broiler chicks has shown that  aflatoxin exposure was significantly 
linked to the down regulation of the IGF1 gene and the subsequent reduction in body 
weight (Yarru et al. 2009). These findings may support the hypothesis that the 
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mechanistic action of aflatoxin on child growth occurs through a disruption of the 
IGF system, either by directly lowering IGF1 levels or affecting other components in 
the IGF axis. Although, there has been no evidence of changes to the IGF axis in 
relation to aflatoxin exposure-associated child growth impairment, reduced serum 
IGF1 levels have been linked to HCC and liver cirrhosis in hepatitis C patients (Su et 
al. 2010; Elsammak et al. 2006; Lorenzo-Zúñiga et al. 2007).  
A series of experiments were used to assess the mechanistic association between 
child aflatoxin exposure and impaired growth via reduced IGF1/IGFBP3 levels using 
available serum samples collected from school-aged children for a previous study 
based in the Makueni District in Kenya, a high aflatoxin risk region. Additionally, a 
non-tumourigenic human liver cell line was used to ascertain the in vitro effects of 
AFB1 on expression of genes and levels of proteins that play a key role in the IGF 
system.  
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3.2 Materials and Methods 
3.2.1 Human study 
3.2.1.1 The subjects  
The study site  (Wilson et al. 2007b) was based in the Makueni District in Kenya, 
which is characterised by biannual seasonal rains, falling in November-December 
and April-May. The study population was based in two neighbouring village 
schools: Matangini Primary in Lower Mangelete in the East and Yumbuni Primary 
in the West. Lower Mangelete has several permanent streams and irrigational canals 
while the surface water in Yumbuni is mainly seasonal. Maize based dishes, githeri 
and ugali, constitute the main dietary staple in this area (Wilson et al. 2007b) and 
thus are a potential source of aflatoxin exposure in human populations.  
Recruited school-aged children were a sub-set from a cross-sectional study in which 
56.4% of children were stunted with a significant association with presentation with 
hepatomegaly (Wilson et al. 2007b; Gong et al. 2012). About 70% of the children 
were negative for schistosomiasis and all recruited children were positive for 
malarial infection. Available serum samples collected in May/June 2002, 119 from 
Yumbuni and 61 from Matangini, were used in the current study. Height was 
measured to the nearest eighth of an inch and converted into centimetres while 
weight was measured to the nearest half kilogram (Wilson et al. 2010). The male to 
female ratio for these children was 1:1 and the age range was 6-17 years. Informed 
consent was obtained from the parents or guardians of the recruited children. Ethical 
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approval was obtained from the Kenya Medical Research Institute Ethical Review 
Committee. 
 
3.2.1.2 Serology 
Serum samples were analysed for aflatoxin-albumin adduct (AF-alb) levels by a 
competitive ELISA (Chapot and Wild 1991) described in Chapter 2, Section 2.1.1. 
IGF1 and IGFBP3 levels in the serum samples were measured using the IGF1 and 
IGFBP3 Quantikine ELISA kits (R&D Systems, Abingdon, UK) as described in 
Chapter 2, Section 2.2.1.  
 
3.2.1.3 Infection and disease status 
Malarial infection status was determined by ELISA measurement of Plasmodium 
falciparum schizont antigen IgG3 (Pfs-IgG3) levels, which is a marker of chronic 
exposure to Plasmodium infections (Wilson et al. 2007a). Schistosomiasis was 
diagnosed based on the S. mansoni egg count from five separate stool samples with 
two Kato Katz slides being prepared from each sample (Wilson et al. 2007b). 
Each participant was clinically examined by palpation for enlarged livers and spleens 
in the supine position. An organ was considered enlarged if it was palpable more 
than 2 cm below the costal line. Children were grouped into four categories: no 
organomegaly, firm/hard splenomegaly, firm/hard hepatomegaly or firm/hard 
hepatosplenomegaly (Wilson et al. 2007b).  
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3.2.2 HHL-16 cell-based study 
HHL-16, a non-tumourigenic human liver cell line (Clayton et al. 2005), was kindly 
provided by Dr. Arvind H. Patel (MRC Virology Unit, Glasgow) and utilised in this 
model. 
 
3.2.2.1 Cytotoxicity assay 
HHL-16 cells were treated with 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 µg/ml, 5 µg/ml, 10 
µg/ml, 20 µg/ml, 50 µg/ml and 100 µg/ml AFB1 and cytotoxicity was assessed as 
described in Chapter 2, Section 2.3.2. 
 
3.2.2.2 AFB1 treatment for cell gene expression and cell media 
protein analysis 
HHL-16 cells were treated with 0.5 µg/ml, 5 µg/ml and 20 µg/ml AFB1 dissolved in 
DMSO for either 24 or 48 hours in triplicate. The former two doses were selected 
due to limited cytotoxicity. The higher dose was selected to assess effects on cells in 
extreme cases.   
DMSO levels for cells treated with 0.5 µg/ml and 5 µg/ml were at 0.0025% and 
those for cells treated with 20 µg/ml were at 0.1% DMSO.  Cells treated with DMSO 
levels corresponding to treatment DMSO levels served as controls to exclude 
potential toxicity from DMSO alone. Cells were treated for 1-2 days before RNA 
was harvested using an RNeasy Mini kit (Qiagen Ltd, West Sussex, UK) described 
in Chapter 2, Section 2.3.5 Quality and quantity of extracted RNA was determined 
using the Nanodrop ND-1000 spectrophotometer (Thermo Scientific, DE, USA).  
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3.2.2.3 Reverse transcription real-time qPCR 
Total RNA was reverse transcribed and amplified following the method described in 
Chapter 2, Section 2.3.6. Primers for GAPDH and IGF1 and IGFBP3 are shown in 
Table 5.  
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 Table 5: Primer sequences for GAPDH, IGF1, IGF2, IGFBP3 and IGF1R. 
 
Gene Forward primer (5' to 3') Reverse primer (3' to 5') Product Size 
GAPDH TTGTCAAGCTCATTTCCTGGTAT TCTCTCTTCCTCTTGTGCTCTTG 150 bp 
IGF1 CCCAACCCAGCCCTTATTAT CCCCATCTCACAAAAAGGAA 146 bp 
IGF2 GAAGGACCCCAGAAATCACA TGATGGAAAAGGGAGTGAGG 132 bp 
IGFBP3 GTGGATCCCTCAACCAAGAA TAGGTTCCCAGAGTGCCCTA 139 bp 
IGF1R CCATTCTCATGCCTTGGTCT TGCAAGTTCTGGTTGTCGAG 114 bp 
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3.2.2.4 Cell media protein analysis 
Following AFB1 treatment of cells for 24 and 48 hours, conditioned cell media were 
collected and centrifuged at 1000 g for 5 minutes to separate cell debris. The 
supernatant was enriched using Vivaspin 2 ultrafiltration columns with 3000 
Molecular Weight Cut Off (MWCO) polyethersulfone (PES) membrane (Sigma-
Aldrich, Dorset, England, UK). The columns were centrifuged at 4000 g for 50 
minutes at room temperature to obtain approximately 30-times concentrated media, 
which were analysed immediately.  
IGF1 and IGFBP3 protein levels in concentrated cell media were measured using the 
IGF1 and IGFBP3 Quantikine ELISA kits (R&D Systems, Abingdon, UK) as 
described in Chapter 2, Section 2.2.2. 
 
3.2.3 Statistical Analyses 
As AF-alb, IGF1 and IGFBP3 levels were not normally distributed all three 
parameters were natural-log transformed before statistical analysis. Geometric means 
and 95% confidence intervals (CI) for AF-alb, IGF1 and IGFBP3 are presented 
unless otherwise stated. Multivariate and univariate regression analyses were carried 
out to determine if AF-alb was inversely associated with child growth parameters. 
Stata IC software was used for these analyses (version 10, StataCorp, College 
Station, TX, USA). Regression and structural equation modelling for path model 
analyses were constructed to determine if AF-alb was associated with impaired child 
height through lower IGF1/IGFBP3 levels using Amos Graphics (version 5, Amos 
Development Corporation, IBM Corp, NY, USA). Standardised and non-
standardised coefficients were calculated based on the path model involving AF-alb, 
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IGF1, height and age. Confidence intervals and P values were calculated employing 
a bootstrap approach. For the in vitro normal HHL-16 liver cell model, student’s t-
test was used to compare each treatment with their respective controls and P values 
< 0.05 were considered statistically significant. 
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3.3 Results 
3.3.1 Aflatoxin-albumin adduct, IGF1 and IGFBP3 protein 
levels in Kenyan school children 
A description of the study population, including measured AF-alb, IGF1 and 
IGFBP3 levels is summarised in Table 6.  There were no significant differences in 
the mean age, height and weight between children from the two schools, although 
boys were taller and heavier than girls. There were no significant differences in IGF1 
and IGFBP3 levels in children from the two schools. Both parameters were 
significantly higher in boys compared to girls [geometric mean: 123.1 ng/ml (95% 
CI: 110.3, 138.4) vs 87.2 ng/ml (79.3, 96.1) for IGF1 and 2065.4 ng/ml (1913.2, 
2229.1) vs 1776.6 ng/ml (1654.3, 1908.3) for IGFBP3)] and increased with age 
(regression coefficient: 0.07, P < 0.001 for IGF1 and 0.02, P = 0.02 for IGFBP3).  
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Table 6: Characteristics of the children in the Kenyan study. 
 Mean ± standard deviation or Geometric mean (95% CI)a 
Variable Yumbuni Matangini Total 
N 119 80 199 
Age (y) 11.7±3.0 12.6±2.8 12.0±3.0 
Height (cm) 133.0±13.5 134.4±13.0 133.5±13.3 
Weight (Kg) 27.3±8.1 29.2±8.9 28.1±8.4 
AF-alb (pg/mg)
a 72.2 (60.7-86.0) 207.7 (172.3-250.4)* 110.5 (95.4-127.9) 
IGF1 (ng/ml)
a 105.0 (94.8-116.2) 98.1 (86.5-111.3) 102.2 (94.4-110.5) 
IGFBP3 (ng/ml)
a 1959.8 (1825.4-2104.2) 1819.8 (1685.9-1964.4) 1902.3 (1674.4-1875.8) 
a 
geometric mean (95% CI) presented for these parameters 
* P < 0.001 
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AF-alb levels were significantly higher in children from Matangini compared to 
those from Yumbuni (207.7 pg/mg vs. 72.2 pg/mg; P < 0.001) (Gong et al. 2012). 
Differences in the AF-alb mean levels were not significant (P > 0.05) between sexes, 
and there was no significant association (P > 0.05) between AF-alb and child age. 
There was no significant difference in malarial infection status between Yumbuni 
and Matangini. However, schistosomiasis infection egg counts were significantly 
higher in children belonging to Matangini than in those belonging to Yumbuni 
(Gong et al. 2012). Both malaria and schistosomiasis infection status were not 
significantly associated (P > 0.05) with either IGF1, IGFBP3 or AF-alb adduct 
levels.  
 
3.3.2 AF-alb, IGF1 and IGFBP3 and growth 
There was no significant correlation (P > 0.05) between AF-alb and child height or 
weight. The schoolchildren were dichotomised using an AF-alb cut-off at 400 pg/mg 
as this was the point at which the relationship between AF-alb levels and height 
became linear. Using this criterion, a significant 3.8 cm decrease in body height was 
observed in children belonging to the higher exposure group compared to those in 
the lower exposure group after adjusting for age, sex, school, disease state and 
infection status (overall adjusted R
2 
of model = 0.636, P = 0.018). Linear regression 
analysis revealed that AF-alb was inversely associated with IGF1 (regression 
coefficient: -0.27 (95% CI: -0.524, -0.014), P = 0.039) and with IGFBP3 (-0.39 
(95% CI: -0.778, -0.007), P = 0.046).  
Path analysis using structural equation modelling was introduced to establish the 
path and directionality of the relationship between AF-alb, height and IGF1 or 
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IGFBP3 levels with age as an effect mediator, as both IGF1 levels and height are 
influenced by age. This work was done with input and advice from Dr. Yu-Kang Tu, 
University of Leeds. The model shown in Figure 5 had an acceptable fit (χ2 = 0.343, 
degrees of freedom = 1; P = 0.558). The non-standardised and standardised 
regression coefficients as well as the P values were obtained using the statistical 
software Amos Graphics with these results being summarised in Figure 5. 
Approximately 16% of the effect of AF-alb on child height can be attributed to lower 
IGF1 levels (estimated using standardised coefficients of the direct and indirect 
effects) (P = 0.052). A similar path diagram was tested for IGFBP3 but an indirect 
effect of AF-alb on height through IGFBP3 was not significant (P = 0.26).  
 
Figure 5: Diagram of the path analysis result for the effects of aflatoxin on height depicting 
both direct and indirect effects. Age was used as an effect mediator. Non-standardised 
regression coefficients (with standardised displayed in parentheses) are displayed for each 
path (represented by an arrow). P values are also shown with those considered to be 
statistically significant displayed in bold. AF-alb is inversely associated with child height 
through a direct pathway. An association between AF-alb and child height through altered 
IGF1 levels can be observed (P = 0.052). IGF1 and age significantly influence child height 
while age has a strong effect on plasma IGF1 levels. 
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3.3.3 Cytotoxicity of AFB1 on HHL-16 cells 
Cell viability following 24 hour, 48 hour and 72 hour AFB1 treatment was 
determined relative to the DMSO controls (Figure 6).  There was a significant 
reduction in viability at 20 µg/ml AFB1 and higher doses at 24 hours of treatment (P 
< 0.05) and at 10 µg/ml AFB1 and above at 48 and 72 hours of treatment (P < 0.05). 
At 48 hours treatment, cell viability was less than 50% in all doses above 10 µg/ml. 
After 72 hour treatment, viability was as low as 6% in cells treated with 100 µg/ml 
AFB1. 
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Figure 6: Cytotoxicity test at 24, 48 and 72 hours of treatment with 9 AFB1 doses along with DMSO controls for HHL-16 liver cells. Acute toxicity is 
observed in cells treated with 20 µg/ml AFB1 or above following 48 and 72 hours of exposure while no significant toxicity can be seen in untreated and 
DMSO controls.
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3.3.4 IGF gene expression in AFB1 treated HHL-16 
IGF gene expression, measured using reverse transcription qPCR, across control and 
treatment groups is shown in Figure 7. After 24 hours of treatment with AFB1, very 
little change was observed in IGF gene expression levels, although at the highest 
dose, significantly lower expression was observed for IGFBP3 (2.4 fold change 
compared to control, P = 0.005). Expression of both IGF genes was significantly 
reduced following a 48-hour treatment with 5 and 20 µg/ml AFB1 with an average 2 
fold change in expression compared to controls (P < 0.05). 
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Figure 7: Graphs depicting gene expression relative to untreated cells (NT) in HHL-16 cells for IGF1, IGF2, IGFBP3 and IGF1R across 
treatment groups- Untreated (NT), 0.0025% DMSO (D5), 0.1% DMSO (D20), 0.5 µg/ml AFB1 (A0.5), 5 µg/ml AFB1 (A5) and 20 µg/ml 
AFB1 (A20). * P < 0.05. 
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3.3.5 IGF1 and IGFBP3 protein levels in AFB1 treated 
HHL-16 
IGF protein levels in cell culture media were measured by ELISA, following 24 and 
48 hour AFB1 treatment. As with the trend observed in expression, protein levels 
were also reduced with increasing AFB1 dose (see Figure 8). Overall, IGF protein 
expression increased with incubation time, although this was more obvious for 
IGFBP3 levels. However, the effects of AFB1 on protein levels were still apparent. 
IGF1 levels were significantly lower in cells treated with 20 µg/ml AFB1 after 24 
hours (P < 0.05) and at 5 µg/ml and 20 µg/ml AFB1 after 48 hours (P < 0.001). 
IGFBP3 protein levels were significantly lower at 5 µg/ml and 20 µg/ml AFB1 
following 24 hours and at all three doses after 48 hours of treatment. Protein levels 
were drastically reduced at the highest AFB1 dose with a 2-fold average decrease (P 
< 0.001) (Figure 8).  
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Figure 8:  Graphs depicting cell media protein levels relative to untreated cells (NT) in HHL-16 cells for IGF1 and IGFBP3 across treatment 
groups- Untreated (NT), 0.0025% DMSO (D5), 0.1% DMSO (D20), 0.5 µg/ml AFB1 (A0.5), 5 µg/ml AFB1 (A5) and 20 µg/ml AFB1 (A20). * 
P < 0.05; ** P < 0.01. 
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3.4 Discussion 
This work aimed to determine if the IGF growth axis plays a role in the mechanism 
of aflatoxin-associated child growth impairment in humans. The current study 
extends previous research to provide some evidence of the mechanistic action of 
aflatoxin on child growth. Aflatoxin exposure through contaminated feed has been 
implicated in severe growth retardation in ducks, pigs and broiler chicks (Han et al. 
2008; Dersjant-Li et al. 2003). This association has also been seen in West African 
children exposed to aflatoxins through consumption of maize and groundnut-based 
food (Gong et al. 2002; Gong et al. 2004). Observations in the current study 
corroborate this finding as exposure to 400 pg/mg or more AFB1 was associated with 
a significant 3.8 cm decrease in child height compared to children with lower AFB1 
exposure, after adjusting for confounding factors including age, sex, schistosomiasis, 
malarial infection status and school.  
The role of the major components of the IGF axis in growth is well established 
(Grimberg and Cohen 2000). IGF2 is a very important factor in human foetal growth 
(Randhawa and Cohen 2005), and following birth, IGF1 plays a prominent role in 
child growth (Grimberg and Cohen 2000). The presence of binding proteins, 
particularly IGFBP3, regulate the growth axis by controlling the levels of free IGF1 
in circulation and prolonging the half-life of IGF1 (Grimberg and Cohen 2000). The 
growth promoting effects of IGF2 and IGF1 during the different phases of child 
growth are mostly manifested through IGF1R (Grimberg and Cohen 2000). 
Therefore, the growth retardation associated with AFB1 exposure may be caused by 
changes to the expression of key members of the IGF growth axis. 
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Through the use of a population-based study and an in vitro liver cell-based model, 
this study provides evidence that aflatoxin exposure-induced disruption of the IGF 
growth axis contributes to growth impairment. Serum IGF1 and IGFBP3 levels in 
school-age children were lower when children were exposed to higher levels of 
aflatoxin. Results from the path analysis approach revealed that ~16% of the effect 
on child height by aflatoxin exposure was attributed to reduced IGF1 levels (P = 
0.07), indicating a potential pathway between aflatoxin and child stunting. While 
schistosomiasis and malarial infection status may have been confounders due to their 
potential impact on child growth, it has already been shown that in the current cohort 
of school children, neither infection was associated with growth stunting (Wilson et 
al. 2010). Other factors contributing to aflatoxin exposure-associated child stunting 
may include immune function changes and infections and possible damage to gut 
function through aflatoxin exposure leading to poor nutrient absorption (Wild and 
Gong 2010). A multi-component path effect may be responsible for the total effect of 
aflatoxin exposure on reduced child height gain.  
To examine the effects of AFB1 on IGF axis components, an in vitro model was set 
up using non-tumourigenic liver cells, HHL-16. More commonly studied liver cell 
lines such as HepG2 were not utilised in this study to avoid any bias towards gene 
expression and protein analysis due to cancer-related changes. Derived from a 
healthy human liver, HHL-16 cells have been immortalised with Moloney’s mouse 
leukaemia virus and retain primary hepatocyte characteristics, expressing 
hepatocyte-specific markers as well as cytochrome P450 enzymes (Clayton et al. 
2005). In the present study, these cells were treated with three AFB1 doses for one to 
two days- conditions chosen based on cytotoxicity data. Reverse transcription qPCR 
as well as ELISA analyses correlated well showing that AFB1 inhibited gene and 
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protein expression of IGFs in liver cells, particularly following 48 hours treatment 
with the higher AFB1 doses. These observations provide substantial evidence that 
AFB1 exposure alters expression and production of IGF axis components that play a 
key role in growth. 
Previously, it was reported that primary human hepatocytes exposed to 0.02 µg/ml 
and 0.12 µg/ml of AFB1 had repressed IGFBP3 and IGF1 expression (Josse et al. 
2012). Interestingly, exposure to other mycotoxins has been associated with a 
decrease in IGF gene expression or IGF1 protein levels. For instance, ochratoxin A 
was found to down regulate IGFBP1 and IGF2 gene expression in the human 
hepatocellular cell line, HepG2  (Hundhausen et al. 2009), while it has been 
proposed that another mycotoxin, DON causes growth retardation in mice by 
lowering plasma IGF1 and IGF-ALS levels (Amuzie and Pestka 2010). These 
changes suggest that mycotoxin-associated growth impairment may follow a similar 
pathway involving the disruption of the IGF growth axis.  
It has been shown that maternally ingested aflatoxins can cross the placental barrier 
and are metabolised to produce aflatoxicol, which is carcinogenic (Partanen et al. 
2010; Maxwell et al. 1989). As it has been observed that aflatoxin exposure can 
occur during weaning as well as later in life (Gong et al. 2003; Wild and Gong 
2010), the effects it may have on the IGF growth axis may occur during critical early 
development altering some or all of the major components necessary for the normal 
functioning of the growth axis.  
Results from this study provide evidence for the hypothesis that reduced IGF1 levels 
contribute to aflatoxin-associated growth impairment. Other factors involved in 
growth and development may also be involved in the mechanism. Additionally, 
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aflatoxin exposure causes a significant reduction in IGF axis gene and protein 
expression in a non-tumourigenic liver cell line providing further support to its 
effects on the IGF axis.  
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4 Seasonal and gestation-stage associated 
differences in dietary aflatoxin exposure 
in pregnant Gambian women 
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4.1 Introduction 
The development of aflatoxin exposure biomarkers has facilitated advances in 
aflatoxin research and has contributed to our understanding of causal relationships 
between dietary exposure and health effects. Measurement of the blood AF-alb 
biomarker revealed that exposure to aflatoxin is prevalent in many people living in 
sub-Saharan Africa and other low- to middle-income regions (Wild and Gong 2010). 
The AF-alb biomarker has contributed to the discovery that chronic dietary exposure 
to aflatoxin is not only associated with development of hepatocellular carcinoma 
(Gomaa et al. 2008; Wild and Montesano 2009) but also with child growth faltering 
(Gong et al. 2002; Gong et al. 2004) and immune function impairment (Turner et al. 
2003; Jiang et al. 2005).  
Aflatoxin contaminates a large proportion of the world’s staple foods, including 
maize and groundnuts (Wild and Gong 2010). Seasonality has been identified as an 
important factor in determining aflatoxin exposure in West Africa (Hell et al. 2000; 
Wild et al. 2000; Cotty and Jaime-Garcia 2007). Contamination levels are usually 
higher following harvest and a period of storage during the annual dry season from 
November to May, when compared to levels during the rainy season from June to 
October (Wild et al. 2000). The latter has also been called the ‘hungry’ (as compared 
to the dry ‘harvest’) season because it is a period of intense physical activity but with 
depleted stores of staple foods (Thomson et al. 1966).   
Exposure to aflatoxin has been consistently reported to be high in The Gambia 
(Allen et al. 1992; Wild et al. 2000; Turner et al. 2000). Maternal exposure to 
aflatoxin has been significantly associated with lower height and weight gain in 
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infants during the earlier years of life (Turner et al. 2007). Additionally, it is known 
that aflatoxin can cross the placental barrier leading to fetal exposure during 
pregnancy (Partanen et al. 2010). This is supported by the fact that AF-alb can be 
detected in cord blood samples (Abdulrazzaq et al. 2002; Turner et al. 2007). 
However, it is unclear whether aflatoxin exposure changes during pregnancy, and 
how such change may adversely affect the health of the mother and her child. The 
implications of exposure to aflatoxin in utero are significant, as exposures at this 
crucial stage can have long term-effects, including epigenetic modifications that can 
alter gene expression, potentially affecting the immune system, growth and 
development. This part of the study aimed to understand aflatoxin exposure status at 
the early and later pregnancy in rural Gambian women and explored possible 
interactions with seasonal impact on the aflatoxin exposure. 
 
4.2 Methods 
4.2.1 Study subjects 
The current study utilised samples collected from two parallel studies in rural 
Gambia. Both studies were designed and executed by Dominguez-Salas et al., MRC 
International Nutrition Group, London School of Hygiene and Tropical Medicine, 
London, UK. The first study was a trial of pre-natal and infant nutritional 
supplementation on infant immune development: the ‘ENID’ Trial (Early Nutrition 
and Immune Development; ISRCTN49285450) (Moore et al. 2012). The second 
study, ‘Methyl Donors and Epigenetics’ (MDEG), was embedded within the ENID 
Trial, and followed a sub-cohort of women who conceived during the peak 3 months 
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of the rainy or dry seasons to study the impact of nutrition at the time of conception 
on DNA methylation patterns in offspring (Dominguez-Salas et al. 2013). The ENID 
and MDEG studies were performed in the West Kiang region of The Gambia, a rural 
subsistence farming community of savannah and farmland. All women, aged 18-45 
years, were invited to participate in both studies, and informed consent was obtained. 
Once enrolled, women were visited monthly by a field assistant to record the date of 
last menstrual period. Where a menses had been missed, pregnancy and date were 
confirmed by a urine pregnancy test and for those testing positive, a subsequent 
ultrasound test was arranged in the MRC Keneba clinic. Also, a blood sample was 
collected before 16 weeks of pregnancy. At 16-33 weeks gestation, further blood 
samples were collected as part of the ENID study. Data on height, weight, village 
and self-reported ethnicity was also collected for all women.  
Blood samples from 134 women recruited for the MDEG study were available for 
analysis. These blood samples, collected before 16 weeks of pregnancy as part of the 
MDEG study, were defined as early pregnancy samples, with the sampling falling 
either in the rainy (June to October) or dry (November to May) seasons. For 99 of 
these women, blood samples were also available for a second AF-alb test from a 
collection at a later time during pregnancy (between 16-33 weeks), which was 
collected as part of the ENID study. These samples were defined as later pregnancy 
samples in this study. The 99 paired blood samples collected from both the early and 
later pregnancy time points were subsequently used to investigate aflatoxin exposure 
changes between pregnancy stages. For individual women, there was at least six 
weeks between the collection of the early and later blood samples. 
Blood collected into EDTA vacutainer tubes was centrifuged at 2750 g for 10 
minutes at 4ºC. They were then stored at -80°C before being shipped to the 
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University of Leeds, UK for blood albumin and AF-alb biomarker analysis. Ethical 
approval was obtained from the Gambia Government/MRC Gambia Joint Ethics 
Committee and written informed consent was obtained from each participating 
woman.  
 
4.2.2 Blood albumin and AF-alb biomarker analysis 
Plasma samples were analysed for AF-alb using a modified competitive ELISA, as 
previously described in Chapter 2, Section 2.1.1 (Chapot and Wild 1991). Plasma 
albumin levels were measured according to the method described in Chapter 2, 
Section 2.1.1.  
 
4.2.3 Gambian diet 
Dietary information was unavailable for the pregnant Gambian women included in 
the study. Therefore, data on intake of groundnut and maize-containing dishes for 
non-pregnant women of reproductive age were analysed to gauge dietary trends in 
Gambian women. This data was collected by Dominguez-Salas et al., MRC 
International Nutrition Group, London School of Hygiene and Tropical Medicine, 
London, UK.  
A total of 61 Gambian non-pregnant women aged 18-45 years belonging to 
Jiffragong, Janneh Kunda and Keneba villages in the rural area of West Kiang were 
recruited and followed from July 2009 to June 2010. Women were excluded from the 
study if pregnant, severely anaemic, at menopause, using contraceptives or planning 
to move away during the course of the study. Ethical approval was obtained from the 
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joint Gambian Government/MRC Ethics Committee (SCC/EC 1151) and the London 
School of Hygiene and Tropical Medicine Ethics Committee (EC 5525). Informed 
written consent was obtained from each woman prior to participation.  
The main dietary composition and food weights were determined per day for each 
woman. Food intake was determined by a 24-hour weighed dietary record on two or 
more days per month. All meals including snacks were weighed and recorded. In the 
current work, intake of groundnuts and maize were important as potential sources of 
aflatoxin contamination. For this reason, only dishes clearly containing groundnuts 
or maize were included. Some dishes utilised groundnuts as part of a recipe where 
the dish constituted another main ingredient. However, the exact amount of 
groundnuts per dish was difficult to extract from each recipe. Therefore, cases where 
groundnuts were noted clearly to be part of a sauce or snack or eaten raw were 
included. 
To determine groundnut intake, the number of times groundnuts were consumed per 
day and per meal for each woman during each season was calculated. Increase and 
decrease were defined by a difference of at least 5 g/day or 5 g/meal between 
seasons. Groundnut intake frequency was also calculated per woman per season. 
Increase and decrease in frequency were defined by any difference in frequency 
above 0.0 between seasons. 
 
4.2.4 Statistical analysis 
AF-alb was not normally distributed and was natural-log transformed prior to 
statistical analyses. Geometric means (GM) with 95% CI are presented for AF-alb 
levels. Differences in albumin and AF-alb levels by stage of pregnancy and by 
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season of blood collection were tested using the Student’s t-test. ANOVA analysis 
was used to determine associations between AF-alb levels and stage of pregnancy, 
and season of blood collection. An interaction model was constructed to test the 
interaction relationship between the stage of pregnancy and season of blood 
collection.  For the 99 women with paired AF-alb data Spearman rank correlation 
analysis was used to establish correlation between the AF-alb at the two stages of 
pregnancy. Student’s t-test was used to test differences in groundnut intake and 
frequency between seasons. 
A P < 0.05 was considered statistically significant. All data analyses were done on 
Stata IC software (version 11, StataCorp, College Station, TX, USA). 
 
4.3 Results 
At the time the early pregnancy samples were collected, the average age of the 
women (mean ± SD) was 28.9 ± 6.5 years (range, 18-45 years).  Eighty-six % of the 
women were from Mandinka ethnicity background, while the remaining belonged to 
other ethnic backgrounds. 
Early pregnancy samples were obtained from 47 women during the dry season and 
from 87 women during the rainy season. The mean gestation week of these women 
(mean ± SD) was 8 ± 4 weeks, (range 0-15 weeks). Of the 99 women who were 
followed-up for AF-alb measurement during later pregnancy, 47 provided samples 
during the dry season and 52 during the rainy season. The mean gestation week at 
the second sampling was 27 ± 3 weeks (range 16-33 weeks). There was an average 
19 ± 5 weeks (range 6-33 weeks) gap between the two collections.  
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4.3.1 Blood albumin and AF-alb biomarker analysis 
The blood albumin and AF-alb levels by season of blood collection and stage of 
pregnancy are summarized in Table 7. The blood albumin levels were significantly 
higher during the early stages of pregnancy compared to the later stage (37.2 ± 9.1 vs 
48.1 ± 14.9 mg/ml, P < 0.001), and there was no significant difference in albumin 
levels between blood collected during the dry or rainy season (P = 0.649).  
All samples tested had detectable AF-alb levels. AF-alb levels ranged from 4.8 to 
521.6 pg/mg during early pregnancy and from 4.4 pg/mg to 556.5 pg/mg during later 
pregnancy.  AF-alb levels were not compared between villages due to the very small 
number of subjects per village. Age and ethnicity background were not correlated 
with AF-alb levels.  
We assessed aflatoxin exposure by season of blood collection. The blood AF-alb was 
higher during the dry season when compared to the rainy season, in both early and 
later pregnancy stage (68.7 vs 26.6 pg/mg, P < 0.001 for later pregnancy), although 
the difference did not reach a statistical significance at the early pregnancy stage (see 
Table 7 and Figure 9).  
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Table 7: Blood albumin (mg/ml) and AF-alb (pg/mg albumin) levels by season and stage of pregnancy. 
 Albumin 
 Dry Season 
Mean ± SD 
Rainy Season 
Mean ± SD 
Total 
Mean ± SD 
Early pregnancy 
 
50.2 ± 14.6 
(N = 47) 
47.0 ± 15.0 
(N = 87) 
48.1 ± 14.9 
(N = 134) 
Later pregnancy 
 
37.8 ± 8.7* 
(N = 47) 
36.6 ± 9.7* 
(N = 52) 
37.2 ± 9.1* 
(N = 99) 
 AF-alb 
 Dry Season  
Geometric mean (95% CI) 
Rainy Season     
Geometric mean (95% CI) 
Total                                  
Geometric mean (95% CI) 
Early pregnancy 
 
40.6 (29.5, 55.8) 
(N = 47) 
31.6 (26.2, 38.1) 
(N = 87) 
34.5 (29.3, 40.7) 
(N = 134) 
Later pregnancy 
 
68.7 (52.6, 89.7)* 
(N = 47) 
26.6 (21.9, 32.4)
a 
(N = 52) 
41.8 (34.7, 50.3)
b 
(N = 99) 
* Significant difference between data at early and later stages of pregnancy, P < 0.05 
a 
Significant difference between AF-alb levels in dry and rainy seasons at the later stage of pregnancy, P < 0.001 
b 
Significant difference between total AF-alb levels between the early and later stages of pregnancy, P < 0.028 
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Figure 9: Geometric means of aflatoxin-albumin adduct levels presented by month of bleed with amount of rainfall per month collected during 2009-
2010. A- Early Pregnancy (134 women at 0-15 weeks); B- Later Pregnancy (99 women followed up at 16-33 weeks). 
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AF-alb levels were significantly higher during later pregnancy compared to early pregnancy 
(41.8 pg/mg vs 34.5 pg/mg, P = 0.028). The AF-alb showed a marked difference between the 
two pregnancy stages when samples were collected in the dry season (68.7 pg/mg at the later 
stage vs 40.8 pg/mg at the early stage, P = 0.012), but no difference was found between the 
two pregnancy stages when samples were collected during the rainy season (26.6 pg/mg at 
the later stage vs 31.6 pg/mg at early stage, P = 0.234). 
The interaction of season of blood collection and stage of pregnancy was further investigated 
using an ANOVA model (Table 8). The overall model was statistically significant (F = 10.87, 
P < 0.001), A significant interaction effect on AF-alb between pregnancy stage and season 
was found in these women (P = 0.004), with a 2-fold difference between the exposure in the 
later pregnancy at dry season as compared to early or later pregnancy at rainy season 
although using a similar ANOVA approach no interaction on blood albumin was found 
between pregnancy stage and season (P = 0.56).  
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Table 8: ANOVA analysis indicating the interaction of stage of pregnancy and season of blood collection on AF-alb but not on albumin. 
Variables  
Blood  AF-alb 
F,  P 
Blood Albumin 
F,  P 
Pregnancy stage (early vs later pregnancy) 2.14,  0.145 45.5, <0.001 
Season of blood collection (dry vs rainy season) 24.41,  < 0.001 1.55,  0.21 
Pregnancy stage *  season of blood collection 8.29,  0.004 0.33,  0.56 
F – F statistic 
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Correlation between AF-alb at early and later pregnancy was tested using Spearman’s 
correlation analysis. The rank order of AF-alb for each woman at early and later stage of 
pregnancy was positively correlated (Spearman’s coefficient: 0.231, P = 0.022).  The women 
were then dichotomised into high and low aflatoxin exposure groups using the median AF-
alb as cut-off values (31.5 pg/mg and 41.2 pg/mg for early and later pregnancy, respectively). 
When progressing from early to later pregnancy 55% of the women remained in the same 
exposure group, whilst others shifted their exposure groups but in agreement with the 
expected changes due to a shift in blood collection season, i.e. a shift from low to high 
exposure happened when blood collection for early and later pregnancy shifted from rainy to 
dry season, respectively (Table 9).   
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Table 9: Status of aflatoxin exposure (high or low category) of pregnant women by stage of pregnancy (early or later). 
Category of AF-alb at 
early vs later stage of pregnancy 
N. Potential reason for change of exposure group  
Low to Low 28 
55% of the 99 women were in the same exposure group  
High to High 26 
Low to High 24 
79% of the 24 women shifted from rainy to dry season, 8% shifted from dry to rainy 
season,13% remained in the same season 
High to Low 21 
48% of the 21 women shifted from dry to rainy season, 19% shifted from rainy to dry season, 
33% remained in the same season 
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4.3.2 Gambian diet 
Only 18% of the 61 non-pregnant women consumed maize either in the form of flour, roasted 
or as part of a dish over an average of 2 days per month consuming 1-3 portions per day. 
Therefore, no further analysis was done on maize consumption in these women. 
The increase and decrease in groundnut intake by season was determined and is displayed in 
Table 10. A majority of the women had significantly higher groundnut intake during the dry 
season than the rainy season when considering intake per day or intake per meal (P < 0.001). 
This is expected as the rainy season is a period of intense activity and poor food intake due to 
low availability. However, 10-11 women did significantly increase their groundnut intake in 
the rainy season compared to the dry season (P < 0.005). This may be attributed to higher 
availability through purchase from the market or other means for some women during the 
rainy season.   
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Table 10: Change in dietary groundnut intake per day or per meal for each woman by season. 
Change from dry 
to rainy season 
Intake/day Intake/meal 
Number of 
women (%) 
Dry Season 
Mean ± SD (g/day) 
Rainy Season 
Mean ± SD 
(g/day) 
Number of 
women (%) 
Dry Season 
Mean ± SD 
(g/meal) 
Rainy Season 
Mean ± SD 
(g/meal) 
Increase 11 (32.4%) 300.2 ± 140.6 424.0 ± 163.3 * 10 (29.4%) 178.6 ± 88.5 299.4 ± 156.8 * 
Similar 1 (2.9%) 158.5 162.0 1 (2.9%) 76.7 79.5 
Decrease 22 (64.7%) 350.5 ± 237.1 183.1 ± 128.5 * 23 (67.6%) 218.0 ± 112.4 124.5 ± 74.9 * 
* P < 0.005 when comparing dry with rainy season 
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Groundnut intake frequency calculated per woman per season is displayed in Table 11. 
 
Table 11: Change in dietary groundnut intake frequency per day for each woman by season. 
Change from dry to 
rainy season 
Frequency of groundnut intake 
Number of women 
(%) 
Dry Season 
Mean±SD 
frequency 
Rainy Season 
Mean±SD 
frequency 
Increase 15 (44.1%) 1.39 ± 0.39 1.95 ± 0.37 * 
Similar 5 (14.7%) 1.3 ± 0.27 1.3 ± 0.27 
Decrease 14 (41.2%) 1.79 ± 0.47 1.25 ± 0.27 * 
* P < 0.001 when comparing dry with rainy season 
 
A similar number of women either significantly increased or decreased their frequency of 
groundnut intake from the dry season to the rainy season (P < 0.001).  
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4.4 Discussion 
The present work investigated changes in aflatoxin exposure during pregnancy, 
confirmed the effect of seasonality on aflatoxin exposure in Gambian women and 
also revealed differences in exposure between the early and later stages of pregnancy 
during the dry season. Additionally, we found that aflatoxin exposure was likely to 
stay high or low during the early and later pregnancy in the majority of the Gambian 
women studied. A change from low to high aflatoxin exposure status was most likely 
associated with a change in season of blood collection from rainy to dry or vice 
versa. These findings have important implications for in utero child health effects as 
it has been established that aflatoxin B1 can cross the placenta (Partanen et al. 2010) 
and exposure to aflatoxin in utero has been previously linked to impaired child 
growth (Turner et al. 2007).  
In the present study, during the early and later stages of pregnancy, all Gambian 
women had detectable AF-alb levels, which were consistent with exposure data from 
previous studies based in this region (Wild and Turner 2002; Turner et al. 2007). 
Previous analysis has shown that mean levels of AF-alb adducts in Gambian adults is 
at least 5-fold higher than exposure levels observed in adults in the USA and Europe 
(Montesano et al. 1997). Our data shows that the mean exposure levels in the 
Gambian women (34.1 pg/mg during early pregnancy and 41.9 pg/mg during later 
pregnancy) were similar to levels previously reported in Gambian adults (Wild et al. 
1990a; Wild et al. 1992; Wild et al. 2000).  
The diet in West Kiang typically consists of a staple (refined white rice, millet or 
maize) with a groundnut based sauce often mixed with other ingredients such as 
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green leaves, fish or vegetables (Prentice et al. 1993). The most likely sources of 
aflatoxin exposure are contaminated groundnuts and, to a lesser extent, maize, which 
form key components of the diet in The Gambia (Hudson et al. 1992). Harvest of 
groundnuts usually occurs between September and November (Roberts et al. 1982; 
Turner et al. 2000), following which they are either sold or stored in large open 
heaps making them susceptible to insect damage and fungal growth. The higher 
levels of AF-alb observed during the dry season as compared to the rainy season 
reflect the elevated production of aflatoxin in groundnuts and maize during this 
period. In addition, the rainy season is a period of heavy farming activity and food 
shortages (Paul et al. 1979; Roberts et al. 1982), which could result in lower 
consumption of contaminated grains and, therefore, lower exposure.  
Analysis of the diet in non-pregnant Gambian women revealed significant 
differences in groundnut intake between the dry and rainy seasons with over 60% of 
the women consuming less groundnut-containing dishes in the rainy season. Intake 
amounts and frequency would depend on availability, harvest times and trade 
patterns where some families may be able to afford to buy more food than poorer 
families and so would affect the outcome of any analysis. This dietary analysis was 
not conducted in Gambian women recruited for aflatoxin exposure during 
pregnancy. Therefore, the dietary analysis done in this work may have missed any 
differences in diet due to pregnancy, which may influence aflatoxin exposure. 
However, this analysis does reflect the general patterns in diet in Gambian women 
during 2009-2010.  
In the dry season we also observed higher levels of aflatoxin exposure in women 
during later pregnancy compared to early pregnancy. A statistically significant 
interaction exists between the stage of pregnancy and season of blood collection such 
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that the mean AF-alb level was more than doubled in blood collected during the dry 
season at later pregnancy as compared to that in blood collected during the rainy 
season at later pregnancy. It is possible that severe food shortage in the rainy/hungry 
season has restricted the women from consuming more food to meet the increasing 
demand in later pregnancy, whilst in the dry season when food supply is better; the 
increased consumption needed to meet the demand in later pregnancy can be 
satisfied. Thus, higher consumption during later pregnancy in the dry season is 
responsible for the increased aflatoxin exposure, even when the increased 
contamination during the dry season is taken into account. Although it is possible 
that other factors not investigated here could contribute to differences in exposure 
patterns (for example geographical location and socioeconomic status) the finding 
that later pregnancy may be associated with higher exposure may reveal a high risk 
period for in utero exposure.  
It is worth noting that albumin concentrations were lower in later pregnancy versus 
early pregnancy. This is consistent with previous observations in French and 
Canadian women whereby albumin levels dropped as pregnancy progressed (Bacq et 
al. 1996; Walker et al. 1999), possibly due to the observed increase in blood volume 
in later pregnancy (Pirani et al. 1973; Gallery et al. 1979). However, as the AF-alb 
level is presented following adjustment for albumin concentration, a discrepancy in 
albumin concentrations should not make a significant influence to the aflatoxin 
exposure assessment. The changes in albumin levels are one of several physiological 
alterations occurring during pregnancy (Mattison et al. 1991). These changes include 
an increase in the activity of the CYP3A enzyme (Tracy et al. 2005), of which type 
CYP3A4 plays an important role in the metabolism and conversion of AFB1 to the 
toxic AFB1-8,9-epoxide, which then binds DNA or albumin (Guengerich et al. 
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1998). Such modifications to metabolism of AFB1 during later pregnancy may 
explain the higher exposure observed in the present study.      
Blood albumin concentration did not change significantly between the two seasons 
of collection suggesting that the hungry period during the rainy season does not 
adversely affect blood albumin levels. It has been reported that there is no significant 
difference in energy supply for pregnant Gambian women between the dry and rainy 
seasons (Dominguez-Salas et al. 2013) an unexpected finding that was explained by 
potential financial support from extended family permitting purchase of staple foods 
in the rainy/hungry season.  
A critical ‘window of vulnerability’ exists in the early stages of fetal development, 
during which dietary exposures to aflatoxin, as in the case of other environment 
toxins, may affect the genomic programming of the foetus, including epigenetic 
changes that can subsequently modify gene expression (Gluckman et al. 2008). The 
changes introduced at this stage can be maintained throughout life and can adversely 
affect health in adulthood (De Boo and Harding 2006). However, aflatoxin exposure 
throughout pregnancy may also affect foetal development and growth as 
demonstrated in the Gambian study (Turner et al. 2007). The significantly higher 
aflatoxin exposure observed during later pregnancy in the dry season could also 
contribute to adverse effects on foetal development including growth.  
Our data shows that aflatoxin exposure for individual women was significantly 
correlated between early and later stages of pregnancy, suggesting that despite the 
effect of seasonality dietary exposure through contaminated staple food from home 
stores are the key contributor to aflatoxin exposure in these women. Variation in 
storage practices, proximity to water bodies and genetic susceptibility have also been 
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reported as important determinants of aflatoxin exposure (Hell et al. 2000; Gong et 
al. 2012) but cannot be determined from the data collected in this study.    
In summary, this work confirmed the effect of seasonality on aflatoxin exposure in 
pregnant Gambian women and identified reduced blood albumin as pregnancy 
progressed. It demonstrated an interaction between stage of pregnancy and 
seasonality on aflatoxin exposure in these women. Women in later pregnancy during 
the dry season have the highest exposure risk; high aflatoxin exposure usually 
persists throughout pregnancy, with far reaching implications to health of the women 
and their offspring.  
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5 Genome-wide effects of in utero AFB1 
exposure in Gambian infants 
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5.1 Introduction 
Our knowledge of the mechanisms of aflatoxin-associated health effects is still 
incomplete. Advances in scientific technology including whole genome expression 
and DNA methylation analyses are paving the way towards the discovery of 
potential gene targets involved in aflatoxin-related effects. Identification of genes 
involved in different pathways may add to our understanding of the mechanistic 
action of aflatoxins in humans and may also contribute to the discovery of aflatoxin 
specific expression and methylation profiles that can serve as markers of toxin 
effects. 
According to the foetal origins of adult disease, environmental exposures during the 
critical initial stages of foetal development can alter epigenetic patterns, which can 
then influence the risk of adverse health effects in later life (Lucas 1991). 
Additionally, early life environmental factors significantly affect gene expression 
patterns (Gibson 2008). Specific gene expression patterns have been identified in 
infants exposed to arsenic in utero. These expression signatures were highly 
predictive of arsenic exposure and included differential expression of genes involved 
in stress response, inflammation and apoptosis (Fry et al. 2007).  
With the evidence that environmental exposures can alter gene expression in infants 
exposed in utero the possibility exists that aflatoxin exposure may act in a similar 
way. It is therefore important to determine the effects of early life AFB1 exposure on 
genome-wide DNA methylation and gene expression patterns that can potentially 
affect infant development.  
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For this reason, we have selected a mother-child cohort based in The Gambia to 
analyse the effects of in utero AFB1 exposure on whole genome DNA methylation 
and gene expression patterns. The Gambia was selected due to high dietary 
exposures to aflatoxins consistently observed in this region (Turner et al. 2000; Wild 
et al. 2000; Turner et al. 2007). Exposure during pregnancy has been confirmed in 
the selected population in Chapter 4.  
Whilst the liver, as the target organ for AFB1 exposure-related changes, would be the 
ideal source of tissue for the comprehensive study of exposure-associated whole 
genome DNA methylation and gene expression alterations, ethical considerations 
and difficulty of obtaining such samples preclude their use. In such cases, identifying 
an easily accessible source of cells to discover unique DNA methylation and/or gene 
expression markers of exposure that also provide some insight into a potential 
mechanism of exposure-associated health effects is necessary. One of the most 
accessible sources of cells is the blood, which can be easily obtained, processed and 
analysed for DNA methylation and gene expression changes using a number of 
efficient techniques. There are a few studies in the literature supporting the use of 
blood cells as a surrogate for DNA methylation and gene expression changes in 
tissues following environmental exposures.  
In a large epigenotyping study looking at breast cancer risk and DNA methylation 
changes in peripheral blood cells, it was found that specific patterns in the blood 
cells gave a good prediction of breast cancer risk (Widschwendter et al. 2008). Also, 
two different types of breast cancer were associated with different sets of genes that 
were differentially methylated in blood cells. Interestingly, ZNF217, which is 
hypomethylated in several breast cancer cell lines and tissues, was also 
hypomethylated in blood cells even after adjusting for family history and age and 
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was associated significantly with estrogen receptor-α (ER-α) activity in serum 
(Widschwendter et al. 2008).  
Another group was able to successfully predict breast cancer outcome in 82% of the 
samples collected prior to a diagnosis using a gene expression signature in peripheral 
blood cells (PBCs) (Sharma et al. 2005). This was repeated in a larger sample size 
and it was found that the gene expression profiles predicted outcome successfully in 
about 80% of the samples. Additionally, the differentially expressed genes were 
known to be involved in defence response and metabolic processes. These results 
indicate that changes in the gene expression profile of PBCs can be used for the early 
detection of breast cancer and can reflect changes to the target tissue (Aaroe et al. 
2010). In another study, it was found that toxins that affect either the kidney or the 
liver also produce unique gene expression patterns in PBCs (Dadarkar et al. 2010).   
Interestingly, Cui et al were able to detect loss of imprinting of IGF-2 in peripheral 
blood lymphocyte DNA as an epigenetic change of colorectal cancer (CRC) (Cui et 
al. 2003). This change has also been detected in colon tissue of CRC patients (Cui et 
al. 1998) providing support to the possibility of discovering important mechanistic 
and predictive markers in the blood that reflect tissue-specific events.  
Investigations into the effects of early life exposure to AFB1 are crucial to our 
understanding of the health outcomes associated with it. A whole genome approach 
using DNA and RNA samples from infants exposed to AFB1 in utero will provide a 
glimpse into the mechanistic interactions of AFB1 on foetal development. 
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5.2 Gambian DNA methylation analysis 
5.2.1 Methods 
5.2.1.1 Sample selection and preparation 
A total of 97 infant DNA samples collected at 3-6 months of age were available for 
analysis. These infants were born to a subset of Gambian women whose AF-alb 
adduct levels were analysed and described in Chapter 4. A description of the samples 
is presented in Table 12, showing the mean aflatoxin exposure as determined in 
analyses described in Chapter 4. DNA was extracted from whole blood cells 
following the method described in Chapter 2, Section 2.4.1.1.   
 
Table 12: Geometric means (GM) and 95% confidence intervals (in parentheses) of AF-alb 
adducts in the dry and rainy seasons of conception within high and low AFB1 exposure 
groups. 
Season 
High AFB1 Low AFB1 Total 
N GM (pg/mg) N GM (pg/mg) N GM (pg/mg) 
Dry 19 
104.4 (76.0, 
143.3) 
15 
13.8 (10.5, 
18.1)** 
34 
42.7 (28.4, 
64.4) 
Rainy 28 77.7 (60.1, 100.6) 35 
14.6 (12.4, 
17.1)** 
63 
30.6 (23.8, 
39.5) 
Total 47 87.6 (71.9, 106.6) 50 
14.3 (12.5, 
16.3)** 
 
N number of samples per group  
** P < 0.001 between high and low AFB1 exposure groups 
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Samples were assigned a randomised code ID and added to the bead chips, ordered 
by ID. Samples were analysed over four batches and three samples were replicated to 
measure accuracy of the whole genome DNA methylation analysis. Samples were 
bisulfite treated and analysed by pyrosequencing for LINE1 methylation, to ascertain 
he success of bisulfite treatment, as described in Chapter 2, Section 2.4.1.2. This was 
followed by analysis using the Illumina Infinium HD 450K DNA Methylation array 
(Illumina, Freddy van Riemsdijkweg, The Netherlands), described in Chapter 2, 
Section 2.4.1.3. This whole genome sample analysis was done by Geoffroy Durand, 
IARC, Lyon, France.   
 
5.2.1.2 Data analysis of genome wide DNA methylation 
Illumina’s GenomeStudio Methylation module version 1.9 (Illumina, Freddy van 
Riemsdijkweg, The Netherlands) was used to calculate the methylation level at each 
CpG site as the beta (β) value. All data analysis was done with input and advice from 
Dr. Hector Hernandez-Vargas, IARC, Lyon, France. 
The detection P value for each β value, which represents a statistical test for the 
difference between the signal for a given probe and background (the average for all 
negative controls) was also calculated. 
β values were then log transformed to obtain the log ratio called the M value, defined 
as:  
     [
 
     
] 
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M values perform better in detecting true positives in both highly methylated and 
unmethylated DNA. Additionally, due to the transformation, M values are more 
suited to several statistical tests including the t test (Du et al. 2010).  The M values 
were analysed using RnBeads, which is an R package specific for single CpG 
resolution analysis and is used extensively in Infinium data processing (Bock 2012). 
Additionally, the methylumi package sourced from R Studio was used in conjunction 
to normalise the data (Davis S 2010). Data were normalised by scaling the 
methylated and unmethylated channel intensities to a reference array (Davis S 2010). 
Finally, the Combining Batches (ComBat) package was used to remove any batch 
effect through an empirical Bayes framework (Bock 2012). The complete analysis 
produced six modules, which are described in Table 13.  
 
Table 13: Description of RnBeads analysis modules. 
Module Description 
Loading and normalisation Summary of sample loading. Data was normalised 
using the methylumi package 
Quality control Box plots of all quality controls included in the 
450K bead chips 
Filtering Utilises a GreedyCut algorithm which filters out 
probes and samples of low purity. Also removes 
unreliable measurements with P value above 0.01 
Batch effects Determines if any batch effects exist 
Methylation profiles Displays the distribution of methylation values 
over Infinium I and II probes 
Differential methylation Determines differentially methylated probes either 
at the individual level or at the region level 
between sample groups 
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5.2.1.3 Season of conception as a confounder in DNA methylation 
analysis 
The season at the time of conception has been previously significantly associated 
with nutritional differences in the Gambia, which in turn can affect foetal 
development, particularly DNA methylation at this crucial time (Waterland et al. 
2010). For this reason, the current data was adjusted for season of conception. 
However, AF-alb levels were measured a few months following conception. 
Therefore, a separate analysis was conducted only using samples in which the season 
of conception matched the season of blood collection measurement. For example, if 
the season of conception of a sample was dry and the season of blood collection 
measurement for AF-alb analysis was also dry, the sample was included in the 
analysis. A total of 72 samples out of 97 were classed as matched in this way. These 
samples are referred to as ‘matched samples’ in the following sections.  
 
5.2.1.4 Analysis of differential methylation in Gambian infants 
Due to the large amount of data generated from the whole genome analysis, the data 
were corrected for multiple comparisons. CpG sites that were differentially 
methylated between high and low AFB1 exposure groups were identified by using a 
multivariate permutation test (Korn et al. 2007) providing 95% confidence that the 
false discovery rate (FDR) or q value was less than 5%. The FDR is the expected 
proportion of false discoveries that are present among all significant tests (Benjamini 
and Hochberg 1995). Random variance t-statistics were used for each CpG site 
(Wright and Simon 2003). Although t-statistics were used, the multivariate 
permutation test is non-parametric and does not require the assumption of normality. 
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Besides analysing changes at the individual probe level, alterations to DNA 
methylation was also assessed at the region (promoter and gene) level. A change 
occurring to a probe within the promoter or the gene body may be reflected in 
surrounding probes within the region. Additionally, when the same change occurs in 
several sites within a region, there is a greater chance of activation or repression of 
the expression of that particular gene.  
Lists of probes, genes and promoter-level differential methylation were produced 
through RnBeads after correcting for multiple testing, either adjusted for season of 
conception or unadjusted in all samples. A list of promoter-level differential 
methylation was produced for all or matched samples either adjusted or not adjusted 
for season of conception. Lists were filtered to remove all probes/genes with a q 
value above 0.05. A shorter list was produced only including genes with at least a 
3% difference in methylation levels and with a combined rank of 1000. The 
combined rank takes the fold change, the difference in methylation values between 
groups and the corrected P value or q value into account such that the higher the 
rank, the lower the significance, difference or fold change between the two groups. 
Heatmaps were also produced for gene lists derived at the promoter and gene region 
level. 
 
5.2.1.5 Pathway analysis of differentially methylated genes 
Genes identified as being differentially methylated between the two AFB1 classes, 
were examined to determine if they belonged to any pathways involved in varying 
biological processes. The significant gene lists were used in the pathway analysis. 
The pathway list was determined using the Database for Annotation, Visualization 
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and Integrated Discovery (DAVID) v.6.7. DAVID uses sources including GenBank, 
UniGene, KEGG, and Gene Ontology (GO) to compare input gene lists with large 
databases. The functional annotation tool makes use of a batch annotation and GO 
term enrichment analysis to display the most relevant GO terms associated with the 
inputted gene list (Dennis Jr et al. 2003).  
 
5.2.1.6 Validation of differentially methylated genes by 
pyrosequencing 
A total of 30 CpG sites in twelve genes (BRWD1/AS, HOXB2, HORMAD2, 
CREB3L3, USP17L1, PSMA8, SLC17A9, MIR24-2 and CD3D) were selected for 
validation by pyrosequencing in all 97 Gambian infant DNA samples. These CpG 
sites were selected both at the promoter and the gene region-level and only if the 
combined rank was below 1000 and the number of CpG sites within the gene was 
more than 30. The method used for validation is described in Chapter 2, Section 
2.4.1.2. The primer sequences and PCR conditions are summarised in Table 14.  
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Table 14: Pyrosequencing primer sequences and annealing temperatures for genes selected for validation. 
Gene symbol Forward primer (5' to 3') Reverse primer (5' to 3') 
Sequencing primer(s)  
(5' to 3') 
Annealing 
temperature 
BRWD1/AS GAGGAAGTATGGTTTAAGGG TCCTCCTACCTTAATCTTCC ATTTTTTTTTGGTTA 
54.4 
CD3D GTTTTGGGATTATTGGTGTGAG AAACATCTTCTAATTCCTCCCC 
AGTAGTTTTATTTTG (1)  
ATGTTTTATTTTTTAG (2) 
GTTGATTTATAGGTAT (3) 53.0 
CREB3L3 AGGTGGGTTGGGAGTTGTTT CTTTCCCAACCTAAACTCCC 
AGGGTTGTGAGTTTGT (1) 
TGGAGTAGAGATTTT (2) 
56.0 
HORMAD GTATAGGTGGTTTAGGTTGG AACAACCCTCACCTCAACT 
GGTTGTTGAGGGGT (1) 
AAGGTYGTTGATTT (2) 
56.0 
HOXB2 body AGGAGGAAATAGGTTAGGGAA AAACCTCTCCCCTAACCTACA Same as Forward Primer 
53.0 
HOXB2/AS1 GATTTTGGGAGGGGGAGATTT CTCTCTATTTTCCACCAAACCC 
GTTGATAAATATAA (1) 
AAATTTAGGATTTTA  (2) 
AAATTATAGGGAATT(3) 56.0 
MIR24-2 GGAAGGTAGGGGTTGTAGGT AACCCTCACCTCCTCTAACC 
TTAGTTTAGTAGGT (1) 
TGGTAGGTAGATAG (2) 
54.4 
PSMA8 GTTTGGGTGATAAAGGTTGGTAA CCNATAATAATTACTTCCTCACC 
GGAGGTAGTTTGAGG (1) 
TTTTGTAGTTTTGTG (2) 
GAATATGTTTAGGAA (3) 
53.8 
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SLC17A9 TTGTTGGGGTTGAGTTAGGG TCCCAACCCAAACTAACCCA 
GATTTAGTTAGGG (1) 
GTTAGTAGGGTGGGG (2) 
58.0 
USP17L1P ATTTGGAGGAGGAGGAGG CTACCCTCCCAAAACCC GTTTTAATTAGGTTAG 
56.0 USP17L1P (2) ATAGGGAGTTTTTTAGAATG CATCTCCATACTAAAATTAC GTATTTTATATATTG 
USP17L1P (3) GGTAATTGTGYGGTTATTGT CCCACATCATAACTTCTAAA Same as Forward Primer 
For some genes, there were more than one sequencing, forward and/or reverse primers if more than one CpG site was selected. 
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5.2.2 Results 
5.2.2.1 Distribution of differential methylation 
5.2.2.1.1 Probe-level analysis 
A comparison of high versus low AFB1 exposure was done at the probe level. While, 
some probes were identified as being differentially methylated, none had a q value 
(equivalent to FDR) below 0.05 and were therefore not considered to be significantly 
different.   
 
5.2.2.1.2 Promoter-level analysis 
The comparison of high versus low AFB1 exposure was repeated at the promoter 
level in all samples and matched samples either adjusted or not adjusted for season 
of conception. This was done to determine if different methylation patterns would be 
observed if adjusted for season of conception. Matched samples were also analysed 
to test if the fact that AF-alb measurement was done a few months following birth 
had any bearing on methylation patterns. The numbers of significant probes in these 
comparisons are displayed in Table 15.  
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Table 15: Summary of promoter-level differential methylation analysis comparing high versus low AFB1 exposure groups in all or matched samples either 
adjusted or not adjusted for season of conception. Results were corrected for multiple comparisons and loci with q values below 0.05 were considered. 
 
 
 
 
 
 
* adjusted for season of conception 
 
 
Conditions 
All Samples (n = 97) Matched Samples (n = 72) 
Non-adjusted Adjusted* Non-adjusted Adjusted* 
q < 0.05 512 316 213 210 
q < 0.05 and combined rank < 1000 180 120 62 23 
q < 0.05 and mean difference between 
groups of at least 3% in either direction 
38 32 27 24 
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Gene lists from the four different comparisons revealed similar genes in all lists. In 
the matched samples gene lists, there was less power due to the smaller sample size. 
There was a reduced number of significantly different regions compared to gene lists 
produced when analysing all 97 samples. For this reason, the rest of the analysis was 
performed on all 97 samples. Additionally, due to a biological effect of season of 
conception on DNA methylation, all further analysis was done on adjusted data. In 
the final adjusted gene list at the analysing all 97 samples, the number of 
hypomethylated genes in the high AFB1 exposure group compared to the low 
exposure group with at least a 3% difference in mean methylation levels was 19 and 
the number of hypermethylated genes was 13.  
Some of the significant differentially methylated genes in the adjusted gene list 
derived from analysing all samples included CREB3L3, AREG, SLC17A9, IL8, IL18, 
CD3D and USP17L1P, which have roles in immune function regulation, cell growth 
and cell proliferation. A list of significant differentially methylated genes is 
presented at the promoter-level in Table 16.  
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Table 16: Gene list derived from promoter-level analysis of DNA methylation in Gambian infants*.  
Number Mean in High AFB1 group Mean in Low AFB1 group Mean Difference Adjusted P value Gene Symbol 
1 0.2286 0.2935 -0.0649 0.0009 CREB3L3 
2 0.4923 0.5295 -0.0373 0.0018 AREG 
3 0.6996 0.6708 0.0288 0.0024 TRAJ33 
4 0.2455 0.2636 -0.0181 0.0036 SLC17A9 
5 0.3190 0.3370 -0.0181 0.0041 GALNT5 
6 0.8607 0.8257 0.0350 0.0049 USP17L1P 
7 0.2859 0.2569 0.0291 0.0053 TRGV3 
8 0.3004 0.3245 -0.0241 0.0059 PCYOX1 
9 0.6724 0.6402 0.0321 0.0061 TRAC 
10 0.6047 0.5689 0.0358 0.0062 CD3G 
11 0.4748 0.4906 -0.0157 0.0064 ALOX5AP 
12 0.6754 0.6475 0.0279 0.0080 TRAJ24 
13 0.6115 0.5772 0.0343 0.0081 CD3D 
14 0.4773 0.5008 -0.0235 0.0085 CHST4 
15 0.7798 0.7455 0.0343 0.0115 PSMA8 
16 0.6574 0.6897 -0.0323 0.0132 CTAGE5 
17 0.1650 0.1774 -0.0125 0.0135 BCL2L2-PABPN1 
18 0.5990 0.6260 -0.0270 0.0140 MIR1284 
19 0.6836 0.6564 0.0273 0.0142 MIR4761 
20 0.3362 0.3535 -0.0173 0.0149 HORMAD2 
21 0.6512 0.6055 0.0457 0.0151 CRYGEP 
22 0.2379 0.2823 -0.0444 0.0159 HADHB 
23 0.2197 0.2335 -0.0138 0.0160 HOXB-AS1 
24 0.4844 0.4531 0.0313 0.0161 LTA 
25 0.5312 0.5079 0.0233 0.0161 SIT1 
26 0.2784 0.2941 -0.0157 0.0161 TYROBP 
27 0.6567 0.5782 0.0785 0.0164 RRM2P2 
28 0.2966 0.2801 0.0165 0.0169 PGM5P2 
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29 0.2752 0.2991 -0.0239 0.0186 GSN-AS1 
30 0.2020 0.2440 -0.0420 0.0187 IL8 
31 0.8985 0.8389 0.0596 0.0193 OR2T11 
32 0.2539 0.2292 0.0247 0.0213 AGPAT2 
33 0.4007 0.4204 -0.0197 0.0216 NTMT1 
34 0.4649 0.4912 -0.0263 0.0217 FLI1 
35 0.5584 0.5361 0.0224 0.0221 TRAJ25 
36 0.5584 0.5361 0.0224 0.0221 TRAJ26 
37 0.3507 0.3758 -0.0250 0.0226 RTN4 
38 0.7409 0.7715 -0.0306 0.0234 ATP5A1P3 
39 0.5649 0.5942 -0.0294 0.0237 RPL17P40 
40 0.4046 0.4238 -0.0192 0.0263 FES 
41 0.6172 0.6410 -0.0238 0.0265 CCL26 
42 0.6022 0.6332 -0.0310 0.0265 LYZ 
43 0.3822 0.3995 -0.0173 0.0279 ZNF124 
44 0.4496 0.4617 -0.0121 0.0288 C21orf62 
45 0.4682 0.4982 -0.0300 0.0291 EGOT 
46 0.1764 0.1947 -0.0183 0.0295 LINGO3 
47 0.1705 0.1552 0.0154 0.0304 UBXN11 
48 0.3553 0.3692 -0.0139 0.0310 CASP10 
49 0.2287 0.2454 -0.0168 0.0313 BIN2P1 
50 0.5144 0.5380 -0.0236 0.0315 IPCEF1 
51 0.4639 0.4885 -0.0246 0.0319 GPR21 
52 0.2638 0.2847 -0.0209 0.0328 CD9 
53 0.3456 0.3600 -0.0144 0.0332 WDFY4 
54 0.2240 0.2432 -0.0193 0.0338 TRIM13 
55 0.4405 0.4533 -0.0128 0.0346 SIRPB2 
56 0.5719 0.5443 0.0276 0.0351 GP1BB 
57 0.1823 0.2013 -0.0190 0.0369 INTS1 
58 0.3986 0.4144 -0.0158 0.0374 SPI1 
59 0.2265 0.2062 0.0203 0.0389 HSD17B7P2 
60 0.4994 0.5182 -0.0188 0.0395 KDM6B 
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*Only genes with a combined rank less than 1000 are included in the table. 
 
 
 
 
61 0.3590 0.3777 -0.0187 0.0400 ATP2C1 
62 0.3142 0.3315 -0.0173 0.0414 CD302 
63 0.5951 0.6204 -0.0253 0.0424 ANKRD22 
64 0.4503 0.4776 -0.0273 0.0433 C1orf192 
65 0.2851 0.2983 -0.0132 0.0435 MPG 
66 0.2771 0.2556 0.0215 0.0437 GPR56 
67 0.2675 0.2881 -0.0206 0.0444 HPGDS 
68 0.2723 0.2895 -0.0172 0.0453 LMO2 
69 0.3521 0.3650 -0.0129 0.0454 WSB2 
70 0.3717 0.3559 0.0158 0.0459 ZAP70 
71 0.5357 0.5574 -0.0217 0.0460 IL18 
72 0.2580 0.2735 -0.0155 0.0465 MTMR9LP 
73 0.2935 0.2764 0.0171 0.0475 PGM5P1 
74 0.4808 0.4944 -0.0136 0.0479 MMP14 
75 0.5368 0.5587 -0.0219 0.0485 FUT7 
76 0.2897 0.3221 -0.0324 0.0487 ADAM28 
77 0.2171 0.2312 -0.0140 0.0489 C15orf62 
78 0.3706 0.3873 -0.0168 0.0489 FCGRT 
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A heatmap of all significant probes at the promoter region level was also produced 
(Figure 10). Differences between the two exposure groups were not very clear due to 
the significant changes between groups being relatively small. However, some 
patterns can be observed in healthy infants exposed to AFB1.   
 
 
Figure 10: Heatmap of all significant probes at the promoter region level across all 97 
samples when comparing high versus low in utero exposure in Gambian infants. Within the 
heatmap, blue represents hypomethylation while orange represents hypermethylation. The 
samples are divided by exposure groups: high (blue) and low (yellow). 
 
5.2.2.1.3 Gene-level analysis 
The comparison of high versus low AFB1 exposure was also repeated at the gene 
level in all samples adjusted for season of conception. There were 261 differentially 
methylated genes (96 excluding non-annotated genes (NAs)) when comparing high 
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and low AFB1 exposure groups. Twenty-five (11 excluding NAs) of these had a 
combined rank of less than 1000 and a mean difference of at least 3% between 
groups in either direction. The number of hypomethylated genes in the higher AFB1 
exposure group compared to the low exposure group with at least a 3% difference in 
mean methylation levels was 10 and the number of hypermethylated genes was 15.  
Some of the genes in the significant gene list included BRWD1-AS1, CD3D, 
CREB3L3, GDF7, GPR21 and HOXB2. Some of these genes were also differentially 
methylated at the promoter-level. These genes are mostly involved in immune 
function regulation, cell cycle and transcription. A list of the significant differentially 
methylated genes at the gene-level is presented in Table 17. 
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Table 17: Gene list derived from gene-level analysis of DNA methylation in Gambian infants*. 
Number Mean in High AFB1 group Mean in Low AFB1 group Mean Difference Adjusted P value Gene Symbol 
1 0.2614 0.2395 0.0219 0.0010 PGM5P2 
2 0.1764 0.2014 -0.0249 0.0037 MIR628 
3 0.7581 0.7108 0.0473 0.0041 PSMA8 
4 0.4517 0.5057 -0.0540 0.0082 SULT1E1 
5 0.2516 0.2322 0.0194 0.0089 PGM5P1 
6 0.1934 0.2086 -0.0153 0.0106 MIR24-2 
7 0.5932 0.5635 0.0297 0.0117 IGSF6 
8 0.3543 0.3700 -0.0157 0.0120 HOXB2 
9 0.7604 0.7337 0.0267 0.0121 SNORD31 
10 0.3399 0.3577 -0.0178 0.0130 MIR27A 
11 0.6482 0.6250 0.0231 0.0139 SIT1 
12 0.6255 0.5963 0.0291 0.0153 CD3D 
13 0.2862 0.3032 -0.0170 0.0156 NEK4P2 
14 0.5093 0.4807 0.0286 0.0158 LTA 
15 0.6567 0.5782 0.0785 0.0164 RRM2P2 
16 0.3224 0.2808 0.0416 0.0171 GDF7 
17 0.7244 0.7543 -0.0299 0.0173 TNFAIP6 
18 0.4506 0.4787 -0.0281 0.0190 BRWD1-AS1 
19 0.7069 0.6824 0.0244 0.0194 OR10T2 
20 0.8419 0.8102 0.0318 0.0221 ABCD1P3 
21 0.7030 0.6776 0.0254 0.0236 SNORD12 
22 0.5939 0.5628 0.0311 0.0252 KLHL35 
23 0.7495 0.7091 0.0404 0.0272 ANKRD20A19P 
24 0.6250 0.5965 0.0285 0.0298 SNORD97 
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25 0.6379 0.6636 -0.0257 0.0301 SLPI 
26 0.4030 0.3629 0.0401 0.0306 OR4N5 
27 0.3552 0.3754 -0.0202 0.0309 EMR4P 
28 0.3977 0.4384 -0.0407 0.0311 CREB3L3 
29 0.2644 0.2456 0.0187 0.0316 RXFP3 
30 0.1922 0.2122 -0.0200 0.0338 MIR647 
31 0.6485 0.6779 -0.0295 0.0354 CCIN 
32 0.5402 0.5737 -0.0335 0.0377 MIR140 
33 0.2091 0.1940 0.0151 0.0379 CD52 
34 0.4921 0.5158 -0.0237 0.0388 GPR21 
35 0.2529 0.2415 0.0114 0.0400 SNORA14B 
36 0.7647 0.7414 0.0233 0.0418 FASLG 
37 0.6272 0.6546 -0.0274 0.0421 SNORA38 
38 0.7292 0.6970 0.0322 0.0464 PAEP 
39 0.3284 0.3115 0.0169 0.0465 RNU7-27P 
40 0.1509 0.1646 -0.0137 0.0478 CYTL1 
*Only genes with a combined rank less than 1000 are included in the table. 
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A heatmap of all significant probes at the gene region level was produced (Figure 
11). Differences between the two exposure groups were not very clear due to the 
significant changes between groups being relatively small. However, some patterns 
in gene methylation can be observed in healthy infants exposed to AFB1.   
 
Figure 11: Heatmap of significant probes at the gene region level across all 97 samples 
when comparing high versus low in utero exposure in Gambian infants. Within the 
heatmap, blue represents hypomethylation while orange represents hypermethylation. The 
samples are divided by exposure groups: high (blue) and low (yellow). 
 
5.2.2.2 Pathway analysis 
Pathway analysis using DAVID v.6.7 revealed significant pathway categories using 
the Biocarta and KEGG databases both at the promoter and the gene level (Table 18). 
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Table 18: Summary of DAVID pathway analysis for gene lists derived from methylation analyses at the promoter and gene region-level. 
 Pathway term Pathway Category 
Number 
of genes 
P Value Genes 
Promoter level 
Biocarta h_il17Pathway IL 17 Signalling Pathway 5 2.44E-06 CD3G, CD3D, IL8, CD2, CD4 
 h_tcraPathway 
Lck and Fyn tyrosine kinases in initiation 
of TCR Activation 
4 5.33E-05 CD3G, CD3D, ZAP70, CD4 
 h_thelperPathway T Helper Cell Surface Molecules 4 7.08E-05 CD3G, CD3D, CD2, CD4 
 h_CSKPathway 
Activation of Csk by cAMP-dependent 
Protein Kinase Inhibits Signalling 
through the T Cell Receptor 
4 2.14E-04 CD3G, CD3D, ZAP70, CD4 
 h_tcapoptosisPathway HIV Induced T Cell Apoptosis 3 0.001864 CD3G, CD3D, CD4 
 h_tcytotoxicPathway T Cytotoxic Cell Surface Molecules 3 0.003374 CD3G, CD3D, CD2 
 h_IL12Pathway 
IL12 and Stat4 Dependent Signalling 
Pathway in Th1 Development 
3 0.009393 CD3G, CD3D, IL18 
 h_cytokinePathway Cytokine Network 3 0.009393 IL8, IL18, LTA 
 h_inflamPathway Cytokines and Inflammatory Response 3 0.015667 IL8, CD4, LTA 
 h_tcrPathway T Cell Receptor Signalling Pathway 3 0.026153 CD3G, CD3D, ZAP70 
 h_tcrmolecule T Cell Receptor and CD3 Complex 2 0.030301 CD3G, CD3D 
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KEGG hsa04640 Hematopoietic cell lineage 6 4.51E-04 
CD9, CD3G, CD3D, GP1BB, 
CD2, CD4 
 hsa05340 Primary immunodeficiency 3 0.029086 CD3D, ZAP70, CD4 
 hsa04660 T cell receptor signalling pathway 4 0.04901 CD3G, CD3D, ZAP70, CD4 
Gene level 
Biocarta h_tcapoptosisPathway HIV Induced T Cell Apoptosis 2 0.043115 CD3D, FASLG 
KEGG hsa04740 Olfactory transduction 6 0.008521 
OR2A7, OR10T2, OR4N5, 
OR52E4, OR13C8, OR4D6 
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Most of the identified pathways were related to the regulation of the immune 
response including cytokine signalling with CD3D, CD3G, CD4, IL8 and IL18 
featuring in most significant pathways.  
 
5.2.2.3 Validation of differential DNA methylation by 
pyrosequencing 
Validation was done in the 97 DNA samples, already analysed for whole genome 
DNA methylation changes. This was, therefore, a technical validation of the changes 
in specific genes using an alternate method i.e. pyrosequencing. 
Twelve genes with a total of 29 CpG sites were selected for validation by 
pyrosequencing for all 97 DNA samples. This was done to determine if the observed 
changes were present when analysing using an alternate method. Of these, 12 CPG 
sites in CD3D, CREB3L3, HORMAD2, HOXB2, HOXB2 (body), PSMA8 and 
SLC17A9 were significantly different between high and low AFB1 exposure groups 
(Table 19 and Figure 12).  
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Table 19: Number of significant and non-significant CpG sites in 12 genes selected for 
validation by pyrosequencing. 
Gene 
Number of CpG sites 
Total Significant Not Significant 
BRWD1 1 0 1 
CD3D 3 1 2 
CREB3L3 2 2 0 
USP17L1P 3 0 3 
HORMAD2 4 2 2 
HOXB2 7 5 2 
MIR24 2 0 2 
PSMA8 3 1 2 
SLC17A9 4 1 3 
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Figure 12: Graphs of CpG sites successfully validated by pyrosequencing. Methylation percentages are presented per AFB1 exposure group per graph. 
Each dot per graph represents a sample with the median AFB1 level per exposure group represented by a line in each cluster. The P value per comparison 
is displayed beneath the gene symbol and CpG unique Illumina ID. CD3D and PSMA8 are significantly hypermethylated in the high AFB1 exposure group 
relative to methylation in the low exposure group while the remaining genes (CREB3L3, HORMAD2, HOXB2 and SLC17A9) are hypomethylated. 
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5.3 Gambian infant gene expression 
5.3.1 Methods 
5.3.1.1 Sample selection and preparation 
A total of 52 infant whole blood-cell samples collected at 3-6 months of age were 
available for analysis. Total RNA was extracted from the samples and stored in 
RNAlater immediately, as described in Chapter 2, Section 2.4.2.1. RNA quality was 
determined using an Agilent 2100 Bioanalyser (Agilent Technologies, Berkshire, 
UK), as described in Chapter 2, Section 2.4.2.2. All RNA samples had an RNA 
integrity number (RIN) > 6.  
Twenty-two of these samples belonging to the dry season were selected for whole 
genome gene expression analysis. Information on the corresponding maternal 
aflatoxin exposure and season of blood sample collection is displayed in Table 20.   
 
Table 20: Geometric mean levels of AF-alb in AFB1 exposure groups included in the whole 
genome gene expression analysis. 
 
N 
AF-alb 
GM (95% confidence intervals) 
AFB1 exposure group   
Low 11 8.9 (7.0, 11.2) 
High 11 107.5 (76.5, 151.1)** 
N number of samples per group  
** P < 0.001 between high and low AFB1 exposure groups 
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Two samples were duplicated to measure accuracy of the whole genome gene 
expression analysis. Samples were assigned a randomised code ID and added to the 
bead chips, ordered by ID. All samples were analysed in one batch precluding the 
effects of batch variability. Samples were then analysed using the Illumina Human 
HT12-v4 Expression BeadChip Kit (Illumina, Freddy van Riemsdijkweg, The 
Netherlands), described in Chapter 2, Section 2.4.2.2. 
 
5.3.1.2 Data analysis 
Raw data in the form of expression values were imported and analysed on BRB 
ArrayTools software (version 4.3.0, developed by Dr. Richard Simon and BRB-
ArrayTools Development Team) using the lumi package, which is specifically 
designed for Illumina data (Du et al. 2008). The package is installed through R 
statistical software (version i386 2.15.2, RStudio, Massachusetts, USA). This data 
analysis was done with input and advice from Dr. Hector Hernandez-Vargas, IARC, 
Lyon, France.   
Each probe on the BeadChips was identified via a Nucleotide Universal Identifier 
(nuID), which is unique to the oligonucleotide sequence, globally accepted as unique 
indentifiers and includes an algorithm to check for errors (Du et al. 2007b). The lumi 
package makes use of Variance Stabilization Transformation (VST), which takes 
advantage of the large number of technical replicates per array (Du et al. 2008). VST 
stabilises the spatially random technical replicates, reduces both the signal-to-noise 
ratio and the number of false positive identifications (Lin et al. 2008).  
Following the pre-processing steps using lumi, the data was first log2 transformed 
followed by normalisation using Robust Spline Normalisation (RSN), which utilises 
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continuous mapping, preserves the rank order and is not affected by a large number 
of differentially expressed genes as compared to other methods of normalisation 
including Quantile and Loess normalisation. With the RSN form of normalisation, 
the first array is calibrated against a reference array and the intensities of probes of 
differentially expressed genes are down-weighted (Du et al. 2007a). Data was also 
corrected for multiple testing using t-statistics and multivariate permutation analysis, 
which generates a q value per loci per comparison. Only q values < 0.05 were 
accepted.  
 
5.3.1.2.1 Scatter plots and unsupervised clustering 
To check quality control, scatter plots of the technical replicates were produced and 
unsupervised clustering was done to determine if the samples grouped according to 
AFB1 exposure.  
 
5.3.1.2.2 Data filtering 
Following normalisation, the data were then filtered to exclude less than 25% of 
genes that have at least a 1.3-fold change in expression data in either direction of the 
gene’s median expression value. Also, probes with more than 50% of samples 
missing expression values for that probe were excluded from the analysis. These 
settings improved the number of hits obtained following class comparison and 
quantitative trait analyses (Table 21).  
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Table 21: Comparison of different filtering conditions in terms of hits obtained following 
class comparison analysis. 
Data filtering conditions N 
No filter 0 
Excluding genes with more than 50 % missing data 0 
and 20 % genes with less than 2-fold change  0 
and 20 % genes with less than 1.5-fold change 8 
and 20 % genes with less than 1.3-fold change 228 
and 25 % genes with less than 1.5-fold change 7 
and 25 % genes with less than 1.3-fold change 138 
and 30 % genes with less than 1.5-fold change 5 
and 30 % genes with less than 1.3-fold change 15 
N number of probes with a false discovery rate (FDR) or q value less than 10 %  
 
5.3.1.2.3 Class comparison analysis 
Using the filtering conditions of excluding genes with more than 50% missing data 
and 20% genes with at least a 1.3-fold difference in either direction between groups 
and with a q value cut-off at 0.1, a class comparison was conducted to compare the 
high and low AFB1 exposure groups. Unsupervised and supervised clustering and 
heatmaps were then produced for a gene list containing only probes repeated more 
than once and probes with a high fold-change.  
 
5.3.1.2.4 Quantitative trait analysis 
To further analyse the relationship between gene expression and AFB1 exposure, 
Quantitative Trait Analysis (QTA) was conducted using both early and later AF-alb 
levels. This analysis determines the extent of correlation between expression values 
of probes and actual AF-alb levels. 
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5.3.1.3 Pathway analysis 
Genes identified as being differentially expressed between the two AFB1 classes, 
were examined to determine if they belonged to any pathways involved in varying 
biological processes. The final gene list (40 genes), consisting of genes with at least 
two significant probes or at least a 1.5-fold difference between classes, was used to 
in the pathway analysis with DAVID v.6.7.  
 
5.3.1.4 Validation of gene expression changes by qPCR 
Using specific criteria, twelve genes were selected for validation from the gene list 
consisting of only significant probes that were repeated more than once and with a 
high fold-change between exposure groups. These genes along with the selection 
criteria are described in Table 22.  
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Table 22: Gene selection for gene expression validation. 
 Gene 
Symbol 
Fold-
change* 
Selection criteria 
1 BOLA3 1.29 More than one probe; interest 
2 C19orf60 1.36 High fold-change, more than one probe and low FDR 
3 CD3D 1.51 High fold-change and more than one probe 
4 CENPT 1.33 More than one probe and low FDR 
5 ID2 1.26 More than one probe; interest 
6 Il27RA 1.42 High fold change 
7 MBP 0.62 Low fold-change and more than one probe 
8 NCOR2 1.42 High fold change 
9 PTPRC 0.61 Low fold-change and more than one probe 
10 RIOK3 0.37 High fold change and more than one probe 
11 STAT3 0.75 More than one probe; interest 
12 USP4 0.82 
Top gene in Quantitative Trait Analysis (correlation 
coefficient = 0.839) 
* Fold change derived by comparing expression in the low AFB1 exposure group to that in 
the high exposure group. For example, with a fold-change of 1.29, BOLA3 expression is 
higher in the low exposure group than in the high exposure group. 
 
Selected genes were validated by qPCR, described in Chapter 2, Section 2.3.6. The 
primer sequences and PCR conditions for each gene are described in Table 23.  
  
158 
 
Table 23: Primer sequences and annealing temperatures for genes selected for validation by qPCR. 
Gene Symbol Forward Primer (5' to 3') Reverse Primer (5' to 3') 
BOLA3 TTCCACGAGCTACAGCTATAAAAG CATCCAAGGTCTTAAGCAGCA 
C19orf60 TTGTGTGGCTGCAGAGTCAGAT AGAGAGAAGCCACGAAGAGTGAGT 
CD3D CACCTATATATTCCTCGTGGGTCC ATACCAGCATCACATGGGTAGAGG 
CENPT CCAACCCTCCAGACAAGAGA GGCTCGAGCTCAGGAAGTT 
MBP TTTGGCATCACGCTGACTACTCCT TATCCTTCTTAACACCCGCTGGCA 
NCOR2 GCACGAGGTGTCAGAGATCA CTGGCGCATCTGCTTCTC 
PTPRC TGAACTGAGACATTCCAAGAGG TGTTTGACGACCTGAATCATAGA 
STAT3 AACTTCAGACCCGTCAACAAA GGGTCCCCTTTGTAGGAAAC 
ID2 TGTCAAATGACAGCAAAGCAC GTTGTTGTTGTGCAAAGAATAAAAG 
IL27 ATCCTGGAAGTGGAGGAGAT GCTTCTCATACCCAGAGTCAAG 
RIOK3 CCATGATTGTGCCACTGTACT CCACCTCACCTGGCTTATTT 
USP4 GATCGAGTTATGGAGGTTTTCCT CGGCACAGTCACACGGTA 
HPRT1 CATTGTAGCCCTCTGTGTGC CACTATTTCTATTCAGTGCTTTGATGT 
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5.3.1.5 Influence of season of measurement on USP4 and STAT3 
expression 
Univariate regression and correlation between USP4, STAT3 (3 probes); season of 
measurement; and AF-alb levels were tested using Stata v.11 (StataCorp, College 
Station, TX, USA). Season of measurement was defined as the season of blood 
collection for AF-alb measurement. November-May was considered to be the dry 
season while June-October was classed as the rainy season. 
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5.3.2 Results 
The initial stages of the analysis involved determining the quality control of the data. 
A boxplot of the samples with and without RSN normalisation is shown in Figure 
13. One sample appeared to be an outlier compared to the other samples prior to 
normalisation and so was removed from further analysis. This analysis was 
compared to analysis on all samples and was found to be similar. Therefore, for all 
reported analysis, all samples were included. 
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Figure 13: Boxplot of the log intesities of ratios of all genes on the bead chips for 22 (+2 
technical replicates) samples showing raw data (A) and robust spline normalised data (B). 
Several outliers are present potentially due to the variability in gene expression by 
treatment group. Normalisation removes any technical variability by calibrating against 
expression intensities on a reference array. 
 
5.3.2.1 Scatter plots and unsupervised clustering 
Scatter plots comparing overall gene expression in the technical replicates included 
in the analysis (Figure 14) reveal strong correlation of gene expression between them.  
 
A
B
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Figure 14: Scatter plot of technical replicates showing strong correlation of gene expression 
between replicates. 
 
The dendrogram, displayed in Figure 15, shows expected mixed clustering with low 
correlation coefficients according to AFB1 exposure grouping. As the analysed RNA 
samples were from relatively healthy infants, major changes in gene expression 
patterns would not be expected. However, in utero exposure to AFB1 could alter 
gene expression profiles resulting in a AFB1-specific signature.  
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Figure 15: Dendrogram of unsupervised sample clustering showing correlation between 
sample linkages. Most samples are only weakly correlated to each other. A few samples 
(including the technical replicates) cluster closely together with relatively higher 
correlation coefficients. 
 
5.3.2.2 Class comparison analysis 
The complete list of genes that are differentially expressed between the two groups 
using filtering conditions of excluding genes with more than 50% missing data and 
20% genes with at least a 1.3-fold difference in either direction between groups 
conditions and with an FDR below 10% is presented in Table 24.  
A total of 30 probe IDs did not correspond to coding genes and 197 probes 
corresponding to coding genes with differential expression have been associated with 
AFB1 exposure groups.   
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Table 24: Class comparison analysis with at least a 1.3-fold change in differential gene expression between AFB1 exposure groups and with FDR/q value 
below 10 %.  
No. 
Parametric p-
value 
FDR 
Geometric 
mean of 
intensities in 
Low AFB1 
exposure 
group 
Geometric 
mean of 
intensities in 
High AFB1 
exposure 
group 
Fold-change 
Gene 
Symbol 
Gene Name Entrez ID 
1 3.30E-05 0.0387 198.92 274.08 0.73 CENPT centromere protein T 80152 
2 3.98E-05 0.0387 32121.21 24300.87 1.32 CLUAP1 clusterin associated protein 1 23059 
3 4.22E-05 0.0387 35911.06 27147.09 1.32 LAIR1 
leukocyte-associated immunoglobulin-like receptor 
1 
3903 
4 4.92E-05 0.0387 27566.32 20476.92 1.35 SLC7A5P2 
solute carrier family 7 (amino acid transporter light 
chain, L system), member 5 pseudogene 2 
387254 
5 7.24E-05 0.0413 303.9 203.71 1.49 CDK11A cyclin-dependent kinase 11A 728642 
6 9.51E-05 0.0468 405.98 579.94 0.7 C19orf60 chromosome 19 open reading frame 60 55049 
7 0.000156 0.0594 225.38 177.47 1.27 MOSPD2 motile sperm domain containing 2 158747 
8 0.000166 0.0594 1024.87 1823.48 0.56 RPL10A ribosomal protein L10a 4736 
9 0.000209 0.062 374.08 498.89 0.75 MALSU1 
mitochondrial assembly of ribosomal large subunit 
1 
115416 
10 0.000228 0.062 595.75 782.73 0.76 POLR3GL 
polymerase (RNA) III (DNA directed) polypeptide 
G (32kD)-like 
84265 
11 0.000244 0.062 25206.81 19177.2 1.31 NAG18 NAG18 mRNA 57051 
12 0.000299 0.062 1059.28 599.66 1.77 YY1 YY1 transcription factor 7528 
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13 0.000327 0.062 433.72 246.5 1.76 PTPRC protein tyrosine phosphatase, receptor type, C 5788 
14 0.000352 0.062 245.08 343.19 0.71 ZNF266 zinc finger protein 266 10781 
15 0.00037 0.062 632.48 812.37 0.78 CCDC130 coiled-coil domain containing 130 81576 
16 0.000415 0.062 220.82 312.82 0.71 ZP3 zona pellucida glycoprotein 3 (sperm receptor) 7784 
17 0.000443 0.062 958.48 1230.7 0.78 UBXN1 UBX domain protein 1 51035 
18 0.000465 0.062 481.19 649.74 0.74 ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 9138 
19 0.00047 0.062 25268.34 18534.95 1.36 F2R coagulation factor II (thrombin) receptor 2149 
20 0.000471 0.062 336.25 209.3 1.61 ZNF148 zinc finger protein 148 7707 
21 0.000475 0.062 707.79 523.49 1.35 GATAD2A GATA zinc finger domain containing 2A 54815 
22 0.000478 0.062 571.54 777.45 0.74 LSM3 
LSM3 homolog, U6 small nuclear RNA associated 
(S. cerevisiae) 
27258 
23 0.000489 0.062 384.9 518.31 0.74 MRPL21 mitochondrial ribosomal protein L21 219927 
24 0.000513 0.063 518.4 335.49 1.55 CCNY cyclin Y 219771 
25 0.000592 0.0692 510.05 726.2 0.7 IL27RA interleukin 27 receptor, alpha 9466 
26 0.000598 0.0692 192.86 246.14 0.78 CENPT centromere protein T 80152 
27 0.000641 0.0704 41012.61 31243.12 1.31 HBA1 hemoglobin, alpha 1 3039 
28 0.000844 0.0861 1037.41 807.77 1.28 SPOP speckle-type POZ protein 8405 
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29 0.000854 0.0861 545.17 319.18 1.71 MBP myelin basic protein 4155 
30 0.000963 0.0874 444.06 285.27 1.56 MBP myelin basic protein 4155 
31 0.000971 0.0874 299.26 446.11 0.67 FLT3LG fms-related tyrosine kinase 3 ligand 2323 
32 0.000997 0.0874 795.13 1116.6 0.71 ID2 
inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein 
3398 
33 0.001024 0.0874 834.92 1182.37 0.71 AES amino-terminal enhancer of split 166 
34 0.001032 0.0874 213.59 171.49 1.25 GTF2I general transcription factor IIi 2969 
35 0.001079 0.0874 852.26 1118.78 0.76 COMMD3 COMM domain containing 3 23412 
36 0.001116 0.0874 321.34 240.64 1.34 AMD1 adenosylmethionine decarboxylase 1 262 
37 0.001128 0.0874 301.97 223.13 1.35 EIF4E3 
eukaryotic translation initiation factor 4E family 
member 3 
317649 
38 0.001149 0.0874 533.92 292.85 1.82 PTPRC protein tyrosine phosphatase, receptor type, C 5788 
39 0.00118 0.0874 454.88 335.45 1.36 ARID4B AT rich interactive domain 4B (RBP1-like) 51742 
40 0.001209 0.0874 287.5 220.12 1.31 CAMK1D calcium/calmodulin-dependent protein kinase ID 57118 
41 0.001227 0.0874 181.95 232.03 0.78 TMEM141 transmembrane protein 141 85014 
42 0.001244 0.0874 234.41 297.25 0.79 LMF2 lipase maturation factor 2 91289 
43 0.001244 0.0874 459.18 563.86 0.81 DPM1 
dolichyl-phosphate mannosyltransferase 
polypeptide 1, catalytic subunit 
8813 
44 0.001249 0.0874 454.54 563.23 0.81 RABAC1 Rab acceptor 1 (prenylated) 10567 
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45 0.001278 0.0874 42967.7 33338.66 1.29 HBA2 hemoglobin, alpha 2 3040 
46 0.001288 0.0874 248.09 320.5 0.77 SSBP4 single stranded DNA binding protein 4 170463 
47 0.001355 0.0889 185.21 252.4 0.73 ZNF33B zinc finger protein 33B 7582 
48 0.001368 0.0889 243.11 319.35 0.76 FYN FYN oncogene related to SRC, FGR, YES 2534 
49 0.001425 0.0893 174.23 230.7 0.76 CCDC84 coiled-coil domain containing 84 338657 
50 0.001515 0.0893 1593.08 2116.22 0.75 EDF1 endothelial differentiation-related factor 1 8721 
51 0.001537 0.0893 147.18 189.62 0.78 NPHP3 nephronophthisis 3 (adolescent) 27031 
52 0.00156 0.0893 795.04 1073.35 0.74 SRP14P1 
signal recognition particle 14kDa (homologous Alu 
RNA binding protein) pseudogene 1 
390284 
53 0.001569 0.0893 4339.92 5566.81 0.78 SNRPD2 
small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa 
6633 
54 0.001572 0.0893 2111.97 1632.35 1.29 ALKBH5 alkB, alkylation repair homolog 5 (E. coli) 54890 
55 0.001578 0.0893 151.37 206.62 0.73 MIAT 
myocardial infarction associated transcript (non-
protein coding) 
440823 
56 0.001624 0.0893 447.07 611.5 0.73 ACAP1 
ArfGAP with coiled-coil, ankyrin repeat and PH 
domains 1 
9744 
57 0.001629 0.0893 39455.17 30685.92 1.29 HBB hemoglobin, beta 3043 
58 0.001638 0.0893 138 184.58 0.75 ZNF589 zinc finger protein 589 51385 
59 0.001726 0.0893 323.31 415.53 0.78 C19orf60 chromosome 19 open reading frame 60 55049 
60 0.001729 0.0893 360.61 471.91 0.76 ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 476 
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61 0.001763 0.0893 307.76 388.43 0.79 EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) 10436 
62 0.001774 0.0893 382.53 234.2 1.63 EIF2C2 eukaryotic translation initiation factor 2C, 2 27161 
63 0.001803 0.0893 321.91 423.21 0.76 NGDN neuroguidin, EIF4E binding protein 25983 
64 0.001822 0.0893 184.15 221.39 0.83 MDP1 magnesium-dependent phosphatase 1 145553 
65 0.00184 0.0893 2876.88 4314.84 0.67 HCST hematopoietic cell signal transducer 10870 
66 0.001849 0.0893 313.49 421.55 0.74 PPP1R35 protein phosphatase 1, regulatory subunit 35 221908 
67 0.001861 0.0893 181.28 223.75 0.81 C18orf21 chromosome 18 open reading frame 21 83608 
68 0.001872 0.0893 329.35 252.34 1.31 STAT3 
signal transducer and activator of transcription 3 
(acute-phase response factor) 
6774 
69 0.001926 0.0893 238.27 303.24 0.79 RPL34 ribosomal protein L34 6164 
70 0.001931 0.0893 196.97 259.16 0.76 RRP7A 
ribosomal RNA processing 7 homolog A (S. 
cerevisiae) 
27341 
71 0.001955 0.0894 144.59 183.23 0.79 CA5B carbonic anhydrase VB, mitochondrial 11238 
72 0.001988 0.0899 210.3 157.22 1.34 TRIM23 tripartite motif containing 23 373 
73 0.002034 0.0901 1131.18 1517.07 0.75 LTB lymphotoxin beta (TNF superfamily, member 3) 4050 
74 0.002097 0.0901 40246.96 31091.59 1.29 HBG2 hemoglobin, gamma G 3048 
75 0.002108 0.0901 170.38 217.72 0.78 ACYP2 acylphosphatase 2, muscle type 98 
76 0.002148 0.0901 757.34 1065.26 0.71 NDUFS8 
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q reductase) 
4728 
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77 0.002158 0.0901 816.17 1165.21 0.7 RPS27L ribosomal protein S27-like 51065 
78 0.002243 0.0901 394.5 493.86 0.8 MRPL21 mitochondrial ribosomal protein L21 219927 
79 0.002255 0.0901 36973.49 29498.22 1.25 TMSB4X thymosin beta 4, X-linked 7114 
80 0.002261 0.0901 1052.3 1313.62 0.8 AKNA AT-hook transcription factor 80709 
81 0.002269 0.0901 244.88 176.88 1.38 PTPRC protein tyrosine phosphatase, receptor type, C 5788 
82 0.002295 0.0901 671.32 466.92 1.44 WSB1 WD repeat and SOCS box containing 1 26118 
83 0.002296 0.0901 414.94 550.56 0.75 CCNK cyclin K 8812 
84 0.002307 0.0901 339.98 483.89 0.7 ECHDC2 enoyl CoA hydratase domain containing 2 55268 
85 0.002313 0.0901 353.78 236.77 1.49 AKIRIN1 akirin 1 79647 
86 0.002328 0.0901 318.22 422.73 0.75 TSPAN32 tetraspanin 32 10077 
87 0.002356 0.0901 229.81 310.7 0.74 DGKQ diacylglycerol kinase, theta 110kDa 1609 
88 0.002401 0.0901 138.51 170.88 0.81 RPL23AP5 ribosomal protein L23a pseudogene 5 729480 
89 0.002406 0.0901 1529.2 2052.18 0.75 NDUFB2 
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 2, 8kDa 
4708 
90 0.002441 0.0906 1435.51 1870.49 0.77 SS18L2 
synovial sarcoma translocation gene on 
chromosome 18-like 2 
51188 
91 0.002476 0.091 351.48 251.68 1.4 BIRC2 baculoviral IAP repeat containing 2 329 
92 0.002598 0.0915 349.22 218.1 1.6 LBR lamin B receptor 3930 
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93 0.002652 0.0915 212.75 263.14 0.81 FAM111A family with sequence similarity 111, member A 63901 
94 0.002694 0.0915 352.89 467.06 0.76 PPCS phosphopantothenoylcysteine synthetase 79717 
95 0.002702 0.0915 485.35 605.97 0.8 DAP3 death associated protein 3 7818 
96 0.00271 0.0915 277.98 348.19 0.8 CCDC167 coiled-coil domain containing 167 154467 
97 0.002717 0.0915 802.17 1105.36 0.73 C9orf142 chromosome 9 open reading frame 142 286257 
98 0.002726 0.0915 163.47 212.64 0.77 TPM2 tropomyosin 2 (beta) 7169 
99 0.002768 0.0915 159.17 197.69 0.81 IDUA iduronidase, alpha-L- 3425 
100 0.002772 0.0915 674.6 845.39 0.8 DCTN3 dynactin 3 (p22) 11258 
101 0.002776 0.0915 348.17 450.25 0.77 PEBP1 phosphatidylethanolamine binding protein 1 5037 
102 0.002886 0.0915 1083.9 1540.81 0.7 SNRNP70 small nuclear ribonucleoprotein 70kDa (U1) 6625 
103 0.002899 0.0915 1907.71 2863.32 0.67 CD3D CD3d molecule, delta (CD3-TCR complex) 915 
104 0.002904 0.0915 868.06 1196.05 0.73 SNRPB2 small nuclear ribonucleoprotein polypeptide B 6629 
105 0.002932 0.0915 246.53 305.57 0.81 CES2 carboxylesterase 2 8824 
106 0.002937 0.0915 377.57 527.02 0.72 RAB37 RAB37, member RAS oncogene family 326624 
107 0.003064 0.0915 458.96 640.79 0.72 PILRB paired immunoglobin-like type 2 receptor beta 29990 
108 0.003075 0.0915 395.09 502.08 0.79 SIVA1 SIVA1, apoptosis-inducing factor 10572 
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109 0.003076 0.0915 611.59 392.21 1.56 USP10 ubiquitin specific peptidase 10 9100 
110 0.0031 0.0915 2017.17 644.26 3.13 ALPL alkaline phosphatase, liver/bone/kidney 249 
111 0.003107 0.0915 375.29 491.1 0.76 BOLA3 bolA homolog 3 (E. coli) 388962 
112 0.00315 0.0915 302.88 402.22 0.75 MAPK8IP3 
mitogen-activated protein kinase 8 interacting 
protein 3 
23162 
113 0.003151 0.0915 389.45 489.27 0.8 PYCR2 pyrroline-5-carboxylate reductase family, member 2 29920 
114 0.003187 0.0915 370.3 493.79 0.75 CELF2 CUGBP, Elav-like family member 2 10659 
115 0.003224 0.0915 384.9 508.94 0.76 ATRAID all-trans retinoic acid-induced differentiation factor 51374 
116 0.003227 0.0915 555.89 744.08 0.75 NHP2 NHP2 ribonucleoprotein homolog (yeast) 55651 
117 0.003261 0.0915 321.34 418.82 0.77 C7orf55 chromosome 7 open reading frame 55 154791 
118 0.003291 0.0915 20973.88 15402.58 1.36 ANXA2P2 annexin A2 pseudogene 2 304 
119 0.003332 0.0915 435.08 534.84 0.81 DIABLO diablo, IAP-binding mitochondrial protein 56616 
120 0.003335 0.0915 2232.09 3384.84 0.66 CD3D CD3d molecule, delta (CD3-TCR complex) 915 
121 0.003345 0.0915 331.03 435.94 0.76 PSMB5 
proteasome (prosome, macropain) subunit, beta 
type, 5 
5693 
122 0.003349 0.0915 164 210.9 0.78 NUDT14 
nudix (nucleoside diphosphate linked moiety X)-
type motif 14 
256281 
123 0.003385 0.0918 206.44 250.42 0.82 FAM195B family with sequence similarity 195, member B 348262 
124 0.003443 0.0918 230.95 303.36 0.76 LOC338799 uncharacterized LOC338799 338799 
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125 0.003463 0.0918 278.29 361.69 0.77 DPM3 
dolichyl-phosphate mannosyltransferase 
polypeptide 3 
54344 
126 0.003472 0.0918 2629.45 3473.26 0.76 HINT1 histidine triad nucleotide binding protein 1 3094 
127 0.003476 0.0918 514.54 371.74 1.38 STAT3 
signal transducer and activator of transcription 3 
(acute-phase response factor) 
6774 
128 0.003518 0.0921 430.85 552.78 0.78 TMEM147 transmembrane protein 147 10430 
129 0.003569 0.0921 142.65 184.87 0.77 TNFRSF13C 
tumor necrosis factor receptor superfamily, member 
13C 
115650 
130 0.003587 0.0921 377.9 557.6 0.68 PVRIG 
poliovirus receptor related immunoglobulin domain 
containing 
79037 
131 0.003591 0.0921 122.29 150.14 0.81 MYL5 myosin, light chain 5, regulatory 4636 
132 0.003606 0.0921 342.44 474.92 0.72 ZMYM6 zinc finger, MYM-type 6 9204 
133 0.003649 0.0922 409.4 554.63 0.74 VAMP2 
vesicle-associated membrane protein 2 
(synaptobrevin 2) 
6844 
134 0.00377 0.0922 908 1357.91 0.67 SRRM2 serine/arginine repetitive matrix 2 23524 
135 0.003783 0.0922 371.98 469.99 0.79 BOLA3 bolA homolog 3 (E. coli) 388962 
136 0.003805 0.0922 195.2 241.21 0.81 PAAF1 proteasomal ATPase-associated factor 1 80227 
137 0.003849 0.0922 3723.92 5291.54 0.7 RPL36 ribosomal protein L36 25873 
138 0.003864 0.0922 1981.53 2700.8 0.73 SEC61G Sec61 gamma subunit 23480 
139 0.003913 0.0922 245.07 177.82 1.38 GNL3L 
guanine nucleotide binding protein-like 3 
(nucleolar)-like 
54552 
140 0.00392 0.0922 175.44 222.07 0.79 C3orf78 chromosome 3 open reading frame 78 440957 
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141 0.003921 0.0922 1064.55 1384.14 0.77 IMP3 
IMP3, U3 small nucleolar ribonucleoprotein, 
homolog (yeast) 
55272 
142 0.003921 0.0922 1399.33 1782.58 0.79 ZNFX1-AS1 ZNFX1 antisense RNA 1 441951 
143 0.003938 0.0922 309.49 416.42 0.74 CCDC53 coiled-coil domain containing 53 51019 
144 0.004044 0.0923 1006.75 552.51 1.82 NBPF9 neuroblastoma breakpoint family, member 9 400818 
145 0.004068 0.0923 457.62 572.65 0.8 TMEM160 transmembrane protein 160 54958 
146 0.004074 0.0923 377.26 494.11 0.76 LOC148413 uncharacterized LOC148413 148413 
147 0.004132 0.0923 362.24 247.02 1.47 RAD21 RAD21 homolog (S. pombe) 5885 
148 0.004142 0.0923 327.44 415.7 0.79 CCDC115 coiled-coil domain containing 115 84317 
149 0.004151 0.0923 465.89 588.16 0.79 CYB561D1 cytochrome b-561 domain containing 1 284613 
150 0.004199 0.0928 173.87 215.83 0.81 SOCS4 suppressor of cytokine signaling 4 122809 
151 0.004296 0.0944 464.77 628.42 0.74 SNRPN small nuclear ribonucleoprotein polypeptide N 6638 
152 0.00441 0.0961 4175.18 5729.43 0.73 COX7C cytochrome c oxidase subunit VIIc 1350 
153 0.004464 0.0961 1688.62 2149.52 0.79 SSR4 signal sequence receptor, delta 6748 
154 0.004484 0.0961 361.15 484.76 0.75 CD3E CD3e molecule, epsilon (CD3-TCR complex) 916 
155 0.004493 0.0961 602.81 754.05 0.8 U2AF2 U2 small nuclear RNA auxiliary factor 2 11338 
156 0.004498 0.0961 213.58 278.62 0.77 SUGP2 SURP and G patch domain containing 2 10147 
  
174 
 
157 0.004589 0.0975 216.86 262.01 0.83 PPP1R8 protein phosphatase 1, regulatory subunit 8 5511 
158 0.004611 0.0975 189.54 141.12 1.34 USF1 upstream transcription factor 1 7391 
159 0.004646 0.0977 717.47 941.15 0.76 MYO1G myosin IG 64005 
160 0.004695 0.0982 39016.04 29688.06 1.31 HBG1 hemoglobin, gamma A 3047 
161 0.004751 0.0983 358.19 241.47 1.48 AKIRIN1 akirin 1 79647 
162 0.004839 0.0983 591.88 782.88 0.76 RPAIN RPA interacting protein 84268 
163 0.004862 0.0983 674.92 855.25 0.79 RASGRP2 
RAS guanyl releasing protein 2 (calcium and DAG-
regulated) 
10235 
164 0.00491 0.0983 1030.44 1345.85 0.77 CUTA cutA divalent cation tolerance homolog (E. coli) 51596 
165 0.004929 0.0983 595.65 765.75 0.78 DYNLRB1 dynein, light chain, roadblock-type 1 83658 
166 0.004939 0.0983 149.2 186.14 0.8 MRPL2 mitochondrial ribosomal protein L2 51069 
167 0.004969 0.0983 301.43 381.43 0.79 RRP36 
ribosomal RNA processing 36 homolog (S. 
cerevisiae) 
88745 
168 0.005025 0.0983 451.44 575.02 0.79 DPM1 
dolichyl-phosphate mannosyltransferase 
polypeptide 1, catalytic subunit 
8813 
169 0.005041 0.0983 399.06 506.22 0.79 NHP2 NHP2 ribonucleoprotein homolog (yeast) 55651 
170 0.005086 0.0983 200.22 249.58 0.8 ICT1 immature colon carcinoma transcript 1 3396 
171 0.005099 0.0983 312.05 387.84 0.8 STRA13 stimulated by retinoic acid 13 homolog (mouse) 201254 
172 0.005129 0.0983 199.04 262.27 0.76 MIB2 mindbomb E3 ubiquitin protein ligase 2 142678 
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173 0.00513 0.0983 442.77 549.38 0.81 C19orf43 chromosome 19 open reading frame 43 79002 
174 0.00515 0.0983 240.06 181.97 1.32 LMNB1 lamin B1 4001 
175 0.005196 0.0983 956.52 1194.24 0.8 PSMB4 
proteasome (prosome, macropain) subunit, beta 
type, 4 
5692 
176 0.005221 0.0983 329.11 468.77 0.7 NCOR2 nuclear receptor corepressor 2 9612 
177 0.005252 0.0983 283.42 343.01 0.83 DSTN destrin (actin depolymerizing factor) 11034 
178 0.005314 0.0983 636.14 863.73 0.74 TECR trans-2,3-enoyl-CoA reductase 9524 
179 0.005339 0.0983 299.88 383.16 0.78 C1orf131 chromosome 1 open reading frame 131 128061 
180 0.005359 0.0983 325.98 413.56 0.79 ZBTB4 zinc finger and BTB domain containing 4 57659 
181 0.005379 0.0983 824.87 1057.83 0.78 RPP21 ribonuclease P/MRP 21kDa subunit 79897 
182 0.005381 0.0983 342.66 421.94 0.81 KLHL22 kelch-like 22 (Drosophila) 84861 
183 0.005415 0.0983 4122.36 5473.07 0.75 RPL26 ribosomal protein L26 6154 
184 0.005423 0.0983 916.97 1187.79 0.77 DYNLRB1 dynein, light chain, roadblock-type 1 83658 
185 0.005449 0.0983 210.64 264.99 0.79 ID2 
inhibitor of DNA binding 2, dominant negative 
helix-loop-helix protein 
3398 
186 0.005451 0.0983 777.85 1057.66 0.74 LIME1 Lck interacting transmembrane adaptor 1 54923 
187 0.005469 0.0983 287.98 354.89 0.81 GGNBP2 gametogenetin binding protein 2 79893 
188 0.005513 0.0983 223.28 179.13 1.25 AGFG1 ArfGAP with FG repeats 1 3267 
  
176 
 
189 0.005517 0.0983 1575.42 931.63 1.69 NBPF10 neuroblastoma breakpoint family, member 10 100132406 
190 0.005522 0.0983 308.77 377.62 0.82 MED30 mediator complex subunit 30 90390 
191 0.005525 0.0983 604.38 752.11 0.8 C11orf48 chromosome 11 open reading frame 48 79081 
192 0.00562 0.0996 730.44 868.54 0.84 UFC1 ubiquitin-fold modifier conjugating enzyme 1 51506 
193 0.005707 0.0998 285.98 348.91 0.82 MRPL11 mitochondrial ribosomal protein L11 65003 
194 0.005713 0.0998 241.26 306.84 0.79 SEPT6 septin 6 23157 
195 0.005734 0.0998 2511.24 1829.86 1.37 SQSTM1 sequestosome 1 8878 
196 0.005746 0.0998 175.4 220.72 0.79 EPM2AIP1 EPM2A (laforin) interacting protein 1 9852 
197 0.005758 0.0998 211.15 262.79 0.8 FOXK1 forkhead box K1 221937 
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When using a cut-off fold change of at least 1.5 in either direction and including 
genes with at least 2 probes in the significant gene list, there were 40 significant 
probes that corresponded to coding genes of which 22 were upregulated and 18 
probes were downregulated in the high AFB1 exposure group compared to the low 
AFB1 exposure group.  
Unsupervised clustering of the samples within the complete significant gene list 
showed almost complete separation of the low and high AFB1 exposure groups 
although with correlation coefficients ranging from 0.8 to -0.2. This dendrogram was 
partnered with a supervised heatmap to visualise gene expression differences 
between AFB1 exposure groups (Figure 16).  
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Figure 16:  Unsupervised dendrogram and supervised heatmap of gene expression patterns 
by AFB1 exposure groups within the significant gene list (including non-coding probes). 
Blue represents lower expression relative to red. 
 
Several of the significantly different genes are downregulated in the high AFB1 
exposure group compared to the low exposure group. The heatmap for gene 
expression by AFB1 groups in the smaller subset of significant genes is shown in 
Figure 17.  
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Figure 17: Supervised clustering of a small subset of differentially expressed genes between 
high and low AFB1 exposure groups. 
 
Clear patterns can be observed from the heatmaps in both figures with more than 50% 
of the genes, including ID2 and CD3D, being upregulated in the low AFB1 exposure 
group relative to expression in the high AFB1 exposure group. However, genes 
including STAT3 and PTPRC are upregulated in the high exposure group compared 
to the low exposure group. Additionally, there was no correlation between the DNA 
methylation and gene expression changes observed in Gambian infants.  
Sample number
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5.3.2.3 Quantitative trait analysis 
QTA was done to determine if actual AF-alb values correlated with gene expression. 
Early maternal AFB1 exposure was selected for this analysis and resulted in one gene, 
ubiquitin-specific protease-4 (USP4), being significantly correlated with AFB1 
exposure values (correlation coefficient: 0.839; P = 9 x 10
-7
; FDR-adjusted P value = 
0.043) (Figure 18). 
 
Figure 18: Dot plot of log-transformed USP4 gene expression by AFB1 exposure groups. 
A two-tailed t-test with Welch’s correction for unequal variances done on the log 
transformed expression values for USP4 between AFB1 exposure groups revealed a 
significant difference between groups (R
2
 = 0.388; P = 0.002). The QTA was 
repeated with later-gestational-stage AF-alb exposure levels but no significant genes 
with less than 5% FDR were identified.  
5.3.2.4 Pathway analysis 
Pathway analysis using DAVID v.6.7 revealed significant pathway categories using 
the Biocarta database but none with the KEGG database. Of the 40 significantly 
different genes, only two genes belonged to three pathway categories (Table 25). 
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Table 25: Differentially expressed genes in the significant gene list with at least a 2-fold change or repeated probes represented by their associated pathways. 
 Biocarta Pathway Pathway Descriptor Genes 
Number of 
Genes 
P value 
 
h_tcraPathway 
Lck and Fyn tyrosine kinases in initiation of 
TCR Activation 
PTPRC, CD3D 2 0.038 
h_thelperPathway T Helper Cell Surface Molecules PTPRC, CD3D 2 0.041 
h_tcytotoxicPathway T Cytotoxic Cell Surface Molecules PTPRC, CD3D 2 0.041 
  
182 
 
5.3.2.5 Validation of gene expression changes by qPCR 
Genes selected for validation were analysed by qPCR on 52 total RNA samples. As 
the validation was done on several samples that were not analysed for whole genome 
gene expression changes, this was a validation of the specific gene expression 
change in mostly independent samples. The samples were divided into high and low 
AFB1 exposure groups using 33.1 pg/mg as the cut-off value. This value was 
selected on the basis that it is the median of the complete AF-alb data set for early 
exposure. Figure 19 presents the dot plots of the mRNA expression of genes selected 
for validation in the two AFB1 exposure groups. Ten of the 12 genes are not 
significantly different between the two groups. However, USP4 and STAT3 gene 
expression were both significantly upregulated in the high AFB1 exposure group 
compared to the low exposure group (P = 0.01 and P = 0.03, respectively), with a 
similar trend to results obtained from the whole genome study.  
 
  
183 
 
 
Figure 19: Validation of qPCR results for 12 genes comparing gene expression per AFB1 
exposure group. The mean per group is marked in each cluster per graph and the P value 
per graph is displayed below the gene name. 
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5.3.2.6 Influence of season of measurement on USP4 and STAT3 
expression 
Univariate regression with USP4 log expression values and season (classed as dry 
and rainy) found no significant difference in expression by season (P = 0.749). 
However, when dichotomising by season, the correlation between AF-alb values and 
USP4 expression was only significant during the dry season (R
2
 = 0.918; P < 0.001 
for dry season and R
2
 = 0.599; P = 0.09 for rainy season) (Table 26). 
Three probes for STAT3 were significantly different in the gene list and were 
therefore all individually considered in the analysis. Univariate regression did not 
determine any significant differences in STAT3 expression by season (P > 0.05). 
When dichotomising by season, correlation between AF-alb values and STAT3 probe 
expression were only significant during the dry season (Table 26). 
 
Table 26: Correlation coefficients for USP4 and STAT3 per season of measurement. 
Gene 
Dry Season Rainy Season 
Correlation 
coefficient (R
2
) 
P value 
Correlation 
coefficient (R
2
) 
P value 
USP4 0.918 < 0.001 0.599 0.089 
STAT3 probe 1 0.791 0.001 0.412 0.270 
STAT3 probe 2 0.856 < 0.001 0.171 0.661 
STAT3 probe 3 0.722 0.002 0.172 0.659 
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5.4 Discussion  
Exposures to environmental toxins and factors during conception and early life can 
drastically affect the developing epigenome, which can increase the risk of adverse 
health outcomes in later life (Lucas 1991). As pregnant women are exposed to AFB1 
through contaminated diet, the ingested toxin can cross the placenta and can be 
activated to the reactive aflatoxicol at the placental interface (Partanen et al. 2010). 
In this project, a whole genome approach was used to identify altered DNA 
methylation and gene expression patterns in infants exposed to AFB1 in utero. These 
patterns can contribute to our understanding of the mechanistic action of AFB1 
exposure on human health.  
 
5.4.1 Timing of environmental exposures 
While a lot of research has focused on conception being a crucial time of fetal 
vulnerability to exposures, a number of studies have also discovered an association 
between environmental exposures, factors or events and changes to the epigenome or 
genome at different time points of development during pregnancy. For instance, 
prenatal famine has been associated with significant health outcomes in adulthood 
and the effects can be dependent on the time of exposure (Tobi et al. 2009). In Dutch 
people exposed to a famine occurring towards the end of the Second World War, 
differences in methylation of growth and development-related genes INSIGF, IL10, 
LEP, ABCA1 and GNASAS was observed in individuals exposed to famine 
periconceptionally compared to their unexposed siblings (Tobi et al. 2009). However, 
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in people exposed to famine during late gestation, differential methylation of 
GNASAS and LEP was observed (Tobi et al. 2009).  
AFB1 exposure during late gestation has been shown to inhibit growth in rats while 
having no obvious effects when administered earlier during pregnancy (Butler and 
Wigglesworth 1966). This has important implications in humans particularly if 
exposure during mid-late gestation can also affect the epigenome and genome, 
potentially predisposing the child to adverse health outcomes in later life. Of course, 
it cannot be assumed that similar effects will be seen in different species but the rat 
data shows the possibility that exposure during different times of exposure during 
pregnancy could have different outcomes for child health.  
 
5.4.2 DNA methylation differences associated with aflatoxin 
exposure 
One important confounder that has been included in the DNA methylation analysis is 
the season at the time of conception. Season has been identified as a confounder in 
previous studies associating environmental exposures with DNA methylation 
changes (Breton et al. 2009; Madrigano et al. 2011). Indeed, the season of 
conception in The Gambia has been associated with nutritional differences in 
pregnant women, which can influence fetal development, particularly DNA 
methylation at this crucial early time point (Waterland et al. 2010). Due to the 
propensity to alter DNA methylation in the foetus, it is necessary to adjust for season 
of conception in DNA methylation analyses in order to avoid identifying season-
associated changes attributed aflatoxin exposure. However, there is a potential of 
over-adjustment, which may mask the true effects of aflatoxin exposure. For this 
  
187 
 
reason, the analysed data was compared with and without adjustment for season of 
conception. As no major differences were observed between the two groups, and due 
to the potential biological relevance to DNA methylation, the data was adjusted for 
season of conception in the final analysis. 
In this study, no significant differences in DNA methylation were observed at the 
probe level. However, a number of significant differentially methylated genes were 
identified at the gene and promoter level. While changes at individual sites are 
interesting especially if changes occur in the shore (regions near the CpG islands) or 
open seas (isolated CpGs in the genome), consistent alterations to the methylation 
status within the gene body or promoter region would potentially have a greater 
influence on gene expression.  
Several of the identified genes are involved in immune regulation and cytokine 
signalling suggesting that in utero AFB1 exposure can alter methylation patterns that 
may affect the immune response.  
 
5.4.2.1 Association of validated DNA methylation changes in genes 
with health effects 
CpG sites within 6 genes (CD3D, CREB3L3, HORMAD2, HOXB2, PSMA8 and 
SLC17A9) were successfully validated by pyrosequencing. Of these, CD3D is 
involved in the immune response, particularly in T cell development and signal 
transduction. It has recently been proposed as one of many markers of breast cancer 
prognosis where high gene expression is associated with a better clinical outcome 
(Dedeurwaerder et al. 2011b). HORMAD2 is important for meiotic progression and 
is essential during meiosis. It was also identified in a genome-wide association study 
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as a contributing factor to the risk of lung cancer in Han Chinese individuals (Liu et 
al. 2012). PSMA8 encodes for a proteasome subunit, which cleaves peptides in the 
cell. Hypermethylation may result in lower expression of this subunit, which may 
then slow-down the destruction of faulty peptides or invading viruses. SLC17A9 
encodes for a solute carrier gene, which is involved in the vesicular storage and the 
exocytosis of ATP. It is significantly hypomethylated in the higher AFB1 exposure 
group in the current study suggesting that in utero AFB1 exposure can alter and 
potentially disrupt normal cellular processes.  
HOXB2 and CREB3L3, which encode transcription factors, were hypomethylated in 
Gambian infants exposed to higher AFB1. Interestingly, HOXB2 overexpression has 
been observed in lung tumour tissues and has been proposed as prognostic marker 
for stage I lung adenocarcinomas (Inamura et al. 2007). CREB3L3 is a liver-specific 
transcription factor and in mice has been found to encode a growth suppressor 
protein and is under-expressed in hepatoma cells and overall in HCC (Chin et al. 
2005).  
 
5.4.3 Gene expression differences associated with aflatoxin 
exposure 
5.4.3.1 Quality of mRNA for whole genome gene expression analysis 
A number of factors can influence or interfere with transcriptomic analysis including 
varied bench time, storage temperatures and time in cold storage (Hebels et al. 2013). 
In the current study, blood was collected from infants at varying time points between 
3-6 months following birth. Blood cell separation and preparation prior to storage 
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was conducted by trained individuals in the MRC unit, Keneba, The Gambia. Inter-
individual variation in sample handling could be an additional factor in introducing 
some differences in RNA transcripts within the samples. Also, as infants were born 
at different times, variation in time in cold storage existed for these samples, 
although the range of storage time did not exceed more than a few months. In order 
to avoid much of this variation in RNA transcript levels, blood cells were separated 
and immediately stored in RNAlater reagent, which stabilises RNA transcripts. RNA 
extraction from blood cells stored in RNAlater was undertaken by trained 
technicians at the Epigenetics Group, IARC, Lyon, France, where conditions of 
storage and bench time could be controlled more accurately.  
 
5.4.3.2 Changes in gene expression associated with AFB1 exposure 
We have found significant differences in whole genome gene expression when 
comparing AFB1 exposure groups based on early exposure but none when looking at 
exposure during later pregnancy. All highlighted pathways were involved in the T 
cell mediated immune response, which provides some evidence that in utero AFB1 
exposure affects the immune system components.  
Interestingly, BOLA3, which was found to be upregulated in the high AFB1 exposure 
group, has been suggested to be a metastable epiallele in humans following a study 
also based in The Gambia. The study observed that BOLA3 was hypomethylated 
during the dry season at the time of conception (Waterland et al. 2010), which is also 
a period of higher AFB1 exposure (Chapter 4).  
There was no correlation between the observed DNA methylation and gene 
expression changes in these Gambian infants, although a positive correlation would 
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be expected (Hellman and Chess 2007). This could be due to technical or biological 
reasons. While the blood from which both DNA and RNA was extracted was 
collected at a similar time, the actual extraction was carried out at two different time 
points and at two different locations: DNA was extracted at the MRC Unit, Keneba, 
The Gambia shortly after blood collection and blood stored in RNAlater was first 
shipped to IARC, Lyon, France, where RNA extraction was carried out. Any other 
sources of variation including bench time and storage conditions for the two sets of 
samples could have introduced further differences in DNA methylation and gene 
expression.  
As gene expression is not only modulated by DNA methylation but also by other 
epigenetic mechanisms or by mutations (Portela and Esteller 2010), it is possible that 
the significant gene expression changes observed in the current work are controlled 
by mechanisms other than DNA methylation. Furthermore, the actual observed 
changes in the current work do not exceed 2-fold and are indeed changes of a 
relatively low magnitude. In previous studies that have correlated DNA methylation 
with gene expression have done so at loci with at least a 2-fold change between 
groups (Schmelz et al. 2004; Fan et al. 2006). Therefore, this may additionally 
explain the lack of correlation between the observed significant DNA methylation 
and gene expression changes.  
We have successfully validated expression changes in USP4 and STAT3, although a 
total of 12 genes were selected. This may be because of the relatively small changes 
in expression observed. While these changes are statistically significant, it is not 
known if they are biologically relevant and therefore may not reflect real AFB1-
associated changes.  
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Additionally, the effect of season of blood measurement was examined. Seasonality 
is known to be one factor in the variation of AF-alb levels (See Chapter 4). 
Interestingly, both USP4 and STAT3 expression was more significantly associated 
with AF-alb during the dry season than during the rainy season. However, this may 
be attributed to the fact that AF-alb levels are higher during the dry season. 
Univariate analyses did not find any associations between gene expression and 
season suggesting it is not relevant to variations in expression levels.  
 
5.4.3.3 Role of USP4 in carcinogenesis 
USP4 is an enzyme responsible for deubiquitinating the A2A-adenosine receptor, 
among other targets. USP4 binds to the carboxyl terminus of the A2A receptor, which 
then relaxes the stringent quality control of the endoplasmic reticulum and enhances 
cell surface expression. This then allows misfolded proteins to move out of the ER to 
the plasma membrane (Milojević et al. 2006). USP4 gene expression has been 
consistently elevated in prostate and urinary bladder cancers, suggesting a role in 
cancer development. Indeed, it has also been shown to lead to the inhibition of p53 
by binding ARF-BP1, which is involved in the degradation of p53 (Zhang et al. 
2011). 
 
5.4.3.4 The role of STAT3 in development 
STAT3 or signal transducer and activator of transcription-3 is an important member 
of the JAK/STAT signalling family. In response to cytokines and growth factors (for 
example. IL6 and human growth factor), STATs are phosphorylated, form dimers 
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and translocate to the nucleus to activate transcription of genes responsible for cell 
growth and apoptosis (Rawlings et al. 2004).  
STAT3 plays an important role in tumour cell proliferation, survival and invasion as 
well as restraining the anti-tumour immune responses. However, it also induces the 
expression of cytokines and growth factors, with the respective receptors activating 
STAT3 resulting in a feedforward loop between the tumour and the immune system 
(Yu et al. 2009). 
De Benedetti et al. (De Benedetti et al. 1997) studied transgenic mice, which carry 
the neurospecific enolase promoter overexpressing human IL6 cDNA. The study 
found that the overexpression of IL6, which activates the STAT3 pathway, resulted 
in a reduced growth rate with transgenic mice 50-70% the size of non-transgenic 
littermates. When the IL6 receptor was blocked with a monoclonal antibody, the 
growth impairment was partly reverted. Interestingly, circulating IGF1 levels were 
significantly lower in the transgenic mice. Furthermore, administration of the same 
strain of IL6 to non-transgenic mice led to a reduction of circulating IGF1 levels. 
Also, in 21 children with systemic juvenile rheumatoid arthritis, circulating IL6 
levels were negatively correlated with IGF1 levels (De Benedetti et al. 1997).  
In transgenic mice overexpressing IL6 and with growth impairment, gene expression 
of the suppressor of cytokine signalling-3 (SOCS-3) was elevated. SOCS are also 
inhibitors of the STAT and GH signalling. IL6 induces expression of STAT3, which 
in turn activates SOCS, which is thought to be part of the mechanism of growth 
impairment by IL6 (Lieskovska et al. 2003).   
DON, a Fusarium mycotoxin, which has been associated with growth impairment in 
mice (Amuzie and Pestka 2010), has been associated with increased mRNA and/or 
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protein expression of IL6 in macrophage cell lines and in mice (Sugita-Konishi and 
Pestka 2001; Amuzie et al. 2009). Moreover, following IL6 upregulation, SOCS-3 
mRNA expression was also increased in the liver, muscle and spleen of DON-
exposed mice (Amuzie et al. 2009). Also, hepatic SOCS expression was 
significantly associated with a 75% suppression of IGF-ALS subunit, which together 
with IGFBP3 is important in prolonging the half-life of IGF1 in circulation (Amuzie 
et al. 2009). Indeed, SOCS proteins are known to modulate the GH-IGF1 growth 
axis and consequently play a role in linear growth (Ahmed and Farquharson 2010).  
In the present work, STAT3 expression was upregulated in the high AFB1 exposure 
group. Therefore, it is possible that mechanism of AFB1-associated growth 
impairment is through elevated IL6 levels, which in turn induce expression of 
STAT3. It may accomplish this either by altering the IGF growth axis and/or through 
the activation of SOCS. Identification of STAT3 upregulation may be an important 
clue to aid our understanding of the mechanism of growth impairment in children 
exposed to high levels of AFB1.  
 
5.4.4 Conclusions 
Patterns of DNA methylation and gene expression changes associated with in utero 
AFB1 exposure have been identified. Most of the altered genes are involved in the 
immune response and cell cycle progression while a few including CD3D, HOXB2, 
USP4 and STAT3 have been previously associated with carcinogenesis and growth 
impairment. While the observed changes in DNA methylation and gene expression 
were statistically significant, they must be considered with caution. The differences 
in methylation and gene expression levels are not very high, which is expected as the 
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infants in the study were relatively healthy. Additionally, these changes were 
observed in white blood cells, which can have different patterns of DNA methylation 
depending on cell type (Reinius et al. 2012). However, the identification of some key 
altered genes does contribute to our understanding of the effects of early life AFB1 
exposure on human health and potentially represent markers of adverse health 
outcomes in later life.  
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6 Genome-wide effects of AFB1 exposed 
cultured liver cells 
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6.1 Introduction 
The use of blood as a surrogate for liver-specific changes following AFB1 exposure 
has already been discussed. However, a system whereby changes in the liver can be 
explored is also important in building a picture of the underlying mechanisms 
involved in AFB1-associated health effects. Studies using a cell-based model have 
been widely used to explain the mechanistic action of toxins. For instance, using an 
insulin-producing β cell line, INS-1 (832/13), Fu et al were able to show that low 
arsenic exposure induced an adaptive oxidative stress response. This increased 
antioxidant levels and disrupted reactive oxygen species (ROS) signalling involved 
in glucose-stimulated glucose secretion. These events resulted in altered β-cell 
function, thereby linking them to arsenic exposure-associated  type 2 diabetes (Fu et 
al. 2010).  
The use of cells enables the study of the effects of acute and chronic exposures in a 
tissue-specific manner. Additionally, time-course studies are easily designed and can 
be rapidly accomplished in an in vitro study compared to an epidemiological study. 
However, some limitations do exist including the difficulty in mimicking in vivo 
exposures and the removal of the cells from their ‘normal’ environment, which 
ignores any contribution of surrounding cells in exposure-related effects (Devlin et 
al. 2005).   
Despite these failings, in vitro work with cells can contribute greatly to our 
understanding of various pathways and systems involved in AFB1-associated 
carcinogenesis and growth impairment. Additionally, using a cell-based model may 
also reveal important markers of exposure and effects.  
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Indeed, global hypomethylation and hypermethylation of the p53 gene were 
observed in caco-2 cells (a human colon cancer cell line exposed to selenium and 
arsenic for 7 days (Davis et al. 2000). Environmental exposures have also been 
associated with significant changes to gene expression patterns. Benzo(a)pyrene 
altered expression of several genes involved in xenobiotic metabolism, cell cycle 
regulation and DNA repair in MCF-7 (a human breast cancer cell line) and HepG2 
cells. Furthermore, it was identified that a large number of changes were associated 
with p53 signalling (Hockley et al. 2007).  
AFB1 exposure for 24 hours has been associated with early gene expression changes 
to non-tumourigenic liver cells, HepaRG, including alterations to p53 signalling and 
DNA repair. Additionally, a direct effect on p53 protein levels upon AFB1 exposure 
was identified using a small interfering RNA against p53 (Josse et al. 2012).  
A whole genome approach was adopted to identify early events in DNA methylation 
and gene expression associated with AFB1 exposure in non-tumourigenic liver cells 
(HHL-16). Cells exposed to three varied AFB1 doses at two time points were 
analysed using Illumina arrays to determine early patterns of exposure that could 
provide a better understanding of aflatoxin-induced health effects.   
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6.2 Cultured cell DNA methylation analysis 
6.2.1 Methods 
6.2.1.1 Sample preparation 
HHL-16 non tumourigenic cells at passage 11 were treated with AFB1 and DNA was 
extracted from them as described in Chapter 2, Section 2.3.4.  Samples were 
prepared in triplicate and incubated with AFB1 for 24 and 48 hours (Table 27).  
 
Table 27: Description of cell sample control and treatment groups. 
Group Description 
NT Untreated cells (no treatment) 
D5 Cells treated with 0.0025% DMSO (control for A0.5 and A5) 
D20 Cells treated with 0.1% DMSO (control for A20) 
A0.5 Cells treated with 0.5 µg/ml AFB1 (≈ 1.09 µM) 
A5 Cells treated with 5 µg/ml AFB1 (≈ 10.94 µM) 
A20 Cells treated with 20 µg/ml AFB1 (≈ 43.76 µM) 
 
Prior to further analysis, samples were assigned a randomised code ID and added to 
the bead chips, ordered by ID. All samples were analysed in one batch precluding the 
effects of batch variability. Samples were bisulfite treated and analysed by 
pyrosequencing to ascertain the success of bisulfite treatment. This was done to 
assess methylation in LINE1 at this stage prior to analysis using the Illumina 
Infinium HD 450K DNA Methylation array (Illumina, Freddy van Riemsdijkweg, 
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The Netherlands), as described in Chapter 2, Sections 2.4.1.2 and 2.4.1.3. The whole 
genome work was done by Geoffroy Durand, IARC, Lyon, France.  
 
6.2.1.2 Data analysis and normalisation 
Illumina’s GenomeStudio Methylation module version 1.9 (Illumina, Freddy van 
Riemsdijkweg, The Netherlands) was used to calculate the methylation level at each 
CpG site as the beta (β) value. The data analysis was done with input and advice 
from Dr. Hector Hernandez-Vargas, IARC, Lyon, France. 
The detection P value for each β value was also calculated. β values were then log 
transformed to obtain the M value. The M values were analysed using RnBeads. The 
methylumi package was also used in conjunction to normalise the data. The analysis 
produced six modules, which are described in Table 28.  
Table 28: Description of RnBeads analysis modules. 
Module Description 
Loading and normalisation Summary of sample loading. Data was normalised 
using the methylumi package 
Quality control Box plots of all quality controls included in the 
450K bead chips 
Filtering Utilises a GreedyCut algorithm which filters out 
probes and samples of low purity. Also removes 
unreliable measurements with P value above 0.01 
Batch effects Determines if any batch effects exist. In the current 
work, all samples were analysed in the same batch 
Methylation profiles 
Displays the distribution of methylation values 
over Infinium I and II probes 
Differential methylation 
Determines differentially methylated probes either 
at the individual level or at the region level 
between sample groups 
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6.2.1.2.1 Analysis of differential methylation 
The data were corrected for multiple comparisons using a multivariate permutation 
test, which provided 95% confidence that the false discovery rate (FDR) or q value 
was less than 5%. Random variance t-statistics were used for each CpG site (Wright 
and Simon 2003).  
Lists of probes, genes and promoter-level differential methylation were produced 
through RnBeads following correction for multiple testing to determine differential 
methylation patterns in cells treated with AFB1. Lists were filtered to remove all 
probes/genes with a q value above 0.05. Additionally, a shorter list was produced 
only including probes/genes with at least a 5% difference in methylation levels. 
 
6.2.1.3 Pathway analysis 
Pathway analysis was performed using DAVID v.6.7, which uses sources including 
GenBank, UniGene, KEGG, and GO to compare input gene lists with large 
databases.  
 
6.2.1.4 Comparison with Gambian DNA methylation changes 
Each gene list from different treatment versus control comparisons at the promoter or 
gene level was compared with the gene list derived from Gambian infants exposed to 
AFB1 during fetal development to determine if any of the differentially methylated 
genes match between gene lists. 
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6.2.2 Results 
6.2.2.1 Differential methylation 
6.2.2.1.1 Probe-level analysis 
Each comparison of treatment versus control group was done at the probe level to 
determine if AFB1 exposure in vitro affected individual CPG site methylation status. 
However, none of the differentially methylated probes were significantly different, 
with q values (equivalent to FDR) above 0.05. This suggests that changes at the 
individual probe level may not be apparent at the doses and time points assessed in 
this study. 
 
6.2.2.1.2 Gene-level analysis 
The comparisons of treatment versus control groups were repeated at the gene region 
level to identify changes to the methylome that potentially affect gene expression. 
The results from this analysis are displayed in Table 29. The differential methylation 
observed following a 24-hour treatment was dose-dependent with the number of 
differentially methylated genes increasing with increasing dose. Following a 48-hour 
treatment, differential methylation only appeared to be dose-dependent up to A5 with 
the number of differentially methylated genes being much lower at the highest dose. 
Additionally, at both time points, the number of hypomethylated genes in the AFB1-
treated cells compared to the DMSO controls was much higher than the number of 
hypermethylated genes at all three doses.  
  
202 
 
Table 29: Number of significant differentially methylated genes at the gene region level for different control versus treatment comparisons in cultured liver 
cell DNA. 
Time 
Point 
Comparison 
Number of 
significant 
gene regions 
Number of 
significant gene 
regions with at 
least 5% 
difference in 
methylation 
(including NAs) 
Number of 
Hypomethylated 
gene regions 
Number of 
Hypermethylated 
gene regions 
Significant gene regions with at least 
5% difference in methylation 
(excluding NAs) 
24 
hours 
D5 vs A0.5 65 15 13 2 
MAS1, MIR943, PABPC1P6, POTEJ, 
VCX2 
D5 vs A5 105 32 29 3 
DNM1P32, GSN-AS1, HIST3H3, 
MIR4297, PABPC1P6, PPP1R2P2, 
PPY2, RNASE3, RPL15P3, 
TBC1D3P4, USP17L7 
D20 vs A20 188 52 40 12 
ANKRD20A14P, C19orf76, CCNJP1, 
CFHR1, E2F3-IT1, GOLGA6B, 
GPR42, KRTAP20-3, LINC00341, 
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MIR24-2, MIR4508, MIR551B, OLR1, 
OR2D2, OR4L1, OR5AC2, OR5H1, 
OXCT2P1, PFN1P1, PROL1, RN5-
8S3, SCARNA3, STC1, TGM7, TUG1 
48 
hours 
D5 vs A0.5 158 14 14 0 
CYLC2, NTM-IT1, OR5W2, OR6B1, 
RHOXF2, RPS26P34, SPTLC3 
D5 vs A5 221 33 33 0 
ABCA6, AK4P5, C5, CYLC2, KERA, 
KIF4B, MIR2276, PABPC1P1, 
RNU5F-2P, SLC15A5, SPTLC3, 
SUMO4, TAS2R43, UQCRFS1P1 
D20 vs A20 58 34 24 10 
FOXQ1, IL2, KIAA0125, LINC00413, 
LINC00596, LINC00615, MBL2, 
MIR410, MIR4458, NT5CP2, 
SNORD1140-31 
NA – probes in non-annotated regions 
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Gene lists, consisting of significant differentially methylated genes, were analysed 
by comparing treatment versus control groups. A comparison of these significant 
gene lists from each set shows that few genes are in common between the lists 
(Figure 20).  
 
 
Figure 20: Venn diagrams comparing gene lists derived from treatments versus control 
groups at 24 and 48 hour time points. Very few genes were in common between the three 
gene lists. 
 
The five genes in common between A0.5 and A5 (24hr) were: PABPC1P6, 
RNASE13, RRH, SNORA52, USP17L7. The one gene in common between A0.5 and 
A20 (24hr) was: MIR24-2. The two genes in common between A5 and A20 (24hr) 
were: ANKRD20A14P and PPY2. The ten genes in common between A0.5 and A5 
(48hr) were: AGR3, CFC1B, CYLC2, KRTAP10-9, KRTAP4-2, SPTLC3, TAS2R43, 
TLR12P, TNFS8 and UQCRFS1P1.  
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6.2.2.1.2.1 Gene-level pathway analysis 
Pathway analysis by DAVID identified only one significant pathway (Olfactory transduction) for the D20 versus A20 comparison at 24 hours 
and the D5 versus A5 comparison at 48 hours (Table 30).         
 
Table 30: Pathway analysis by DAVID at the gene region-level in gene lists derived from AFB1 treatment versus control comparisons. 
Comparison Pathway Descriptor 
Number 
of genes 
Genes P value 
D20 vs A20 
(24hr) 
hsa0474
0 
Olfactory transduction 8 
OR56A1, OR10G8, OR52I2, OR2D2, OR4L1, 
OR7D4, OR51I1, OR5AC2 
 
2.62E-05 
 
D5 vs A5 (48hr) 
hsa0474
0 
Olfactory transduction 6 
OR5P2, OR4C15, OR2T12, OR3A2, OR2T6, 
OR10H4 
0.001746 
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6.2.2.1.3 Promoter-level analysis 
The comparisons of treatment versus control groups were performed at the promoter region level. The results from this analysis are displayed in 
Table 31.  
 
Table 31: Number of significant differentially methylated genes at the promoter-region level for different control versus treatment comparisons in cultured 
liver cell DNA. 
Time 
Point 
Comparison 
Number of 
significant 
promoter 
regions 
Number of significant 
promoter regions with 
at least 5% difference 
in methylation 
(including NAs) 
Number of 
hypomethylated 
significant 
promoters 
Number of 
hypermethylated 
significant 
promoters 
Significant promoter regions with 
at least 5% difference in 
methylation (excluding NAs) 
24 
hours 
D5 vs A0.5 59 16 11 5 
ANKRD20A4, LRRC3C, MIR4758, 
PABPC1P6, PPP1R3A, PRINS, 
SFXN5, SNORD113-3, TRIM48, 
ZNF211 
D5 vs A5 114 25 20 5 
ACTG1, AMY1B, CTAGE9, 
FAM90A24P, MIR455, PABPC1P6, 
PRINS, RPL15P3, RPL18AP2, 
SFXN5, SNORD113-3 
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D20 vs A20 353 48 36 12 
ARPC3P1, C12orf59, C5, GPR42, 
HSD3BP5, KRT8P33, KRTAP5-11, 
LCE1A, PR5AC2, RN5-8S3, 
RPS3AP3, SNORDA65, SNORD71, 
SYS1, TRAV22, ZNF806 
48 
hours 
D5 vs A0.5 159 14 11 3 CFC1, CFC1B, RPS26P34 
D5 vs A5 265 44 41 3 
ABCA6, C4BPB, COL3A1, EAF1-
AS1, EMB, EVI2B, GATA4, LRIT3, 
MRS2P2, OR13J1, PABPC1L2A, 
PABPC1P1, RASGRP3, SKOR1, 
SMEK2, TRGV10, TTC18, 
UQCRFS1P1 
D20 vs A20 96 46 28 18 
AMELX, CYP2C19, EAF1-AS1, 
GSTA3, HBE1, IGHD7-27, IGHJ1, 
IGHJ1P, IGHJ2, IGHJ2P, IGHJ3, 
IGHJ4, IQCA1P1, LINC00413, 
MIR370, MIR4458, MIR5683, 
NPBWR1, NT5CP2, OPRK1, RPA3, 
RSPH10B, SGCZ, SNORD113-3, 
TRGV2 
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At the promoter region-level, a similar trend to the gene region-level analysis in the 
numbers of differentially methylated genes was observed. Following a 24-hour 
treatment, differential methylation was dose-dependent with increasing number of 
differentially methylated genes with increasing dose. However, following a 48-hour 
treatment, the number of differentially methylated genes was higher in A5 cells than 
in A0.5 cells but much lower in A20 cells. Once again, AFB1 exposure was 
associated with higher levels of hypomethylation than of hypermethylation. A 
comparison of the significant gene lists from each set showed that very few genes 
were in common between the lists (Figure 21).  
 
 
Figure 21: Venn diagrams of DNA methylation changes comparing gene lists derived from 
treatments versus control groups at 24 and 48 hour time points. Very few genes were in 
common between the three gene lists. 
 
The ten genes in common between D5 vs A0.5 and D5 vs A5 at 24 hours were: 
ANKRD20A4, C9orf131, DEFB124, LINC00319, PABPC1P6, PPP1R3A, PRINS, 
SFXN5, SNORD113-3 and ZNF883.  
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The one gene in common between D5 vs A5 and D20 vs A20 at 48 hours was EAF1-
AS1. The five genes in common between D5 vs A0.5 and D5 vs A5 at 48 hours 
were: DCX, EPT1, GPR56, SETP10 and UQCRFS1P1.  
 
6.2.2.1.3.1 Promoter-level pathway analysis 
Pathway analysis by DAVID did not identify any significant pathways for gene lists 
derived from each comparison between controls and treatment groups at both time 
points.  
 
6.2.2.2 Comparison with Gambian DNA methylation changes 
A few genes were in common with a significant gene list derived from Gambian 
infant samples (Table 32). At the promoter level, G-protein coupled receptor 56 
(GPR56) was differentially methylated in cells treated with 5 µg/ml AFB1 at both 
24- and 48-hour time points as well as in Gambian infants. At the gene level, 
microRNA 24-2 (MIR24-2) was differentially methylated in cells treated for 24-
hours with 0.5 and 20 µg/ml AFB1 and in Gambian infants. Also at the gene level, 
mannose-binding lectin-2 (MBL2) was differentially methylated in cells treated with 
20 µg/ml AFB1 at both time points.  However, of these three genes, only one 
(MIR24-2) showed the same type of change in methylation (hypomethylation in this 
case) in both gene lists.  
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Table 32: Differentially methylated genes identified in Gambian infants and in cultured 
liver cells following AFB1 exposure. 
Gene 
Symbol 
Gene Name 
Change in 
Gambian infants 
(high exposure 
versus low 
exposure) 
Change in liver 
cells  
(high exposure 
versus low 
exposure) 
Region 
level 
GPR56 
G-protein 
coupled 
receptor 56 
Hypomethylated Hypermethylated Promoter 
MBL2 
mannose-
binding 
lectin-2 
Hypomethylated Hypermethylated Gene 
MIR24-2 
microRNA 
24-2 
Hypomethylated Hypomethylated Gene 
 
 
6.3 Cultured cell gene expression analysis 
6.3.1 Methods 
6.3.1.1 Sample preparation 
Total RNA was extracted from AFB1-treated HHL-16 cells following the method 
described in Chapter 2, Section 2.3.5. Samples were prepared in triplicate and 
incubated with AFB1 for 24 or 48 hours.  
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Prior to further analysis, samples were assigned a randomised code ID and added to 
the bead chips, ordered by ID. All samples were analysed in one batch precluding the 
effects of batch variability. Samples were analysed using the Illumina Human HT12-
v4 Expression BeadChip Kit (Illumina, Freddy van Riemsdijkweg, The Netherlands), 
described in Chapter 2, Section 2.4.2.2. This whole genome analysis was done by 
Geoffroy Durand, IARC, Lyon, France.  
 
6.3.1.2 Data analysis and normalisation 
Raw data in the form of expression values was imported and analysed on BRB 
ArrayTools software (version 4.3.0, developed by Dr. Richard Simon and BRB-
ArrayTools Development Team) using the lumi package, which is specifically 
designed for Illumina data (Du et al. 2008). This data analysis was done with input 
and advice from Dr. Hector Hernandez-Vargas, IARC, Lyon, France. 
Each probe on the BeadChips was identified via a nuID. Following the pre-
processing steps using lumi, the data was first log2 transformed followed by 
normalisation using RSN. Data was also corrected for multiple testing using t-
statistics and multivariate permutation analysis, which generates a q value per loci 
per comparison. Only q values < 0.05 were accepted. 
 
6.3.1.3 Clustering 
Unsupervised clustering was done to determine the distribution and correlation 
between the treated samples and controls at the two time points. 
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6.3.1.4 Data filtering 
Following normalisation, the data were then filtered to exclude less than 20 % of 
genes that have at least a 1.3-fold change in expression data in either direction of the 
gene’s median expression value. Also, genes with more than 50 % missing data were 
excluded from the analysis. These settings improved the number of hits obtained 
following class comparison analysis while excluding genes with missing values or 
with a very small change in expression between classes (Table 33).  
 
Table 33: Comparison of different filtering conditions in terms of hits obtained following 
class comparison analysis of the 48-hour D5 vs A5 comparison. 
Data filtering conditions N 
No filter 2007             
Excluding genes with more than 50 % missing data 2007 
and 20 % genes with less than 2-fold change  125 
and 20 % genes with less than 1.5-fold change 488 
and 20 % genes with less than 1.3-fold change 1116 
and 25 % genes with less than 1.5-fold change 451 
and 25 % genes with less than 1.3-fold change 1009 
and 30 % genes with less than 1.5-fold change 368 
and 30 % genes with less than 1.3-fold change 850 
N number of probes with a q value less than 5%  
 
6.3.1.5 Class comparison analysis 
Using the filtering conditions of excluding genes with more than 50% missing data 
and 20% genes with at least a 1.3-fold difference in either direction between groups, 
and with a significance threshold of 0.01, a class comparison was conducted to 
compare the different control versus treatment groups.  
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6.3.1.6 Pathway analysis 
Pathway analysis was done DAVID v.6.7, which uses sources including GenBank, 
UniGene, KEGG, and GO to compare input gene lists with large databases.  
 
6.3.1.7 Transcription factor gene set comparison 
Gene set expression comparison was done to determine if any transcription factor 
targets and pathways were differentially expressed due to AFB1 exposure. This 
analysis was only produced for the 48-hour D5 vs A5 and D20 vs A20 comparisons 
as a result of the higher number of significant changes in gene expression.   
 
6.3.1.8 Comparison of gene expression changes between liver cells 
and Gambian infants 
The list of significantly different expression of genes in AFB1-exposed Gambian 
infants (Chapter 5) was compared with gene lists derived from AFB1-exposed liver 
cells at 5 µg/ml and 20 µg/ml doses following 48-hour treatments.    
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6.3.2 Results 
6.3.2.1 Normalisation 
Raw data was first compared with normalised data to check if any extraneous 
variation was removed. A boxplot of the samples with and without RSN 
normalisation is shown in Figure 22.  
 
  
215 
 
 
Figure 22: Boxplot of the log intensity of log ratios of all genes on the Bead Chips for 36 
samples showing raw data (A) and robust spline normalised data (B). Several outliers are 
present potentially due to the variability in gene expression by treatment group. 
Normalisation removes any technical variability by calibrating against expression 
intensities on a reference array. 
 
6.3.2.2 Clustering 
Unsupervised clustering (see Figure 23) showed separation of the two treatment time 
points with a correlation coefficient (R
2
) of -0.6. Most samples clustering together 
display strong correlation with correlation coefficients between 0.7 and 1. Within the 
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24 hours treatment time, the controls and treatments clustered together without any 
obvious separation between the type of treatments. However, duplicates of all 
controls and treatment groups did cluster together with the third sample per group 
clustering separately. Within the 48 hours treatment time, there was a clearer 
separation between controls and A5 and A20 treatments. A weak correlation existed 
between the three A20 treatments and the rest of the sample groups (R
2
 = 0.2). 
Additionally, the A5 triplicates clustered together but away from the other groups 
with a correlation coefficient of 0.7.  
 
 
Figure 23: Unsupervised clustering of controls and treatment groups at two time points 
showing correlation between sample linkages. Samples clustering together are strongly 
correlated to one another, while samples at 24 hours are negatively correlated to those at 48 
hours (R
2 
= -0.6). Within the 48 hour treatment time, A20 and A5 cluster separately to the 
rest of the sample groups (R
2
 = 0.2; 0.7 respectively). 
 
6.3.2.3 Class comparison analysis 
Table 34 displays the number of significant differentially expressed probes between 
classes with at least a 2-fold change is displayed. 
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Comparisons between NT and both DMSO controls at 24 hours showed that no 
probes were significantly different between the groups suggesting that the vehicle of 
AFB1 treatment had no effect on gene expression patterns. Furthermore, only one 
probe corresponding to EGR1 was identified as being differentially expressed 
between NT and DMSO controls following 48 hours treatment. 
Very few to no significant differently expressed genes were observed following a 24-
hour treatment. After a 48 hour treatment, several gene expression changes were 
observed between controls and treatment groups. These changes were more apparent 
with at least a 2-fold change in either direction in cells treated with 5 µg/ml and 20 
µg/ml AFB1. Several changes were unique to the 48 hour treatment period. There 
was a dose dependent difference in gene expression with increasing numbers of 
genes being differentially expressed in cells treated with 5 µg/ml compared to those 
treated with 0.5 µg/ml, and again in cells treated with 20 µg/ml compared to those 
treated with 5 µg/ml AFB1.  
A few key genes IL6, IL8, GADD45A, HBEGF and CCL20 were differentially 
expressed at both 24- and 48-hour treatment times and are described in Table 35. 
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Table 34: Number of significant probes with at least a 2-fold change in either direction following exposure to AFB1 at two time points. 
Time 
Point 
Data Set 
No. of significant 
upregulated probes  
(at least 2-fold change) 
No. of significant 
downregulated probes  
(at least 2-fold change) 
Total no. of significant 
probes  
(at least 2-fold change) 
Top Genes 
24 hours 
D5 vs A0.5 0 0 0 - 
D5 vs A5 0 0 0 - 
D20 vs A20 1 0 1 IL6 
48 hours 
D5 vs A0.5 0 0 0 - 
D5 vs A5 
33 10 43 
IL8*, CXCL1, CSF2, BIRC3, 
HMOX1, HSPA1A, HSPA1B, 
HSPA6, LAMP3 
D20 vs A20 
280 183 463 
IL8*, CSF2, PTGS2, BIRC3, 
HMOX1, INHBE, ALOX5AP, 
HAPLN1, HSPA1A 
* probe repeated twice in top gene list 
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Table 35: Description of differentially expressed genes common to all AFB1 treatments versus controls. 
Gene 
Symbol 
Gene Name Function 
Expression change in 
exposed cells versus controls 
Reference(s) 
CCL20 
Chemokine (C-C 
motif) ligand 20 
Also known as liver and activation-regulated 
chemokine. Elevated protein expression observed in 
HCC  
Upregulated 
(Soliman et al. 
2012) 
GADD45A 
Growth arrest and 
DNA-damage-
inducible, alpha 
Involved in DNA repair and cell growth 
suppression. Increased protein expression observed 
in HCC 
Upregulated 
(Gramantieri et al. 
2005) 
HBEGF 
Heparin-binding 
EGF-like growth 
factor 
Involved in wound healing. Increased mRNA 
expression observed in HCC 
Upregulated (Inui et al. 1994) 
IL6 Interleukin-6 
Pro- and anti-inflammatory cytokine involved in the 
immune response. Elevated serum levels observed 
in HCC and in growth suppressed mice 
Upregulated 
(Giannitrapani et 
al. 2002; 
Lieskovska et al. 
2002) 
IL8 Interleukin-8 
Chemokine involved in angiogenesis. Potentially 
involved in the progression of HCC 
Upregulated (Ren et al. 2003) 
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6.3.2.3.1 Comparison of D5vsA5 and D20vsA20 analyses 
A Venn diagram was prepared comparing the gene lists derived from the D5 versus 
A5 and D20 versus A20 comparisons (Figure 24).  
 
 
Figure 24: Venn diagram depicting the number of genes in common or unique to each gene 
list derived from D5 versus A5 and D20 versus A20 comparisons. 
 
The 40 probes in common between the two gene lists included IL8, IL6, IL7R, 
BIRC3, GADD45A, E2F2, NFKB1 and MCM7. The two probes unique to D5 versus 
A5 were CXCL6 and THBS1 while some of the 414 genes unique to D20 versus A20 
were AEN, ASS1, CD44, CD83, CYP1A1, CYP1B1, IL24, MGMT, RIOK3, TGFBR2 
as well as additional probes for BIRC3 and GADD45A.  
6.3.2.4 Pathway analysis 
The 43 genes, identified as having at least a 2-fold change in expression in the D5 
versus A5 comparison, were imported into DAVID v. 6.7 to determine the associated 
KEGG and Biocarta pathway descriptors. These pathway categories are displayed in 
Table 36. 
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Table 36: Differentially expressed genes in the D5 versus A5 comparison with at least a 2-fold change represented by their associated pathways. 
 Pathway Descriptor Genes 
Number 
of Genes 
P value 
KEGG 
hsa04621 
NOD-like receptor signalling 
pathway 
CXCL1, IL6, CCL2, IL8, CXCL2, NFKB1, 
TNFAIP3, BIRC3 
8 2.08E-08 
hsa04060 
Cytokine-cytokine receptor 
interaction 
CXCL1, CSF2, IL6, CCL2, IL8, CCL20, 
CXCL2, CXCL6, IL7R 
9 4.21E-05 
hsa04062 Chemokine signalling pathway 
CXCL1, CCL2, IL8, CCL20, CXCL2, 
NFKB1, CXCL6 
7 3.54E-04 
hsa05120 
Epithelial cell signalling in 
Helicobacter pylori infection 
CXCL1, IL8, HBEGF, NFKB1 4 0.005318 
hsa05222 Small cell lung cancer E2F2, PTGS2, NFKB1, BIRC3 4 0.009557 
hsa05219 Bladder cancer E2F2, IL8, THBS1 3 0.020516 
hsa05200 Pathways in cancer E2F2, IL6, PTGS2, IL8, NFKB1, BIRC3 6 0.026985 
hsa04115 p53 signalling pathway RRM2, THBS1, GADD45A 3 0.0499 
Biocarta h_stemPathway 
Regulation of haematopoiesis by 
cytokines 
CSF2, IL6, IL8 3 0.014135 
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h_p53hypoxiaPathw
ay 
Hypoxia and p53 in the 
Cardiovascular system 
HSPA1A, HSPA1B, NQO1, GADD45A 3 0.034759 
h_inflamPathway 
Cytokines and Inflammatory 
Response 
CSF2, IL6, IL8 3 0.040329 
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A similar analysis was done for the 463 differentially expressed genes with at least a 2-fold change derived from the D20 versus A20 
comparison (Table 37).  
 
Table 37: Differentially expressed genes in the D20 versus A20 comparison with at least a 2-fold change represented by their associated pathways. 
 
Pathway Descriptor Genes 
Number 
of Genes 
P value 
KEGG 
hsa04621 
NOD-like receptor signaling 
pathway 
CXCL1, IL6, CCL2, IL8, CXCL2, NFKBIA, 
IL1B, NFKB1, TNFAIP3, BIRC3, BIRC2 
11 1.42E-05 
hsa05222 Small cell lung cancer 
TRAF1, CCNE2, E2F2, LAMB3, PTGS2, 
LAMC3, LAMA5, NFKBIA, NFKB1, BIRC3, 
BIRC2 
11 2.06E-04 
hsa04512 ECM-receptor interaction 
LAMB3, CD44, LAMC3, LAMA5, COL1A2, 
COL1A1, COL11A1, THBS3, COL5A1, 
HMMR 
10 9.38E-04 
hsa04110 Cell cycle 
CCNE2, E2F2, CDC45, MCM7, CDKN2D, 
PKMYT1, CHEK1, PTTG1, GADD45B, 
MCM4, GADD45A, CDC25A 
12 0.001372 
hsa03030 DNA replication RFC3, MCM7, POLE, POLA2, MCM4, FEN1 6 0.004332 
hsa04060 
Cytokine-cytokine receptor 
interaction 
CXCL1, CSF2, IL6, CCL2, IL8, CXCL5, 
CXCL2, TGFBR2, IL24, CX3CL1, IL7R, 
IL11, CCL20, IL20RB, INHBE, IL1RAP, IL1B 
17 0.005763 
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hsa05200 Pathways in cancer 
TRAF1, E2F2, IL6, FGFR3, IL8, PTGS2, 
MITF, TGFBR2, NFKBIA, CDH1, NFKB1, 
NFKB2, BIRC3, BIRC2, CCNE2, LAMB3, 
LAMC3, LAMA5, SLC2A1 
19 0.010304 
hsa05020 Prion diseases EGR1, IL6, IL1B, HSPA1A, HSPA5, HSPA1B 5 0.020858 
hsa00330 Arginine and proline metabolism 
ODC1, PYCR1, ASS1, P4HA2, P4HA1, 
AMD1 
6 0.021823 
hsa00240 Pyrimidine metabolism 
RRM2, RRM1, POLE, UPP1, TXNRD1, 
POLA2, TK1, POLR2A 
8 0.025121 
hsa04210 Apoptosis 
IRAK2, IL1RAP, NFKBIA, IL1B, NFKB1, 
BIRC3, BIRC2 
7 0.048622 
Biocarta 
h_il1rPathway Signal transduction through IL1R 
IRAK2, IL6, MAP2K3, IL1RAP, NFKBIA, 
IL1B, NFKB1 
7 0.001201 
h_nthiPathway 
NFkB activation by Nontypeable 
Hemophilus influenzae 
IL8, MAP2K3, TGFBR2, NFKBIA, IL1B, 
NFKB1 
6 0.003077 
h_stemPathway 
Regulation of hematopoiesis by 
cytokines 
CSF2, IL6, IL8, IL11 4 0.025061 
h_LDLpathway 
Low-density lipoprotein (LDL) 
pathway during atherogenesis 
IL6, CCL2, LDLR 3 0.025323 
h_tnfr2Pathway TNFR2 Signaling Pathway TRAF1, NFKBIA, NFKB1, TNFAIP3 4 0.03519 
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Several of the pathways associated with the gene lists derived from the A5 versus D5 
and A20 versus D20 groups involve immune regulation, cytokine signalling and 
cancer development. Additionally, transcription factor pathways, including NF-κB, 
are significantly associated with AFB1-associated gene lists.  
 
6.3.2.5 Transcription factor gene set comparison 
In order to further explore the involvement of transcription factors (TF) in AFB1-
associated gene expression changes, gene set enrichment was carried out. When 
comparing gene sets associated with known TFs, it was determined that several 
significant differentially expressed genes belonged to 15 TF pathways for the D5 vs 
A5 comparison and to 17 TF pathways for the D20 vs A20 comparison (Table 38). 
 
Table 38: Genes related to A5 and A20 exposures with associated transcription factor 
pathways (P < 0.001). 
Transcription 
Factor Pathway 
Number of 
significant 
genes 
Genes in pathway 
D5 vs A5 
E2F-1_T01542 3 EDN1, ALOX5AP, POLA2 
E2F-4_T01546 3 E2F2, GADD45A, POLA2 
ETS1_T00112 2 CSF2, HMOX1 
ETS2_T00113 1 CSF2 
FOS_T00123 2 HSPA1A, NQO1 
NFIC_T00176 4 EDN1, HMOX1, HSPA1A, IL6 
NFKB1_T00591 11 
BIRC3, CXCL1, EDN1, HMOX1, IL6, IL8*, 
NQO1, GADD45A, CCL2, CXCL2 
POU2F1_T00641 4 CSF2, IL8*, GADD45A 
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RARA_T00719 4 IL6, IL8*, GADD45A 
REL_T00168 6 CSF2, CXCL1, IL6, IL8*, CCL2, CXCL2 
RELA_T00594 9 
BIRC3, CSF2, CXCL1, IL6, IL8*, CCL2, 
CXCL2, CCL20 
SP3_T02338 3 CXCL1, EXO1* 
TFAP2A_T00035 8 
HMOX1, HSPA1A, IL6, IL8*, ALOX5AP, 
NQO1, IL7R 
TP53_T00671 11 
BIRC3, E2F2, HSPA1A, IL6, IL8*, THBS1, 
NDRG1, GADD45A, MCM7, DKK1 
WT1_T00899 2 HSPA1A, THBS1 
D20 vs A20 
CEBPB_T00581 4 IL1B, IL6, IL8* 
CEBPD_T00583 3 ALOX5AP, IL1B, IL6 
E2F-1_T01542 22 
ALOX5AP, CDC25A, FEN1*, GCLM*, 
IL1B, INHBE, NPTX2, PLAU, SLC13A5, 
TK1, IER3, POLA2, RAD54L, EDN1, 
CX3CL1, RRM1, HERPUD1*, RFC3*, 
E2F-2_T01544 1 PLAU 
E2F-4_T01546 19 
CDC25A, E2F2, FEN1*, GADD45A*, TK1, 
AURKB, BARD1, CYP1B1, POLA2, 
RAD54L, RRM1, CHEK1, KIF4A, RFC3*, 
HMMR, PTTG1 
ERG_T00265 3 HMOX1, TGFBR2* 
ESR1_T00261 7 
CDH1, GADD45A*, IL8*, CYP1B1, 
GADD45B 
FLI1_T02066 6 
COL1A1, HMOX1, BARD1, TGFBR2*, 
UPP1 
LEF1_T02905 2 MMP7* 
NFIC_T00176 9 
COL18A1, COL1A1, HMOX1, HSPA1A, 
IL6, EDN1, PCK2*, SCD 
NFKB1_T00591 26 
BIRC3*, COL1A1, CXCL1, CXCL2, 
GADD45A*, HMOX1, IL1B, IL6, IL8*, 
NQO1, PLAU, IER3, NFKBIA, PTHLH*, 
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EDN1, CCL2, CD83*, BIRC2*, CXCL5*, 
POU2F1_T00641 9 
CSF2, GADD45A*, IL8*, PLAU, TXNRD1*, 
AKR1C3 
RARA_T00719 12 
GADD45A*, IL6, IL8*, PLAU, PTHLH*, 
SCD, RARRES3, GADD45B, SERPINF1 
REL_T00168 9 
CSF2, CXCL1, CXCL2, IL1B, IL6, IL8*, 
NFKBIA, CCL2 
RELA_T00594 17 
BIRC3*, CCL20, COL1A1, CSF2, CXCL1, 
CXCL2, IL1B, IL6, IL8*, NFKBIA, PCK2*, 
CCL2, BIRC2* 
TFAP2A_T00035 23 
ALOX5AP, CA9, COL11A1*, COL1A1, 
EGR1, HMOX1, HSPA1A, IL6, IL8*, 
MMP7*, NQO1, TK1, IL7R, LOX, ODC1, 
HK2, PDE5A, CXCL5*, FGFR3 
TP53_T00671 33 
BIRC3*, E2F2, EGR1, GADD45A*, 
GCLM*, HSPA1A, IL1B, IL6, IL8*, 
NDRG1, TK1, DKK1, FBLN2*, IER3, 
PTHLH*, CX3CL1, TIMP3, CHEK1, 
MCM7*, BIRC2*, EEF1A1, ANTXR1, 
PTTG1 
Genes marked with * have more than one probe that is significantly different 
 
The majority of the genes (92% for D5 vs A5 and 72% for D20 vs A20) within these 
pathways were upregulated and therefore activated in AFB1-treated cells compared 
to the DMSO controls. The nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway including NF-κB1, Rel and RelA was particularly highlighted 
in both A5 and A20 analyses with a large number of genes associated with these TFs.  
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6.3.2.6 Comparison of gene expression changes between liver cells 
and Gambian infants 
The gene symbols as well as the direction of changes were compared between gene 
lists derived from the Gambian infant comparison and liver cell D5 versus A5 and 
D20 versus A20 comparisons. The gene lists used for this purpose were the complete 
lists with FDR below a threshold (5% for cells and 10% for Gambian infants) 
including probes repeated only once and with lower fold change.   
The Venn diagram in Figure 25 depicts this comparison with a table (Table 39) 
describing the genes in common between both lists as well as the direction of 
expression changes. Fifty % of the genes in common between the lists show the 
same trend in gene expression changes. These genes were COMMD3, FAM111A, 
ID2, LSM3 and WSB1. Comparison of gene lists consisting only of genes with 
repeated probes and/or a high fold change did not identify any genes in common.  
 
 
Figure 25: Venn diagram showing the relation between gene lists derived from Gambian 
infants and liver cells exposed to AFB1. 
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Table 39: Description of the trend of gene expression direction in genes common to 
Gambian infants and liver cells. Genes displaying similar trend in gene change direction 
are highlighted. 
 
Direction of change  
(high exposure versus low exposure) 
Gene Symbol Gambian infants Liver cells 
BIRC2 Downregulated Upregulated 
COMMD3 Upregulated Upregulated 
DSTN Upregulated Downregulated 
FAM111A Upregulated Upregulated 
FYN Upregulated Downregulated 
ID2 Upregulated Upregulated 
LSM3 Upregulated Upregulated 
NBPF10 Downregulated Upregulated 
TMEM141 Upregulated Downregulated 
WSB1 Downregulated Downregulated 
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6.4 Discussion  
A genome-wide approach with the aim to identify the effects of in vitro AFB1 
exposure in liver cell DNA methylation and gene expression patterns was explored.   
 
6.4.1 Whole genome DNA methylation in AFB1-exposed 
liver cells 
Illumina’s 450K bead chip arrays explore DNA methylation changes at the 
individual CpG site level. While a site-level analysis would enable identification of 
minute changes to a single site in the methylome following an environmental 
exposure, it vastly increases the number of multiple comparisons necessary (Wang et 
al. 2012). Additionally, a change at the individual site level may not reflect any 
biological changes. For instance, a change occurring in one CpG site in the gene 
body may not be sufficient to produce an alteration in gene expression. In this case, a 
region-level analysis would be informative as it would take into account the changes 
occurring within the gene body or promoter region, which could reflect consistent 
changes related to the phenotype of interest. This would reduce the number of 
multiple comparisons necessary and would potentially reflect real changes within the 
mechanics of gene expression regulation by DNA methylation (Wang et al. 2012).  
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6.4.2 DNA methylation differences associated with aflatoxin 
exposure 
In the current study, no significant changes were observed at the probe or site-level 
suggesting that changes at individual CpG sites were not associated with AFB1 
exposure. However, when grouping these sites by gene or promoter level, a number 
of significant changes were observed.  
Some of the genes identified in the gene lists are involved in immune function 
regulation (IL2, IGHJ2, IGHJ3), while pathway analysis revealed that some genes 
belonged to olfactory transduction. However, there were no genes in common 
between all three treatments versus controls. Of the genes in common between any 
two of the comparisons at either time points, a few have a potential role in the 
mechanism of AFB1-related health effects.  
USP17 is a subfamily of deubiquitinating enzymes, which are induced by cytokine 
stimulation and can influence cell growth and survival (Burrows et al. 2010). Indeed, 
USP17 overexpression has been observed in biopsies from colon, lung and cervix 
tumours as well as in a number of tumour-derived cell lines (Mcfarlane et al. 2010). 
In the present study, USP17L7 was hypomethylated in AFB1 exposed cells compared 
to the DMSO controls. It is possible that deubiquitinating enzymes may play a role 
in AFB1-associated carcinogenesis.  
Another gene in common to the gene lists was GPR56, which was hypomethylated 
in AFB1-treated cells compared to controls. Overexpression of GPR56 was observed 
in glioblastoma tumours and was found to inhibit glioma cell adhesion causing cell 
rounding. Furthermore, upregulation of GPR56 was observed to activate the NF-κB 
signalling pathway (Shashidhar et al. 2005).  
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Interestingly, a comparison of the differentially methylated genes in Gambian infants 
and in cultured treated liver cells revealed that a few genes (GPR56, MIR24-2 and 
MBL2) were altered in both cases with only MIR24-2 showing the same trend in 
methylation change. MicroRNA-24 (miR24) has been identified as a foetal liver 
microRNA (Fu et al. 2005). Also, overexpression of miR24 has been shown to 
suppress p16 activity in cervical carcinoma and human diploid fibroblast cells (Lal et 
al. 2008) and to inhibit cell cycle regulatory genes such as MYC and E2F2 and 
prevented differentiation of HepG2 cells (Lal et al. 2009). The latter effect is most 
likely due to the inhibition of hepatocyte nuclear factor 4α, an important factor in 
hepatocyte differentiation, in HepG2 cells with overexpressed miR24 (Takagi et al. 
2010).  
In this study, MIR24-2 was hypomethylated in high exposure groups suggesting that 
mir24-2 expression is higher in these infants/cells. It is possible that at an early stage 
of AFB1 exposure, changes occur in response to treatment including survival 
mechanisms that prevent the differentiation of damaged cells. Interestingly, miR24 
clearly has an important role in hepatocyte differentiation but also in disruption of 
tumour suppression at the cellular level.   
Overall, it appears that AFB1 exposure in vitro does affect the liver cell methylome 
resulting mainly in hypomethylation of several genes encoding immunoglobulins, 
interleukins and some cancer-associated genes. Additionally, the observed changes 
to DNA methylation in Gambian infants (Chapter 5) exposed to AFB1 in utero were 
also involved in the immune response. Therefore, the current results provide some 
support to the significant differentially methylated genes identified in Gambian 
infants.  
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However, no dose-dependent genes have been identified. This may suggest that the 
changes observed are potentially temporary. Additionally, pathway analysis did not 
reveal any realistic patterns of AFB1-induced differences. It is possible that at 
alternate time points, cells display a clear signature pattern of AFB1 exposure on 
DNA methylation. Furthermore, long-term exposure assessment may replicate 
changes occurring in humans and may reveal a DNA methylome signature of 
exposure.  
 
6.4.3 Whole genome gene expression in AFB1-exposed liver 
cells 
While very few changes were observed following a 24-hour treatment, several genes 
were differentially expressed after 48 hours of exposure, with these changes being 
dose dependent. However, five genes common to all AFB1 treatments were 
identified suggesting a general mechanism of exposure-associated effects. All five 
genes (COMMD3, FAM111A, ID2, LSM3 and WSB1) have been previously linked to 
HCC development, prognosis or progression (Ren et al. 2003; Giannitrapani et al. 
2002) suggesting that these changes occur at an early stage following exposure and 
can be potential markers of carcinogenesis. Additionally, increased IL6 expression 
has been observed in these cells, which has previously been associated with growth 
impairment (Lieskovska et al. 2002; Lieskovska et al. 2003).   
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6.4.4 Pathways involved in AFB1 exposure-associated effects 
Several of the differentially expressed genes were associated with p53 and cytokine 
signalling and cancer pathways. These alterations represent early changes to the 
genome in normal liver cells in response to AFB1 exposure. Chronic exposure can 
therefore induce repeated insults, which can ultimately lead to carcinogenesis as well 
as disruption to other important biological pathways. This type of alteration by 
chronic exposure to an environmental carcinogen has been previously shown for 
arsenic exposure in normal human keratinocytes. At levels lower than the limit 
permitted in drinking water, chronic arsenic exposure induced alterations to gene 
expression, some of which were then maintained throughout the treatment period of 
up to 14 days (Rea et al. 2003).  
 
6.4.4.1 The NF-κB pathway 
Notably, the NF-κB pathway was activated in AFB1-exposed liver cells, after 48 
hours. The NF-κB family of transcription factors while traditionally thought to only 
regulate the inflammatory and immune response, have also been found to influence 
transcriptional regulation of cell survival, differentiation and proliferation (Hayden 
and Ghosh 2008). The NF-κB family comprises 5 members: p50 (precursor p105), 
p52 (precursor p100), p65, c-Rel and RelB, which are encoded by NF-κB1, NF-κB2, 
RELA, REL and RELB. These transcription factors all have an N-terminal Rel 
homology (RHD) in common, which is responsible for DNA binding and 
dimerization. NF-κB hetero- or homo-dimers regulate transcription by binding to the 
κB sites in the promoters or enhancers of target genes. p65, c-Rel and RelB are 
thought to activate transcription due to the presence of a transcriptional activation 
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domain (TAD). However, p50 and p52 lack a TAD and are thought to repress 
transcription unless associated with a transcriptional activating member of the NF-
κB family (Dolcet et al. 2005).  
NF-κB members are inactivated by binding to IκB proteins, IκBα, IκBβ or IκBƐ 
encoded by IKBA, IKBB or IKBE genes respectively. Initially, it was thought that 
this inactivation prevented the NF-κB dimers from moving from the cytoplasm to the 
nucleus. However, it has been noted that the IκBα, while bound to the p65/p50 dimer, 
masks the nuclear localisation sequence (NLS) of p65 leaving the NLS of p50 
exposed. It has also been discovered that this complex shuttles between the 
cytoplasm and nucleus, although the presence of a nuclear export signal (NES) on 
IκBα immediately expels the complex forcing it to return to the cytoplasm (Ghosh 
and Karin 2003).   
In response to inducing stimuli, the two serines present in IκBs are phosphorylated 
by IκB kinases (IKKs), which then marks them for ubiquitination and consequently 
proteasomal degradation (Hayden and Ghosh 2008). There is a broad range of 
stimuli including cytokines and growth factors that have been identified as factors 
initiating the degradation of the IκBs and therefore releasing NF-κB dimers, which 
are then free to regulate transcription of target genes (Dolcet et al. 2005).  
NF-κB plays a key role in the progression of liver disease that can be brought about 
by chronic injury or exposure. In response to injury, the NF-κB pathway is activated 
to initiate an inflammatory response as a protective measure. However, if the balance 
of this pathway is tipped in either direction, it can contribute to the onset of 
hepatocarcinogenesis (Luedde and Schwabe 2011).  
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Regardless of aetiology, the activation of the NF-κB pathway seems to be a 
consistently early event in human liver cancers (Liu et al. 2002).  Also, it has been 
shown that in HepG2 cells treated with 10 µM AFB1 (similar in concentration to A5 
in the current work) there was an 8-fold increase in NF-κB transcription factor and a 
6-fold increase in AP1 transcription factor following a 24 hour treatment. 
Additionally, it was observed that incubation with AFB1 resulted in increased 
induction of p65 (Rel-A), p50, c-JUN and c-FOS complexes compared to the control 
(Banerjee et al. 2000).  
6.4.4.2 Role of NF-κB and STAT3 pathways in HCC 
The STAT3 pathway, activated by growth factors and cytokines including IL6, has 
been linked to HCC development. In fact, phosphorylated nuclear STAT3, indicative 
of its activation, has been observed in 60 % of human HCCs (He et al. 2010). A 
number of the transcription targets for both NF-κB and STAT3 pathways overlap 
and are involved in cell proliferation, survival and the stress response (Karin 2009). 
In carcinogen-induced hepatocyte death, IL1α is produced, which activates the NF-
κB pathway in Kupffer cells. In response, these cells then produce IL6, which 
activates STAT3 in hepatocytes, resulting in cell proliferation compensatory to the 
initial hepatocyte death- events eventually leading to HCC development (He and 
Karin 2010). However, NF-κB can also act as a negative regulator of STAT3 in 
HCC cells. Suppression of IKKβ, which is responsible for the activation of NF-κB, 
results in the accumulation of ROS. Oxidation of Src homology region 2 domain-
containing phosphatase-1 (SHP1) or SHP2, which dephosphorylate JAK2 and 
STAT3, inhibits their catalytic activity leading to an accumulation of activated JAK2 
and STAT3. These then lead to hepatocyte proliferation and tumourigenesis (He et 
al. 2010).  
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In the present work, STAT3 expression was higher in infants exposed to higher AFB1 
in utero, while no significant change in IL6 was observed. In normal liver cells 
exposed to AFB1, IL6 and NFKB1A expression were elevated compared to controls. 
These results suggest a positive interaction between the NF-κB and STAT3 
pathways in AFB1-induced changes to the genome. Furthermore, these observed 
differences in gene expression in cultured liver cells support the identified genes and 
pathways in Gambian infants.  
 In a more direct exposure system i.e in the liver cells, AFB1 potentially activates 
STAT3 via increased expression of IL6 and NF-κB family members. These initial 
changes following a 2-day exposure could contribute to hepatocarcinogenesis 
leading to HCC development. In Gambian infants, potentially chronic exposure 
during gestation can also activate the STAT3 signalling either via a similar 
mechanism involving IL6 or through alternate pathways. However, the limitations of 
the Gambian infant study must be taken into account when considering the 
implications of these findings. One of the main limitations was the use of RNA 
derived from whole blood with potential disruption from globin RNA to mRNA 
expression. Also, as infant blood was collected 3-6 months after birth, other factors 
such as viruses, may have influenced the methylation and expression of genes.  
Nevertheless, they do provide a link between AFB1 exposure and activation of the 
STAT3 and NF-κB pathways, which could potentially be implicated in 
hepatocarcinogenesis. Additionally, the association between AFB1 exposure and IL6 
induced STAT3 signalling, with SOCS-3 activation and consequently IGF1 down-
regulation, could be part of the mechanism of AFB1-related growth impairment.  
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6.4.5 Conclusions 
AFB1 exposure in cultured non-tumourigenic liver cells indeed alters the methylome 
and gene expression patterns. These findings suggest that exposure to AFB1 can 
induce early events and cellular disruptions that can lead to aberrant mechanisms of 
cell survival, growth and development. Although a DNA methylation signature was 
not identified, specific changes in the regulation of expression of key genes, 
including those encoding immunoglobulins, indicate a disruption of the immune 
response.  
A clearer signature of gene expression changes in liver cells was determined. 
Activation of the NF-κB and STAT3 signalling pathways imply that these early 
events mark the start of important changes to the genome. These key alterations 
potentially reflect a predisposition to cancer development and also provide some 
evidence for mechanisms of AFB1-associated growth impairment.  
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7 Overall discussion and conclusions 
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7.1 Introduction 
Following the discovery and characterisation of aflatoxins in the 1960s, several 
studies have focussed on the impact they have on animal and human health. The 
identification of AFB1 adducts in the blood and urine as biomarkers of exposure 
have furthered our understanding of the various health effects associated with AFB1 
exposure. The mechanisms of AFB1-associated liver carcinogenesis, growth and 
immune function impairment have been widely explored. A major finding about the 
mechanism of AFB1 liver carcinogenesis was the G->T transversion in codon 249 of 
the p53 gene observed in liver cancers in regions of high AFB1 exposure. However, 
the mechanism of exposure-associated growth and immune function impairment is 
not understood. Additionally, AFB1 exposure occurring during foetal development 
can cause growth retardation in new-borns through an unknown mechanism. In the 
present work, we have 1) tested a hypothesis exploring the role of IGF in AFB1-
associated child growth impairment; 2) determined AFB1 exposure at two time 
points during pregnancy and examined the effects of seasonality on exposure; and 3) 
identified potential signatures of DNA methylation and gene expression changes 
following AFB1 exposure in both Gambian infants and cultured liver cells.  
 
7.2 AFB1-associated growth impairment 
At the start of this study, little was known about the mechanism of AFB1-associated 
growth impairment, but based on the results presented here, it can be seen that this 
mechanism is multi-faceted with the involvement of a few key factors that can 
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disrupt normal developmental processes. We have found that approximately 16% of 
the overall effect of AFB1 exposure on height reduction in a population of Kenyan 
school children was through an indirect mechanism involving reduced IGF1 protein 
levels. In non-tumourigenic liver cells, a direct effect of AFB1 exposure on IGF axis 
component gene and protein expression was also observed, providing supporting 
evidence for the role of an altered IGF axis in AFB1-associated growth impairment.  
While these findings explain a part of the effect of AFB1 on growth impairment, 
other routes of growth impairment are probably involved in the overall mechanism. 
In Gambian infants with in utero exposure and in AFB1-treated liver cells, IL6, 
STAT3 and NFKB1A were upregulated in the higher exposure groups. These genes 
belong to the interlinked JAK/STAT and NF-κB pathways, which are involved in 
several developmental processes including growth, cell proliferation and apoptosis. 
The STAT pathway, via STAT3, is activated either directly through elevated IL6 
levels or indirectly through the NF-κB pathway. This, in turn, increases the 
expression of SOCS-3, which is a negative regulator of the GH-IGF1 signalling 
pathway (Lieskovska et al. 2003). Indeed, exposure to another mycotoxin, DON, has 
been observed to overexpress IL6 followed by upregulation of SOCS-3 in the liver, 
which then lowers IGF-ALS levels in mice (Amuzie et al. 2009). This has been 
suggested to be the mechanism through which DON induces growth impairment in 
mice (Amuzie and Pestka 2010).  
Taken together, the changes in the expression of key genes involved in JAK/STAT 
and NF-κB signalling appear to contribute to the mechanism of growth impairment 
in infants highly exposed to aflatoxins during development. The fact that these 
changes are observed following in utero exposure in infants and also in non-
tumourigenic cells treated with AFB1, we may conclude that the upregulation of 
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STAT3, IL6 and NFKB1A occurs in response to early life exposure or as an early 
event of AFB1 exposure. If dietary AFB1 exposure persists, as a result of important 
changes to the genome, a significant alteration to the phenotype is probable. 
Additionally, the timing of AFB1 exposure may have an important bearing on the 
consequences of exposure. The earliest stages of foetal development are a crucial 
time during which any exposure or external insults can alter the development of the 
methylome (Chmurzynska 2010). While we have observed changes in some key 
genes potentially involved in a mechanism of AFB1-associated health effects, further 
enquiry into the changes immediately following birth with assessment of cord blood 
AF-alb levels may provide more clues into the mechanisms involved. Furthermore, 
exposure at alternate times may be reflected by different mechanisms ultimately 
affecting health outcomes. 
 
7.3 Effect of AFB1 on immune function and 
inflammation-related liver carcinogenesis 
The mechanism of AFB1-associated liver carcinogenesis has been explored 
previously resulting in the identification of the G->T transversion in p53 (Lasky and 
Magder 1997) as well as in hypermethylation of key tumour suppressor genes 
including RASSF1A and p16 (Zhang et al. 2002; Zhang et al. 2003; Zhang et al. 
2006). However, very little is known about the impact of early life AFB1 exposure 
on health.  
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An important finding of this study was the global increase in expression of factors 
involved in the immune response. These factors included immunoglobulins (IGHJ1, 
IGHJ3) and cytokines (IL2, IL6, IL8, IL18). These factors were either significantly 
hypomethylated or highly expressed in Gambian infants or cells exposed to high 
levels of AFB1. Also, cell-surface markers (CD3D, CD2, CD4, CD3G) were 
hypermethylated in Gambian infants in the higher AFB1 exposure group.  
These changes are similar to previous findings where IL6 expression was increased 
and CD14 expression was decreased in a murine macrophage cell line, J774A.1 
exposed to low doses of AFB1 (Bruneau et al. 2012). Indeed, IL6 overexpression 
was also observed in pigs fed diets containing AFB1 (Meissonnier et al. 2008).  
The alteration of the factors responsible for the immune response can affect 
susceptibility to infections and can also promote inflammation eventually leading to 
cancer development. Indeed, inflammation manifesting through NF-κB signalling 
can exert pro-tumourigenic effects (Karin and Greten 2005). In hepatocarcinogenesis, 
the NF-κB pathway is activated as a result of chronic injury or insult in hepatocytes, 
which in turn activate the Kupffer cells. IL6 is produced by activated Kupffer cells 
and plays a very important role in inflammation. Under normal conditions, IL6 is 
present in low quantities in the serum but is overexpressed under stress. Increased 
amounts of IL6 then activate the JAK/STAT pathway resulting in compensatory 
proliferation, which eventually leads to malignant transformation (Naugler and Karin 
2008). These pathways potentially form the basis of the mechanism of AFB1-
associated liver carcinogenesis. A model of inflammation-induced 
hepatocarcinogenesis due to chronic insult is shown in Figure 25.  
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Figure 26: Model of hepatocarcinogenesis induced by chronic injury or insult including 
AFB1 exposure resulting in an inflammatory response. Chronic injury or exposures result 
in death of vulnerable hepatocytes, which trigger signals in the form of IL1R or other 
factors. These signals activate the NF-κB signalling pathway in Kupffer cells prompting the 
production of IL6, which contributes to the inflammatory response and also activates 
JAK/STAT signalling. This pathway together with a trigger from dead hepatocytes 
promotes the compensatory production of new cells, which can eventually lead to 
malignant transformation through mutations. Components potentially altered via aberrant 
gene expression or methylation as a result of early life or in vitro exposure to AFB1 are 
marked with a red star. Image modified from (Naugler and Karin 2008). 
 
A common element in these reported changes is inflammation, which may be the 
driver in AFB1-induced health effects. Exposure to AFB1 can trigger inflammatory 
events with overexpression of IL6 and NFKB1A, which in turn activate the 
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JAK/STAT and NF-κB pathways. Repeated insult would eventually lead to 
carcinogenesis, growth and immune function impairment.  
Further work on the mechanism of AFB1 exposure-associated health effects through 
the NF-κB, IL6 and STAT signalling pathways is necessary to confirm their 
involvement and to fully understand the association with growth impairment and the 
conversion of a normal, healthy cell into a cancerous cell. This work could include in 
vitro analysis to study the pathways at the protein level using techniques such as 
immunofluorescence. Further work would also potentially identify additional 
markers of AFB1 exposure.     
 
7.4 Limitations of this study 
A number of factors may have influenced the results obtained throughout this work 
and therefore need to be addressed.  
In order to ascertain the role of a disrupted IGF growth axis on child growth 
impairment, a population of children with a more homogeneous age range would be 
beneficial. In the work presented in Chapter 3, children were aged 6-17, which 
included children undergoing puberty thereby becoming a major confounder to the 
impact of dietary AFB1 on growth. Additionally, infection status and other health 
effects would also have to be taken into account as potential confounders to growth 
impairment and alteration to IGF levels and expression. To overcome these issues, a 
cell model was added to the study providing additional evidence for AFB1-induced 
disruption of IGF. However, cell models may not always reflect the exact nature of 
the effects of a toxin due to altered expression of cell surface molecules or the fact 
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that the cells are not in their natural environment and may behave differently (Kaur 
and Dufour 2012).  
Another major limitation of this study was that all whole genome analyses were done 
using whole blood cells rather than the target tissue. As it is unethical to obtain and 
study liver tissue from new born babies, an easily accessible source i.e. blood, was 
utilised instead. However, it is important to note that DNA methylation patterns vary 
by blood cell type. For instance, in healthy males it was found for that for 
methylation levels were different for 22% of the probes analysed for mononuclear 
and granulocyte cells (Reinius et al. 2012). Therefore, any differences in WBC 
counts between infants due to an infection or due to natural variation would skew the 
DNA methylation results considerably. The total white blood cell count was 
unavailable for the infant blood samples analysed in the present study and therefore 
all significant differences in DNA methylation should be considered with caution.  
Blood samples analysed for whole genome DNA methylation and gene expression 
were obtained from infants aged 3-6 months. Preferably, cord blood samples would 
have provided a better idea of the changes occurring as a result of in utero exposure. 
Due to the amount of time between birth and sample collection, other factors 
including infection, may have confounded the results.   
Additionally, the moment of conception would have been the ideal point at which 
changes could occur in the methylome and genome of developing embryos following 
an exposure (Heijmans et al. 2008) including AFB1. In the current study, AFB1 
exposure at an early point during pregnancy i.e. 0-15 weeks was analysed. Therefore, 
for some infant blood samples, exposure would have been measured towards the end 
of the ‘early’ period.  Another important variable that could skew the results at this 
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stage would be season of exposure. The study was conducted with the assumption 
that a woman belonging to a high AFB1 exposure group during conception would 
likely remain in the same group a few months into pregnancy. The season at the time 
of conception would also influence DNA methylation (Khulan et al. 2012). However, 
the season during a later time point following conception may be different to the 
season at the time of conception. For this reason, only women who conceived during 
a season that matched the season at the time of blood collection for AF-alb 
measurement were analysed separately. Nevertheless, the observed DNA 
methylation changes were similar to changes observed when including all women in 
the analysis.   
Another potential limitation of the study was the relatively high P value threshold 
used in the whole genome analyses. In DNA methylation or gene expression 
analyses comparing only a few loci between groups, a P value less than 0.05 or 0.01 
is usually acceptable. However, when comparing large numbers of loci as is the case 
in genome-wide analyses, the proportion of false positives among the list of total 
positives is greatly increased. Therefore, a more stringent cut-off (such as P < 0.0001 
or lower) is necessary to reduce the chance of identifying false positives (Storey and 
Tibshirani 2003). In the current study, a cut-off of 0.01 was used to filter out genes 
with a P value above this value. This is a particularly high threshold, which may 
have increased the number of false positives in the final gene lists. The validations 
for DNA methylation and gene expression in Gambian infants may have been 
unsuccessful for some loci due to the observed changes being false positives. 
However, an acceptable FDR (q value) of < 0.10 or < 0.05 was adopted to minimise 
the proportion of false positives. Additionally, while a higher threshold would 
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increase the number of false positives, it would also increase the chances of 
identifying small changes in biologically sensible loci that can be explored further.  
 
7.5 Conclusion 
AFB1 exposure at an early stage in life can affect normal protein levels (IGF1, 
IGFBP3) and is associated with significant DNA methylation and gene expression 
changes in infants exposed to AFB1 in utero as well as in non-tumourigenic cultured 
liver cells.  
Despite the limitations in this study, key genes involved in inflammation, growth and 
cell proliferation have been identified as being differentially methylated or expressed 
following AFB1 exposure. This is the first time that such altered epigenetic and 
transcriptomic patterns in association with aflatoxin have been observed in exposed 
children. Interestingly, these important changes have been observed in both Gambian 
infants and in cultured liver cells. A mechanism involving NF-κB, IL6 and STAT3 
potentially play a central role in AFB1-associated immune function and growth 
impairment and liver carcinogenesis. The involvement of the IGF growth axis also 
provides a better understanding of the mechanism of growth impairment.  
Overall, the current study has identified potentially key players in AFB1 exposure-
related health effects. The involvement of these important proteins in the 
manifestation of the adverse health effects associated with aflatoxin contributes to 
our understanding of the impact of early life exposure to aflatoxins.  
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